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Zusammenfassung 1
Zusammenfassung
Insbesondere seit den 80er Jahren des letzten Jahrhunderts finden Entlassungen von Arz-
neimitteln und/oder der zugeho¨rigen Indikation aus der Verschreibungspflicht (Rx) in den
Bereich Selbstmedikation (OTC), so genannte
”
Rx-to-OTC Switches“, nicht nur in den USA,
sondern zunehmend auch in Europa Verbreitung. Patienten profitieren dabei von einem direk-
teren und schnelleren Zugang zu einem breiteren Arzneimittelspektrum, dem andererseits die
Risiken einer fehlenden a¨rztlichen Kontrollinstanz gegenu¨berstehen. Nichtsdestotrotz hat sich
heute, ausgehend von der anfa¨nglichen Entlassung von Medikamenten zur Behandlung aku-
ter, leichter und selbstlimitierender Krankheitsbilder, eine Tendenz hin zur Entlassung zuneh-
mend komplexerer Arzneimitteltherapien zur Behandlung und Pra¨vention (semi-)chronischer
Erkrankungen etabliert. Der Wert dieser Entwicklung fu¨r das Gesundheitswesen ergibt sich
dabei nicht nur aus dem wachsenden Bewusstsein der Bevo¨lkerung fu¨r Krankheitsrisiken und
–folgen sowie entsprechende eigenverantwortlicher Therapiemaßnahmen, sondern auch aus
einer damit verbundenen langfristigen Entlastung der Gesundheitssysteme. Wachsende An-
forderungen an Arzneimittelinformation sowie eigensta¨ndiges Therapiemanagement und vor
allem Therapiesicherheit als notwendige Begleitelemente gehen damit zwangsla¨ufig einher.
Innovative Entwicklungen im Bereich Selbstmedikation durch den Rx-to-OTC Switch geeig-
neter Therapieoptionen zeichnen sich demnach zwar durchaus ab, sind jedoch grundsa¨tzlich
von Komplexita¨t und hoher Ressourcenbindung gepra¨gt, was eine angemessene Un-
terstu¨tzung durch das gesetzliche und regulatorische Umfeld erforderlich macht. Der eu-
ropa¨ische Gesetzgeber hat daher mit Einfu¨hrung von Artikel 74a, Richtlinie 2004/27/EC, die
Mo¨glichkeit der Vergabe einer einja¨hrigen Exklusivita¨tsperiode etabliert, sofern der Switch
auf Basis
”
signifikanter“ pra¨klinischer oder klinischer Daten beschieden wurde. Das Instru-
ment
”
Datenexklusivita¨t“ geho¨rt zu den geistigen Eigentumsrechten und untersagt in diesem
Fall den Arzneimittel-Zulassungsbeho¨rden, sich im Rahmen der Pru¨fung generischer Zulas-
sungsantra¨ge auf origina¨re Switchdaten zu beziehen, was die Bearbeitung und gegebenenfalls
Zulassung letzterer faktisch erst nach Ablauf eines Jahres mo¨glich macht.
Zielstellung: Ziel der vorliegenden Arbeit war es, die folgenden Hypothesen bezu¨glich der
Mo¨glichkeit der Vergabe von Datenexklusivita¨t fu¨r Rx-to-OTC Switches in Europa zu
u¨berpru¨fen bzw. zu substantiieren:
Hypothese 1: Anhand der angegebenen Kriterien und Datenkategorien ist es unter den
aktuellen gesetzlichen Rahmenbedingungen in Europa praktisch nicht mo¨glich,
Datenexklusivita¨t fu¨r Rx-to-OTC Switches zu erhalten.
Hypothese 2: Vorhandene Kriterien und Datenkategorien mu¨ssen pra¨zisiert und neue
definiert werden, um die Vergabe und den Erhalt von Datenexklusivita¨t bei Rx-
to-OTC Switchen mo¨glich zu machen.
Methodik: Eine umfangreiche Literaturrecherche zu den Themen
”
Rx-to-OTC Switch“
und
”
Datenexklusivita¨t“ bildete die Grundlage der Status-quo-Analyse und der Hy-
pothesengenerierung. Der Hypothesenu¨berpru¨fung diente eine retrospektive Analy-
se des Rx-to-OTC Switches von Clotrimazol zur Behandlung von Vaginalmykosen
2 Zusammenfassung
(am Beispiel des Originatorpra¨parates Canesten
®
GYN von Bayer) unter den ge-
genwa¨rtigen Pra¨missen zur Vergabe von Datenexklusivita¨t. Daru¨ber hinaus wurden
ausgewa¨hlte nationale und internationale Experten mithilfe eines qualitativen Frage-
bogens zur Einscha¨tzung der aktuellen gesetzlichen Rahmenbedingungen und zu Vor-
schla¨gen bezu¨glich deren Pra¨zisierung bzw. Novellierung unter den Aspekten OTC-
Relevanz, Qualita¨t und Machbarkeit interviewt. Auf Basis einer weiteren Literaturre-
cherche wurde der Einsatz sogenannter
”
Propensity Scores“ bei der statistischen Aus-
wertung von Beobachtungsstudien zur Erho¨hung der Datenvalidita¨t als mo¨gliches Qua-
lita¨tskriterium fu¨r eine Exklusivita¨tsvergabe diskutiert. Eignung und Praktikabilita¨t
dieses Ansatzes wurden nachfolgend anhand eines existenten Datensatzes u¨berpru¨ft.
Ergebnisse: Beide Hypothesen konnten durch die Forschungsergebnisse besta¨tigt werden.
Die retrospektive Analyse des Clotrimazol-Switches zeigt, dass sich fu¨r einen im Le-
benszyklus weit fortgeschrittenen Switch-Kandidaten in Anbetracht umfangreicher
pra¨klinischer und klinischer Daten vor und fu¨r die Rx-Zulassung kaum eine Mo¨glichkeit
fu¨r die Generierung neuer potentiell
”
signifikanter“ Daten bietet. Vor allem die Sinnhaf-
tigkeit pra¨klinischer Daten wurde in diesem Zusammenhang von einem Großteil der
Experten hinterfragt. Die
”
Signifikanz“ neuer Daten wurde vielmehr im Sinne einer
Relevanz fu¨r die mit der Statusa¨nderung angestrebte Selbstmedikation gesehen. Vor
diesem Hintergrund sind die aktuell in den Gesetzestexten verwendeten Terminologien
und Datenkategorien nicht nur unspezifisch, sondern auch praktisch kaum anwendbar,
sofern in rein konservativem Sinne interpretiert. In der zugeho¨rigen Switchguideline
aufgefu¨hrte Kriterien sind ebenso wenig ausreichend konkret. Fu¨r eine erfolgreiche
Vergabe von Datenexklusivita¨t im Rahmen zuku¨nftiger Rx-to-OTC Switches ist folg-
lich eine Pra¨zisierung vorhandener bzw. die Definition neuer Kriterien und Datenka-
tegorien unter Beru¨cksichtigung der Besonderheiten der Selbstmedikation no¨tig. Dies
wurde von den Befragten auch mit Blick auf die steigenden Anforderungen im Rahmen
der Entlassung zunehmend komplexerer Therapieoptionen im Grundsatz mehrheitlich
befu¨rwortet.
Von besonderer Bedeutung ist dabei in erster Linie eine Erweiterung der Definition
klinischer Daten u¨ber die klassischen Phase I-III bzw. IV Daten hinaus. In Anbe-
tracht der fehlenden a¨rztlichen U¨berwachung im angestrebten Status der Selbstme-
dikation sollte diese explizit auch Daten zu Selbstdiagnose, Patientenverhalten und
Arzneimittelutilisation aus nicht-interventionellen Beobachtungsstudien (NIS) einbe-
ziehen, um Wirksamkeit und Sicherheit auch unter OTC-Bedingungen antizipieren
zu ko¨nnen. Unter Einhaltung wissenschaftlich anerkannter Qualita¨tsstandards liefern
letztere wichtige Erkenntnisse bezu¨glich Therapiepraxis, -erfolg und -sicherheit unter
Alltagsbedingungen. Durch den nicht-experimentellen Studiencharakter kann es jedoch
unter Umsta¨nden zu Verzerrungen der Studienergebnisse kommen. Mithilfe bestimm-
ter statistischer Verfahren wie der sogenannten Propensity-Score-Analyse ko¨nnen diese
minimiert und damit die Validita¨t der Ergebnisse erho¨ht werden. Als wesentliches Qua-
lita¨tskriterium fu¨r NIS Daten sollte diesem Ansatz daher bei deren Bewertung fu¨r die
Vergabe von Datenexklusivita¨t Rechnung getragen werden.
Zusammenfassung 3
Im Bereich
”
Pra¨klinik“ lassen sich dagegen nur wenige Szenarien wie z.B. die Ermitt-
lung von Interaktionspotentialen als potentiell OTC- und damit exklusivita¨tsrelevant
definieren.
Die Re-analyse bereits existenter pra¨klinischer und klinischer Studienergebnisse unter
OTC-Aspekten wird als exklusivita¨tsunterstu¨tzend, jedoch nicht ausreichend erachtet.
Durch die Aufnahme einer zusa¨tzlichen
”
nicht-klinischen“ Datenkategorie in den re-
levanten Gesetzestext sollten daru¨ber hinaus auch Erkenntnissen aus epidemiologi-
schen oder Marktforschungsuntersuchungen sowie Umfrage-Ergebnissen entsprechende
Beru¨cksichtigung finden. Nicht selten liefern diese fu¨r eine Switchentscheidung essenti-
elle Informationen zu Compliance, Patientenzufriedenheit, Lebensqualita¨t etc. Konzep-
te zur Risikominimierung im Falle der Entlassung komplexerer Therapieoptionen inklu-
sive umfangreicher Informations- und Edukationsprogramme fu¨r Patienten wie Fach-
personal, Abgabemodelle oder auch Therapiemanagement/–monitoring Instrumente
fu¨r Patienten wu¨rden ebenfalls hierunter fallen, sofern nicht in die klinische Datenge-
nerierung z.B. im Rahmen einer NIS eingebunden.
Schlussfolgerung: Um ihre Funktion hinsichtlich der Initiative innovativer, komplexer Rx-
to-OTC Switches zuku¨nftig faktisch erfu¨llen zu ko¨nnen, mu¨ssen die gegenwa¨rtigen
gesetzlichen Rahmenbedingungen fu¨r die Vergabe von Datenexklusivita¨t spezifiziert
bzw. modifiziert werden. In der vorliegenden Arbeit wurden Vorschla¨ge fu¨r Kriterien
und Datenkategorien fu¨r die Qualifikation von Daten fu¨r die Vergabe von Datenexklu-
sivita¨t bei Rx-to-OTC Switches erarbeitet. Unter dem Aspekt der damit verbundenen
Anforderungen und Anstrengungen auf Seiten des pharmazeutischen Unternehmers,
vor allem aber mit Blick auf die fu¨r eine erfolgreiche Einfu¨hrung und Etablierung eines
Switches no¨tige Transparenz und Konsistenz hinsichtlich essentieller Begleitmaßnah-
men wie z.B. Information und Edukation, wird zudem eine Verla¨ngerung der derzeitigen
einja¨hrigen Exklusivita¨tsperiode empfohlen.
In jedem Fall ist es vor dem Hintergrund der in dieser Arbeit diskutierten Thematik
wu¨nschenswert, im Rahmen von oftmals unterschiedlichen Interessen oder Meinun-
gen unterliegenden Rx-to-OTC Switchentscheidungen eine fundierte wissenschaftliche
Bewertung als zentralen Bestandteil eines solchen Prozesses zu etablieren, die der an-
gestrebten Statusa¨nderung angemessen und entsprechend transparent ist.
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1 Introduction
1.1 Background
Patients’ increasing empowerment in managing their own health and their demand for wider
and convenient access to self-medication with over-the-counter (OTC) drugs based on en-
hanced knowledge about their disease status are major factors that have contributed to a
constantly growing OTC-business worldwide. Moreover, the increasing economic burden of
national health care systems has to be accounted for. In consequence, a rising number of
Rx-to-OTC switches is currently seen both in the United States (US) and in the European
Union (EU), with the United Kingdom (UK) as the cutting-edge, as well as in Asian Pacific
countries which are increasingly following suit. Having started in the 2nd half of the 20th
century, the Rx-to-OTC movement now seems to have reached a new “era”: there is a trend
in self-medication from treating acute, easily recognizable, and self-limiting conditions in
the past towards the prevention or treatment of (semi-)chronic risk factors and conditions
today. This evolution is obviously associated with major challenges, such as a clear defi-
nition of a successful disease management process, of conditions concerned, and the active
role of the stakeholders involved. In this respect the temporal and costly investment usually
undertaken by the pharmaceutical company initiating and enforcing the switch of a certain
drug substance or product points out the importance of the provision of adequate incentives
to envisage accordant Rx-to-OTC switches eventually resulting in benefits not only for pa-
tients, but for national health care system and its various actors as well. In its Directive
2001/83/EC, as amended by Directive 2004/27/EC, the European Commission, therefore,
implemented Article 74a which addresses the possibility of the provision of one year of data
exclusivity in case of eligibility of the data submitted with the respective Rx-to-OTC switch
application.
1.2 Aim
The European Directive 2001/83/EC, as amended by Directive 2004/27/EC, provides the
legal framework for the reward of data exclusivity as one form of incentive to be granted to
pharmaceutical companies as part of the Rx-to-OTC switch of a certain drug substance or
medicinal product. The wording of the respective Article 74a, however, is rather unspecific
and lacks precise information about what data in particular is required to be eligible for
data exclusivity. To date, the only attempt to interpret this legislation is given in the
“Guideline on changing the classification for the supply of a medicinal product for human
use” (European Commission 2006a). Yet, as this kind of guideline is also relatively unspecific
in this regard, there is an obvious need for a more definite expression of criteria and data
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categories justifying eligibility for data exclusivity against the background of the transfer
of drugs with a long record of safety and efficacy from a highly regulated and monitored
Rx status to an OTC status which is much more dependent on reliable self-control and
self–guidance. Importantly, the setup of such criteria and requirements should be based on a
common understanding of relevant preconditions for treatment with the respective medicinal
products in a self-medication environment by all stakeholders involved in the Rx-to-OTC
switch process and be adapted to its future development.
The present work therefore discusses and sets up an outline of definite, eventually revised and
additional criteria as well as data categories justifying data exclusivity for Rx-to-OTC switch
products with respect to their usage under the particular circumstances of self-medication.
Based on these considerations, the existing one-year period of data exclusivity provided by
the EU legislation will be equally reconsidered with the objective of – if applicable - proposals
for optimization.
Finally, identified items and requirements could provide the basis to eventually derive a
business model which could then at best be used for guidance regarding the fulfillment of
relevant criteria (e.g., in terms of strategy, timing, etc.).
1.3 Methodology
The preparation of the present doctoral thesis was based on several different strategic ap-
proaches and methods including desktop research, case study analyses, and qualitative expert
interviews.
Secondary research in terms of a comprehensive and systematic review of relevant literature
with respect to the topics “Rx-to-OTC switch”, “data exclusivity” , and “propensity score”
(for databases used see Section A.1 in the appendix) as well as the identification, analysis
and discussion of relevant up-to-date case studies publicly accessible via internet initially
contributed to the formulation of the two main research hypotheses (see Section 4.6 and
Subsection 4.6.2).
A case-study analysis based on published and unpublished proprietary data relating to the
original Rx registration of Bayer’s Canesten
®
GYN and its subsequent Rx-to-OTC switch
was used for the purpose of practical exemplification of research results. Data was identified,
retrieved (e.g., dossiers, study reports, publications, etc.), screened, and analyzed from the
retrospective (see Chapter 5).
In addition, a written questionnaire composed of 24 questions related to the issue of data
exclusivity within the context of the legal framework was developed as primary research
instrument in order to discuss the assumed hypotheses. Both multiple choice and open
format questions were used for evaluation. The questionnaire was designed in German lan-
guage and later on translated into English, in order to be able to collect data from inter-
national experts alike (see Section A.2 in the appendix). Experts selected account for the
main stakeholder groups involved in Rx-to-OTC switches: pharmacists, physicians, indus-
try, regulatory/political authorities, third party payers (health insurance companies), and
patients/consumers. Subsequent analysis of questionnaire data was based on descriptive
statistics. A detailed description of the qualitative survey results is given in Chapter 6.
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Within the context of literature review, so-called “propensity score methodology” was iden-
tified and discussed as a possible statistical tool aiming at the reduction of bias effects and
thus increasing the validity of observational study results. Furthermore, in order to demon-
strate practical applicability underlying its potential role in the issue of data eligibility for
the grant of exclusivity, propensity score technique was applied to the analysis of existent,
non-interventional, (i.e., observational) study data (see Subsection 7.2.3).
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2 The Rx-to-OTC switch movement: background, implications
and trends
”The transfer of drugs from prescription to OTC status is a logical and systematic develop-
ment of today’s healthcare environment” (Gossel 1991).
2.1 Evolution of self-care with OTC medications
Today, self-medication with OTC drugs is often called “OTCness” meaning “the widespread
availability of safe and effective nonprescription medicines for responsible consumer self-care,
in accordance with the applicable laws, regulations and voluntary industry codes affecting
manufacturing, packaging, and labeling of quality products and the advertising of those
products in all media” (Soller 1998). Self-medication with OTC drugs is nowadays of great
importance for the management of a wide range of common diseases. According to the
American Pharmaceutical Association, the treatment of 60 - 90 % of illnesses is initiated by
some form of self-care (Marwick 1997), making up around 60 % of the whole medical care in
the US, yet at the same time accounting for less than 2 % of US healthcare spending (Gossel
1991; Marwick 1997). “This makes it likely that, as a low-cost alternative, OTC drug use
will continue to grow” (Marwick 1997).
In fact, self-medication with drugs existed long before any regulation by legislation came up
and users without prescription simply purchased any drugs needed (Gossel 1991). The defi-
nition of “OTC” in the modern sense has evolved slowly over the past years with the OTC
Review process in the US at the core of scientifically based regulatory legislation describing
safety, effectiveness (Hodgson et al. 2007)1 and labeling as the most essential quality criteria
of OTC medication in the sense of a benefit-risk evaluation (Soller 2002). Accordingly, an
OTC drug, if used correctly, should be associated with a low incidence of serious side effects
or adverse events (AEs) as well as a low potential of harm in case of abuse, under conditions
of widespread availability. In terms of effectiveness, the pharmacological effect should result
in clinically significant relief of symptoms as claimed. Labeling should be clear and correct,
providing adequate directions for use and warnings likely to be understood by the ordinary
individual (Soller 1998).
The US OTC Review process started in 1972 and is still ongoing. It is based on the Durham-
Humphrey Amendment from 1951 and amends the Federal Food, Drug, and Cosmetic Act
(FD&C) which was passed in 1938. The FD&C required manufacturers, for the first time, to
1 In general linguistic usage “effectiveness” refers to a treatment effect which is observed under “real-world”
conditions of regular practice. It has to be differentiated from “efficacy” which in contrast relates to a treatment
effect that is demonstrated under strictly defined conditions within clinical randomized controlled trials (Black
1996; D’Agostino 2007; Hlatky et al. 1984; Hodgson et al. 2007).
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establish drug safety and allocate adequate drug labels directed towards healthcare profes-
sionals (HCPs) (Palumbo 1991) and is thus to be considered as the starting point of modern
OTC history (Juhl 1998). The Durham-Humphrey Amendment was to overcome deficien-
cies of the FD&C and provides the statutory base for the categorization of drugs in two
specific classes, namely, prescription and self-medication (Gossel 1991). It assumes OTC as
the default status for drugs unless they cannot be used and marketed safely without medical
supervision and thus should be available prescription only. Specifically, this refers to drugs
with habit forming properties, an inherent unfavorable safety profile, or an approval as the
result of a new drug application for use under professional supervision (Soller 2002). As con-
sequence of the thalidomide tragedy (q.v. Section 5.1), the adoption of the Kefauver-Harris
Drug Amendments in 1962 marks the “pivotal event that triggered the current drug reclas-
sification process” (Gossel 1991; Rosenau 1994). Its overriding aim was to tighten control
- manufacturers now had to prove not only safety, but also effectiveness, for the product’s
intended use (WSMI 2009).
Likewise, a respective philosophy underlies the classification rules of the European Commu-
nity. All medicines should be available without prescription unless they meet one of the
criteria included in Article 71 of the European Community Code (i.e., Article 71 of Directive
2001/83/EC) rendering their supply necessary to medical prescription (Stitching AESGP
Foundation 2002).
“Medicinal products shall be subjected to medical prescription where they
1. are likely to present a danger either directly or indirectly, even when used correctly, if
utilized without medical supervision, or
2. are frequently and to a very wide extent used incorrectly, and as a result are likely to
present a danger to human health, or
3. contain substances or preparations thereof the activity and/or side effects of which
require further investigation, or are normally prescribed by a doctor to be administered
parenterally.”
The statutory premise that drugs are prescription by exception (Soller 2002) is hence at the
core of both EU and US legislative approaches.
2.1.1 The Rx-to-OTC switch movement
The early reclassification movement dates back to the 1950s when paracetamol was switched
from prescription to nonprescription status, resulting in a long record of safety with respect
to usage in self-medication today (WSMI 2009). The modern era of switch was set off in 1984
with the switch of ibuprofen in the US, challenging aspirin as the hitherto predominant non-
steroidal anti-inflammatory drug (NSAID) available OTC. This was succeeded by a number
of reclassifications of substances or drugs suited for the treatment of easily recognizable, self-
limiting and self-manageable acute conditions traditionally being part of the self-medication
arena. In the following, the upcoming global “megatrend” of a heightened health, well-
ness and beauty consciousness is commonly seen as catalyst (CHPA 2000; Stitching AESGP
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Foundation 2002). At the same time, benefits associated with the upcoming reclassification
movement, such as the empowerment of the individual with wider and convenient access to
novel self-care therapeutics, the possibility of the pharmaceutical industry to enhance prof-
itability, and - what is of major importance - substantial cost savings to healthcare systems,
fostered the further development of the Rx-to-OTC switch process (Soller 1998). As a result
of growing confidence of the public and opinion leaders in health and health management,
medicines already available OTC for distinct conditions (e.g., hydrocortisone for contact
dermatitis) were proposed for deregulation, further indications (such as eczema), and longer
term use (Bond 2008). On the other hand, more effective therapeutic options established in
prescription setting were suggested to be released to nonprescription status for the treatment
of traditional, well-established OTC indications (e.g., H2-blockers or PPIs for the treatment
of heartburn). Today, these two “streams” of switch movement have consequently resulted
in the switch of both former Rx drugs as well as indications which tend to be more and more
complex and (semi-)chronic in nature (Stitching AESGP Foundation 2002; WSMI 2009) (cf.
also Figure 1 and Section 2.4).
Figure 1: Development of the Rx-to-OTC movement: widening of the traditional
self-medication arena from minor, self-limiting conditions towards the prevention
and self-management of chronic conditions by increasing the number of Rx-to-
OTC switches of both drugs and indications (from Bond 2008)
In Europe the scope of conditions deemed suitable for self-treatment without medical
direction, including “mild to moderate pain”, “cough and cold”, “constipation” , and minor
skin problems, was quite limited until 1980. However, similar to the US, cultural and politi-
cal changes based on patients’ shift in their attitude towards health management resulted in
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a growing desire to take responsibility for their own health since then seem to have brought
about a “new OTC paradigm” (Shiffman 2008).
Of note, according to Rosenau who dealt with the evolution of self-care as a whole, “the
switch movement has resulted in a substantial, but as yet unrecognized, modification of the
implicit definition of prescription drugs. The Rx designation no longer signifies that a drug
is inherently unsafe, potentially toxic, or harmful except when used under [medical] super-
vision [. . . ]. Increasingly, it indicates a preliminary trial status, necessary until experience
accumulates and an estimate of benefit-to-risk can be established, at which point the drug
can be switched OTC” (Rosenau 1994). Moreover, the continued efforts to identify the in-
formational needs of the general public and HCPs alike, as well as to detect and examine
potential new areas for self-treatment to expand the range of self-manageable conditions
clearly account for the globally growing importance of the Rx-to-OTC switch movement
today.
2.1.2 Definition of “Rx-to-OTC switch”
As can be deduced from the aforementioned, the term “Rx-to-OTC switch” relates to the
process of transferring proven prescription drugs (Rx) to nonprescription, so-called over-the-
counter (OTC) status. Mahecha describes the US Food and Drug Administration’s (FDA)
definition of an Rx-to-OTC switch as “over-the-counter (OTC) marketing of a drug product
that was once a prescription (Rx) drug for the same indication, with the same strength, dose,
duration of use, dosage form, population, and route of administration” (Mahecha 2006). In
most cases, however, due to the absence of control by a physician, the OTC indication,
population, as well as duration of use, etc. are of a narrower and more restrictive scope as
compared to Rx.
2.2 The rationale for Rx-to-OTC switches
In light of the complex nature of the prescription to nonprescription reclassification process
and the fact that there are many stakeholders involved, there is certainly no single “one-size-
fits-all” rationale for Rx-to-OTC switches. The driving forces behind switches are rather
diverse and multifactorial as well as depending on potential benefits implied by a specific
switch for the various advocacy groups affected.
Outside the pharmaceutical industry sector the most important intrinsic driving force be-
hind the Rx-to-OTC switch movement is probably embedded in the ever prevailing need for
the implementation of cost-containment measures and the wish to transfer drug distribu-
tion costs from the government to the individual consumer (Bond 2008). Multiple economic
analyses of Rx-to-OTC switches demonstrated overall cost savings to the health care system
by shifting parts of these costs “from the public purse to the private” (Aronson 2009; Soller
1998; Sullivan 2005). The economic impact on different players in this system, however, has
been discussed controversially.
The trend towards deregulation of prescription medications through switch to nonprescrip-
tion status has also been supported by a fair part of the pharmacy profession. Thus providing
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the possibility for these professionals to prove their skills based on a larger range of effective
treatments for patients as well as - depending on the individual situation – providing further
economic opportunities (Bond 2008; Gossel 1991).
Historically, the predominant party initiating the switch of a certain ingredient or drug
product from Rx to OTC classification has been placed in the ranks of the pharmaceuti-
cal industry. In her analysis of the characteristics of Rx-to-OTC switch processes Mahecha
argues that the motivation of a pharmaceutical manufacturer is mainly based on strategic
reasons regarding drug product sales in the context of life-cycle-management (cf. Figure
2), the defense of generic competition after Rx patent expiration or the enlargement and
growth of an OTC drug portfolio in response to consumer needs and demands for innovative
self-medication products (Gossel 1991; Mahecha 2006; Pawaskar 2007). In doing so, “fos-
tering self-reliance and enhancing consumer choice without compromising the consumer’s
safety and economic well-being [should] stand as the guiding values for the switch evaluation
process” (Stitching AESGP Foundation 2002).
Time
Sales
Product launch Patent expiry
OTC sales of product
Rx sales of product
Opportunity for Rx-to-OTC switch
Figure 2: Life-cycle of a pharmaceutical product with and without reclassifica-
tion from prescription to nonprescription (i.e., OTC) status (based on Bradley
1998)
Furthermore, Palumbo mentions the interesting fact that in countries with an accordant
institutionalized health system, the option to reclassify drug products enables them to “vir-
tually eliminate the specter of third party payer constraints” making certain restrictions
disappear (Palumbo 1991), such as, for example, national price regulations, as well as rebate
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contract, and/or reimbursement issues (if applicable) (Enns et al. 2011).
Based on the preceding arguments it is, thus, not astonishing that almost all of the top-
selling OTC drugs once have been switched from prescription status (Burstein 1994; Soller
1998). In fact, in the US, for example, Rx-to-OTC switch products account for about 50 %
of all OTC sales with some of them building up a completely new self-medication category
previously not available to consumers (e.g., smoking cessation aids or treatments for hair
re-growth) (Mahecha 2006). Likewise, in Europe eight of the top twenty brands are by now
the result of product switches (Tisman 2010).
2.3 Implications of the Rx-to-OTC switch movement
The reclassification of a drug and/or its corresponding indication is associated with a multi-
tude of benefits, but also risks affecting not only the general public as the major user of the
switched products, but also other institutions involved, such as HCPs like pharmacists and
doctors, health insurance companies, managed care organizations (MCOs), and last but not
least the government represented by its accordant authorities.
The impact of the Rx-to-OTC switch movement on the various advocacy groups involved has
been studied in a multiplicity of analyses. Deep insight into the way and extent to how dif-
ferent stakeholders are impacted by individual Rx-to-OTC switches is of major importance
for the understanding of practical implications and potential resistance to certain reclassifi-
cation proposals. However, as such an evaluation is not at the focus of the present work, the
following chapters give a rather short overview of the benefits and risks generally associated
with the Rx-to-OTC switch movement and briefly discuss its overall social, political and
economic consequences without providing an in-depth analysis.
2.3.1 General benefits and risks
Above all, the evolution of the Rx-to-OTC switch movement has provided hundreds of mil-
lions of consumers all over the world with a wider and more convenient access to a steadily
increasing range of appropriate treatment options in self-medication. The importance of this
empowerment of individuals in managing their own health with new switch-derived self-care
choices (Soller 1998; Soller 1999) will increase even more with the necessity of the prevention
of an emerging “global epidemic of chronic non-communicable diseases” (WSMI 2009).
Furthermore, the OTC availability of a wide range of treatment options offers consumers
the opportunity to save costs and time by allowing them to directly self-treat common and
troublesome conditions with easily recognizable symptoms without having to wait for a doc-
tor’s advice (AESGP 2004; CHPA 2000; Stitching AESGP Foundation 2002). A reduced
time interval from onset of symptoms to treatment is particularly crucial for time-critical
products like, for example, emergency hormonal contraception (EHC) which is most effective
when taken without much delay (WSMI 2009).
Moreover, as mentioned before, overall benefits actually not only accrue to the individual,
but to the society as a whole by considerably decreasing overall expenses of social security
and national healthcare costs thus allowing better allocation of limited healthcare resources
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and physician’s time to relevant matters beyond the scope of self-care (AESGP 2004; CHPA
2000; Stitching AESGP Foundation 2002).
Finally, as it is stated in the World Health’s Organization’s (WHO) principal guidelines on
nonprescription medicines, a wider availability of nonprescription medicines is considered
an effective tool for the reduction of the widespread major problem of self-medication with
prescription drugs (WHO 2000).
Apart from the benefits described above, a comprehensive analysis and evaluation of the Rx-
to-OTC switch movement should also contain a critical examination of potential risks and
disadvantages associated with the reclassification of drugs. Importantly, the usage of OTC
drugs heavily depends and relies on consumers’ ability to appropriately self-diagnose and self-
treat (Pawaskar 2007; Stitching AESGP Foundation 2002). In general, greater accessibility
to self-medication lacking medical supervision harbors dangers and risks of incorrect use, a
delay of diagnosis, and/or masking underlying serious conditions and thus the potential for
causing individual harm (Brass 2001; Ferner 2008; Pawaskar 2007). Appropriate strategies
for tackling these potential risks should continuously be developed (Ferner 2008). This is of
major importance especially in light of emerging evidence that the public no longer assigns
the same amount of respect to the potency of an OTC drug as compared to an Rx drug (see
also Subsection 3.5.3). In the UK, for example, potential risks or dangers of nonprescription
medicines seem to be disregarded by consumers in favor of their benefits due to the “widely
held belief that regulatory authorities would not allow ‘dangerous’ medicines to be available
from the community pharmacy” (Gilbert et al. 2006). Consequently, there are legal provi-
sions and means in place enabling an Rx-to-OTC switch decision to be eventually reversed
(see Subsection 3.5.2).
Moreover, in terms of costs, contrary to what is mentioned above, some critics refer to
studies showing that the costs of switches might outweigh the benefits – citing consumers’
out-of-pocket costs for OTC drugs and costs which could derive from inappropriate use of
self-medication (Pawaskar 2007). A detailed analysis of the economic impact of Rx-to-OTC
switches is yet always to be put into perspective in terms of overall healthcare costs. This is
not within the scope of the present thesis, but has repeatedly been addressed elsewhere (see
for example Carlsten 1996; Cohen 2005a; Keeler 2002; Russell 1988; Ryan 1990).
2.3.2 Impact on different stakeholders
The impact of the Rx-to-OTC switch movement on various stakeholders affected in terms of
assumed benefits and potential negative effects is briefly described below and summarized
in Figure 3.
Regulatory Authorities In terms of switching from prescription to nonprescription status,
the main challenge of regulatory authorities is, without doubt, to strike a balance between
the benefits of an enlarged choice of medications for self-treatment and a potential harm to
public health on account of unsupervised or inappropriate use (Ferner 2008; WSMI 2009).
Risk aversion and public health guarantee are of utmost priority. Given the increasing
number of complex switches, there is an obvious need to create new research tools for the
16 Chapter 2 - The Rx-to-OTC switch movement
support of regulatory decision making - a mainly data-driven process - as well as to increase
and ensure adequate know-how on the part of authorities in order to provide better ante-
approval understanding of the anticipated OTC usage patterns.
Besides the potential gain in scope of action for the science of regulatory decision making,
authorities may also benefit from the application of lessons learned on relevant aspects of
switch products (e.g., labeling, etc.), in turn leading to a continued development of tools
ensuring a consumer-friendly and safe intake of OTC drugs.
Finally, the necessity of multiple stakeholder involvement and close industry co-operation
within the reclassification process is likely to contribute to a continual improvement of the
drug approval process ideally complying with the industry’s desire for maximal consistency
and transparency (Soller 1998).
Against this background, it is of interest that contrary to the well-established traditional
approach of manufacturers being the driving forces behind switch applications, the US Food
and Drug Administration is about to explore its legal authority to initiate switches of drugs it
assumes suitable for OTC, thereby relying on foreign data if these drugs are already available
OTC outside the US (Cohen 2005a).
Consumers/Patients Overall, consumers/patients seem to be very satisfied with the evo-
lution and nature of the OTC sector. According to a survey conducted for the Consumer
Healthcare Products Association (CHPA) in the US in 1992, 92 % are satisfied with the med-
ication they have used for self-care (CHPA 2000; Pawaskar 2007). In addition to improved
and timely accessibility and positive convenience aspects mentioned before (see Subsection
2.3.1), a UK survey has identified four factors for patients favoring to buy OTC drugs: pref-
erence for OTC purchase, knowledge of OTC availability of products, prescription charge
liability status, and no current use of other prescribed medicines (Gilbert et al. 2006). Nev-
ertheless, potential hazards of ab-/misuse or masking of underlying diseases have to be taken
into account as drug-associated consumer/patient risks that are largely inherent to the nature
of self-medication.
Pharmacists Based on the national distinctions in the availability of nonprescription
medicines (see also Section 3.1), the role of pharmacists significantly differs among the var-
ious healthcare systems throughout the world. In countries where many OTC drugs are
available only from “behind-the-counter” (BTC) (as is the case, for example, in Germany,
most of the other European countries, as well as in a few countries outside the EU), phar-
macists generally provide assistance by consulting consumers on the proper choice and use
of OTC drugs thereby functioning as “pharmacy class comfort-zone” (Hemwall 2010) in
terms of medical advocates for self-care practices. On the contrary, this active counseling
role seems to take a back seat in countries where the majority of OTC drugs are available
from general stores such as the US, for instance. In that case appropriate pack sizes, as well
as easy-to-understand drug labeling, among other factors display key elements of consumer
and/or patient guidance (Palumbo 1991).
In any event, the continued switch of therapeutic options more and more complex in na-
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ture will enhance the necessity of pharmacists in customer education (Palumbo 1991), an
idea commonly well appreciated as it enables them to make better use of their professional
skills and expand their competence in the field of healthcare (Bond 2008; Ferner 2008).
Rx-to-OTC switches offering the opportunity to recommend effective and affordable OTC
treatments for a wide range of common diseases may frequently be seen as a “vehicle for
achieving recognition and compensation for associated increased responsibilities” (Rosenau
1994). Certainly, the expansion of pharmacists’ field of activity likewise supports an en-
hanced responsibility in their role as safeguards of public health (Juhl 1998). Appropriate
materials such as disease specific protocols or questionnaires for counseling and educational
support of patients in managing or preventing complex and chronic conditions might con-
tribute to pharmacists’ future performance (Stitching AESGP Foundation 2002; Wechsler
2000) and are already used and tested in some progressive countries, such as the UK (CHP
Canada 2010; Hemwall 2010; MISG 2010).
Interestingly, in his forecast of the prospective task of pharmacists against the background
of an advancing Rx-to-OTC switch movement from 1985, Schondelmeyer already viewed
the “pharmacists of the future” in a differentiated and more specialized role. Next to their
traditional duty of counseling consumers as a primary source of information and advice,
Schondelmeyer envisioned pharmacists as key contributors to pharmacovigilance as he con-
sidered the outcome of an individual drug therapy scheme rather than drug products being
central to patients’ and pharmacists’ focus (Schondelmeyer 1985).
Rx-to-OTC switches, hence, offer pharmacists the chance to demonstrate their ability and
the need to assist in the use of cost-effective OTC drug therapy. “Professional pharmacy
bodies have played a key role in the deregulation process which [contributes] to the paradigm
shift of community pharmacists from a technical, supply oriented role to a more clinical, cog-
nitive [counseling] role” (Bond 2008). Their willingness to more fully utilize their profession
in an integrated health care service has been demonstrated and recognized in UK Govern-
ment policy papers, for example (Bond 2008). Yet, unless pharmacists take advantage of
the opportunities provided, there is a certain risk that they will be “left completely out of
the loop” (Palumbo 1991).
Physicians In her critical analysis of a switch’s impact on the medical profession, Byrns
shed a light on physicians’ point of view from both the public health and individual patient
perspectives (Byrns 1998). Physicians generally seem to support OTC drugs as a class, in-
cluding those switched from Rx status, with a view towards wider availability and access to
pharmaceuticals for appropriate self-treatment. The reduced number of patients with minor
and trivial complaints will leave more time for the treatment of patients with serious medical
conditions (Ferner 2008).
Nonetheless, concerns are raised by physicians especially with regards to potential risks
associated with OTC usage in general and with usage by special populations, such as chil-
dren or the elderly, in particular. Another crucial element omitted with self-medication is
the close relationship between patients and their doctors who offer medical guidance and
supervision on medications and their intake, which may also be required for OTC drugs.
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Tracking of OTC drugs may become increasingly difficult, as these are not tracked by most
pharmacy systems and patients often are not asked specifically about the use of such drugs
when medical and drug histories are recorded (Brass 2001). Many caveats are addressed by
the American Medical Association (AMA) which is, for instance, working on: clear labeling
requirements for OTC drugs, disease management, and patient education programs encom-
passing OTC drug usage, and the need for special provisions of OTC drugs for medically
indigent populations. Against this background, there has been discussion about the loss of
control perceived by physicians as a result of change to their supervisory role. As patients
rely consistently more on OTC products for initial therapy, they will present to physicians,
if at all, only late in the course of their illness.
In conclusion, from the physicians’ point of view adequate criteria for switch drugs would
have to be established in an individualized approach, and based on the collaboration of the
pharmaceutical industry, authorities, and HCPs. Pharmacists are considered as important
advisors and gatekeepers in the selection of OTC medication in this approach (Byrns 1998).
Industry Overall, the increasing number of Rx-to-OTC switches has a mainly positive
impact on the pharmaceutical industry. When an Rx drug product approaches patent expi-
ration manufacturers often use switching as a kind of life-cycle instrument that, in theory,
enables them to enlarge their targeted consumer groups and revenue by gaining a foothold
in the market ahead of generic competition (Bond 2008; Cohen 2005b; Creyer 2001; Eu-
romonitor International 2010; Harrington and Shepherd 2002; Pray 2008; Stitching AESGP
Foundation 2002). Ideally, this in turn allows companies to intensify their research and de-
velopment activities in specialist fields of medical research (e.g., diabetes, cancer, etc.).
In addition, by providing greater and easier access to their products, pharmaceutical en-
trepreneurs might strengthen their brand recognition and contribute to an increased aware-
ness of widespread diseases by providing therapeutic and preventive, risk-lowering treatment
options suitable for self-medication and self-management (Euromonitor International 2010).
However, with more and more drugs being switched to nonprescription status and used with-
out medical supervision, regulations for OTC drugs are about to get much stricter largely
owing to safety reasons. In this regard, it is also estimated that the demand for improved
safety and efficacy/effectiveness studies justifying a drug’s usage in self-medication will aug-
ment (Euromonitor International 2010).
Healthcare system: third party payers Third party payers, represented mainly by health
insurance companies and MCOs, such as health maintenance organizations (HMOs), benefit
from savings on Rx drug reimbursements eventually replaced by mostly uncovered OTC
drugs and, hence, from shifting costs to the private purse of patients (Rosenau 1994; Wechsler
2000). Additionally, the switch movement will ultimately reduce the volume of doctor visits
due to easy access to a wider range of self-treatment options. This will certainly help
cut costs by reducing the amount of reimbursement, at least in a short-term perspective
(Pawaskar 2007; Rosenau 1994; Soller 1998). Within this context, the US Rx-to-OTC switch
application of the antihistamine products Claritin
®
(active ingredient: loratadine), Allegra
®
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(fexofenadine), and Zyrtec
®
(cetirizine) in 1998, at a time when these were still under patent,
was unprecedented and groundbreaking. It was the first switch petitioned and initiated by
a 3rd party payer, namely WellPoint Health Systems (health insurer), aiming at a better
control and potential reduction of their immense healthcare expenditures (Pawaskar 2007;
Spencer 2002; Wechsler 2000). As first member of its class, loratadine has been approved by
the FDA and made available OTC in 2002 after patent expiration (Cohen 2005a).
On the other hand, however, it has to be borne in mind, that these short-term cost savings
might be offset over the long-term on the occasion of serious safety problems by reason of
inappropriate use, severe adverse events or suboptimal therapy (Brass 2001). This might
eventually result in an increase in doctor visits or even hospitalization associated with a
dramatic rise in healthcare expenditures (Pawaskar 2007; Rosenau 1994). In fact, “payers
are struggling to determine the best policy to address issues associated with the switched
medications”.
The overall effect of moving prescription medications to nonprescription status on health
plans and third party payers is as complex as the interactions of the various stakeholders
who are a part of this process. Next to distinct characteristics of the various national health
plans, specific conditions of a certain switch (i.e., dosage strength, formulation, etc.) as well
as respective behaviors of physicians, pharmacists, and patients affected seem to be of great
importance (Rosenau 1994).
2.4 Current trends in the Rx-to-OTC switch movement
There are several factors of influence that have to be highlighted in a larger societal context
when it comes to current trends in the Rx-to-OTC swtich movement.
First of all, as previously mentioned (see Subsection 2.1.1), the heightened health conscious-
ness among the general population has become a global “megatrend” bringing forth an
enhanced desire of individual responsibility for self-health management (CHPA 2000; Hoy
1994). The explosion of information access is another megatrend, with the internet as a
growing source of health information (CHP Canada 2010; CHPA 2000) which has in large
part contributed to the medical education of a certain proactive population segment. This
segment is characterized by higher levels of education, income, and “consumer sophistica-
tion”, also termed “Do-IT-Yourself (DIY) Health Care Consumers” (Hoy 1994). Moreover,
aging societies account for rising healthcare cost pressures. A globally increasing number of
chronic diseases and disabilities as well as more retirees per workers provoke greater cost pres-
sures not only on national health economies, but also on societies in general (CHP Canada
2010).
A shift in targeted OTC indications and corresponding medication from the acute treatment
of easily recognizable, minor ailments towards focusing on the prevention and treatment of
chronic, possibly asymptomatic illnesses is one approach in tackling the emerging public
health threat of chronic diseases through empowering people to take better care and con-
trol of their own health. Switching appropriate medications to OTC within the context of
comprehensive switch programs can help modify and control primary risk factors underlying
major non-communicable chronic diseases (WSMI 2009).
20 Chapter 2 - The Rx-to-OTC switch movement
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•Accelerated treatment access to a 
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•Increased convenience
(-)
•Ab-/Misuse
•Masking of underlying serious
diseases (delayed diagnosis)
Rx-to-OTC 
movement
Physicians
(+)
•Less patients with minor complaints
•More time for seriously ill patients
(-)
•Concerns regarding risks of OTC use
•OTC drugs difficult to track
•Perceived loss of control
Third party payers
(+)
•Less Rx drug reimbursements (at
least short-term)
•Less doctor visists for minor illnesses
(-)
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care based on serious safety prob-
lems by reason of inappropriate use
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Industry
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•Stricter regulations on OTC drugs
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Regulatory authorities
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Figure 3: Implications of the Rx-to-OTC switch movement on various stakehold-
ers
In order to identify new areas for switch that might fit into the above mentioned approach,
in 2001 an AESGP task force developed a tool to review indications or conditions that might
come into consideration for a possible expansion of self-medication in the future (Stitching
AESGP Foundation 2002; WSMI 2009). One output was a chart mapping both the range of
indications currently suitable for OTC and other indications under consideration according
to two dimensions. One dimension encompasses various forms and stages of medical man-
agement ranging from self-diagnosis and self-management to doctor consultation, other HCP
advice, and patient self-management with or without medical devices. The other dimension
is to display the duration of drug usage and type of condition – that is, short-term/acute,
recurrent/semi-chronic, and long-term/chronic (see Figure 4). The indications placed in the
top half thereby represent indications of the traditional self-medication arena. The ones lo-
cated in the bottom left emanate from the concept of a so-called “collaborative care setting”
where a doctor initially establishes a medical diagnosis and recurrent symptoms are recog-
nized by patients and treated with OTC drugs under pharmacists’ advice – an approach
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realized in some cases in the UK, for example. New indications which were suitable but not
yet available for self-treatment at that time2 are mapped in the bottom right. They were
considered as potential candidates for self-treatment, e.g., in a collaborative care setting,
after clarification of additional questions regarding:
 type of illness (stable vs. life-threatening condition),
 disease management: self-monitoring and self-treatment of asymptomatic diseases,
treatment regimen (simple vs. dose titration), patient compliance.
Figure 4: Map developed by a task force of the AESGP in 2001 for identification
of potential new areas for self-medication (from Stitching AESGP Foundation
2002)
In summary, the intention to expand the traditional self-care arena in a consumer-/
patient-centered approach should be regarded as a major outcome of this project. Self-
medication, hence, leaves the path of mere symptomatic treatment of self-limiting condi-
tions and is increasingly directed towards the prevention and treatment of more complex,
2 Nowadays some of them are already available OTC in selected countries.
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often asymptomatic chronic disease states. A major challenge in this arena of looser med-
ical direction will surely be the development of a “one-size-fits-all” approach to achieve a
population based benefit (Hemwall 2010). The working group agreed that a potential public
benefit of better management of chronic and symptomless conditions will largely depend on
the collaborative work of HCPs, patients and other stakeholders as well as the provision of
comprehensive training material and high-quality information with respect to the conditions
envisaged. Of course, it has to be recognized that each potential switch is accompanied by
specific questions which will be addressed in miscellaneous ways by the various countries
concerned as they all differ in terms of specific healthcare characteristics such as patient
information and HCP support (Stitching AESGP Foundation 2002; WSMI 2009).
As depicted by Cohen, et al., a similar tendency to the one described above is to be found
in the US. “For patients, the trend towards more switches will take self-care to a new level,
focused increasingly on chronic prevention of serious illnesses”. This movement seems to be
accompanied by important regulatory changes: the FDA consistently evaluates the poten-
tial of OTC status for certain drugs treating chronic conditions thus enlarging the range and
number of medications available for self-treatment (Cohen 2005a).
2.4.1 Switch in support of better healthcare behaviors
First of all, effective and responsible treatment with nonprescription medicines not only en-
ables citizens to control and manage their own health situation, but may also help raise
awareness for certain conditions which formerly caused sufferers not to seek medical treat-
ment due to embarrassment about their situation.
As an example, “urge incontinence” (also known as “overactive bladder”) fits in this category
of conditions that people often are afraid of disclosing and hence present very late to the
doctor. Several studies show that more than 70 % of those with current urinary incontinence
do not tell any healthcare provider and health practitioners are asked about the condition
spontaneously only in 18 % of visits (Hemwall 2010; Soller 2002). In men, the prevalence of
urge incontinence is assumed to be quite high (73 %) and so is the impact on patients’ qual-
ity of life (QoL) (Stitching AESGP Foundation 2002). Experts agree that urge incontinence
constitutes an OTC manageable condition and should be brought to the self-medication area
as it could effectively contribute to the reduction of the large number of “silent sufferers”.
Broad information campaigns could point out that there is something available that can
help already at an early stage of the condition. Moreover, the condition has proven to be
self-recognizable and citizens usually are able to clearly differentiate between “urge” and less
common “stress” incontinence (urine leakage when laughing, coughing or sneezing). Besides,
a potential delay in its diagnosis and treatment is far from life-threatening.
Furthermore, there is a growing need for prevention and treatment of (semi-)chronic diseases
and associated risk factors which has also been addressed by the WHO: “Without action, an
estimated 388 million people will die from chronic diseases in the next ten years. [...] Each
of us has a choice: whether to continue with the status quo, or to take up the challenge
and invest now in chronic disease prevention” (WHO 2005). As already mentioned above,
the majority of these chronic diseases are associated with a set of common, modifiable risk
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factors whose minimization or optimization, respectively, should be paramount to each of a
society’s individuals.
Tobacco use, obesity, or raised cholesterol levels are probably the most prominent examples
of these risk factors. Easily accessible OTC medication targeting their modification can cer-
tainly help them be tackled by empowering, but at the same time pledging people to look
after themselves. Tobacco use is one of the leading preventable causes of death throughout
the world (Shiffman 2008) and so are obesity and raised cholesterol levels – all eventually
bringing forward long-term disease states like hypertension, coronary heart disease (CHD),
diabetes, and at worst premature death (WSMI 2009).
In some countries drugs aimed at the management of the aforementioned risk factors are al-
ready available OTC, yet there are still a number of countries where they are not, often due
not only to safety concerns, but also political reasons. Nicotine replacement therapy (NRT),
for example, has already been widely used in self-medication and has shown a considerable
rate of success. In his ten-year evaluation of the US NRT switch to OTC Shiffman sets the
associated increase of NRT users, i.e. potential former smokers, at a remarkable 152 % - a
safe and at the same time cost-effective approach to reduce tobacco dependence (Shiffman
2008). Self-medication with orlistat as first licensed therapeutic option for weight loss is now
also possible in many European countries as it was approved by the European Medicines
Agency (EMA) in 2009 as the first ever centralized switch (q.v. Subsection 3.5.1). Despite
controversial opinions, simvastatin was reclassified as the first member of the statin class to
a “pharmacy-only” (P) drug in the UK in 2004. It is provided to people at moderate risk of
getting a heart attack within the next ten years for the reduction of their cholesterol levels
upon comprehensive counseling by a pharmacist (cf. also Subsection 3.5.1).
All in all, switching drugs with an adequately established safety and efficacy profile from
prescription to nonprescription status might significantly contribute to the improvement of
individual self-care behavior, benefiting not only individuals but also public health by raising
awareness of certain conditions and the importance of early treatment and prevention.
2.5 Summary and conclusion
Historically, the Rx-to-OTC switch movement is to be seen as a result of cultural, social,
and political influences and developments. The reclassification of a growing number of med-
ications from prescription to nonprescription status has contributed to coping with patients’
increasing demand for self-empowerment in the face of growing public health consciousness.
In general, implications on various stakeholders are multifaceted, resulting in an overall bene-
fit for public health provided that the respective switch candidate turns out to be appropriate
for safe and effective self-medication.
However, the development of the Rx-to-OTC switch movement indicates that the time of
more or less “simple” switch projects targeting acute, minor, and self-limiting diseases seems
to have come to maturity, thus, giving rise to a trend towards increasingly complex switches
involving the prevention or treatment of (semi-)chronic diseases or associated risk factors.
According to the author, this trend should be seized as an opportunity to further raise
people’s disease awareness and their sense of proactive responsibility for their individual
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health status both of which are indispensable preconditions in view of the increasingly bur-
dened health systems’ ability to persist in the long run. Against this background, the author
believes that it will be important and valuable to further encourage and foster innovative Rx-
to-OTC switches presupposing that benefits outweigh risks and the latter are to be managed
accordingly.
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3 The Rx-to-OTC switch process: legal basics, regulatory re-
quirements, and prominent examples
The following chapter will give a short overview of legal and regulatory basic conditions and
prerequisites related to the Rx-to-OTC reclassification process as well as point out to some
noteworthy examples.
3.1 Legal classification of medicinal products
The availability of prescription and nonprescription products strongly differs all over the
world depending on the various legal classification systems. Several influencing factors have
been identified in this regard such as a nation’s economic orientation, wealth, traditions
and political system (Gilbert et al. 2006). In the US, for example, there are two major
classes of drugs, namely prescription and nonprescription. Evidently, prescription drugs
are only available with prescription from qualified prescribers such as doctors, dentists or
supplementary prescribers. On the contrary, apart from few exemptions which are only
available from behind the pharmacy counter, most OTC drugs can be purchased in any
convenience or grocery store without HCP intervention. Other national healthcare systems
(e.g., Australia, New Zealand, and the EU countries of Finland, Sweden, France, Germany,
and the UK) have introduced nonprescription subcategories. A so-called “pharmacist-only”
or “behind-the-counter” class requiring pharmacist assistance next to a “pharmacy-only” or
“pharmacy self-selection” class, e.g., are available in Australia, New Zealand and Canada in
addition to the “general sale” of OTC products through any retail outlet (where applicable)
(Gilbert et al. 2006; Palumbo 1991; WSMI 2009). The UK, for example, allows for three
legitimate means to obtain licensed medicines: prescription-only medicines (POM) from
qualified prescribers, pharmacy-only (P) medicines without a prescription under supervision
of a qualified pharmacist, and general sales list (GSL) medicines without a prescription
avalable from, for instance, a pharmacy or a convenience/grocery store (Aronson 2009).
Moreover, “new technology has allowed a new range of outlets including online sales and
catalog ordering” (Elder 2013). In a wider context, the term “switch” refers to changing
any status of classification, that is, next to the switch from prescription to nonprescription
status it may also apply to the switch from P to GSL status provided that these categories
exist in the respective countries. However, in the present work the term is exclusively used
to refer to a switch from Rx to OTC classification.
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3.2 Switch criteria
A brief overview of the criteria to be addressed and fulfilled in a sufficient way for successfully
change a drug’s legal status from Rx to OTC will be given below.
3.2.1 Evolution of regulatory criteria for switching a medicinal product from prescription
to nonprescription status
Building the basis for the scientific/medical and regulatory decision making process that
determines OTC status, common regulatory switch criteria still valid today have evolved
during the OTC Review process from the fundamental definitions of safety, effectiveness,
and labeling as well as the requirement for a risk-benefit analysis (Soller 2002). In partic-
ular, these definitions authorized safety and effectiveness in relative terms, meaning “a low
incidence of side effects, a low potential for abuse and a reasonable expectation of effective-
ness in the target population under conditions of intended use” (Soller 2002). Furthermore,
the demonstration that the label is written for consumers/patients and ensures safe and
effective product use (CHPA 2000) is viewed as a foundational statutory criterion for OTC
availability. The label of an Rx-to-OTC switch candidate must provide “adequate directions
for use” as it acts as direct intermediary between consumers/patients and the drug with the
physician and the pharmacist (at least partly) left out of the loop (Juhl 1998).
Based on these regulatory principles, in 1989 US FDA’s Center for Drug Evaluation and
Research (CDER) issued, for the first time, a public industry guidance list of 13 criteria for
switching drugs from prescription to nonprescription status, also known as “Peck’s Princi-
ples” (see Table 1). However, in contrast to today’s state-of-the-art criteria, these funda-
mentals primarily focus on the switch candidate itself and do not include current refinements
additionally emphasizing the condition, consumer/patient understanding of product use, and
conditions of actual use (Soller 2002).
Again in the US, with the approval of a number of switches and based on OTC post-
marketing experience, the perspective of switch criteria has gradually changed entailing the
publication of a renewed set of state-of-the-art principles by Dr. Robert DeLap (“DeLap’s
Principles”, see Table 3) in 1998. In addition to the criteria referring to the switch candi-
date itself, these renewed principles reflect the emphasis on patients’ correct self-diagnosis,
label comprehension, and actual use (Soller 2002). On these grounds adequate OTC label-
ing designed for and tested by “average” consumers/patients is regarded as fundamental in
responsible self-medication since the outer packaging allows consumers/patients to quickly
and easily decide about the appropriateness of the medicine for their needs. In accordance
with this view, studies indicate that 96 % of consumers read the label of an OTC drug before
they first use it (Gossel 1991). Beyond that, the US OTC scientific/regulatory paradigm was
enriched by the introduction of “use-effectiveness studies” (i.e., so-called “actual use stud-
ies” (AUS)), in a simulated OTC setting, as “techniques to characterize the potential safety
and effectiveness of OTC ingredients” complementing more or less traditional effectiveness
studies such as well-controlled clinical trials (Soller 1999).
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Table 1: Switch principles elaborated by CDER Director Carl Peck, MD, at
the 1990 Annual CHPA Research and Scientific Development Conference (from
Soller 2002)
Peck’s “Switch Principles”
1. Does the switch candidate have special toxicity in its class?
2. Does the candidate have a large margin of safety?
3. Does the candidate’s frequency of dosing affect its safe use?
4. Has the candidate’s safety profile been defined at high dose?
5. Has the candidate been used for a sufficiently long time on the prescription market to enable a full
characterization of its safety profile?
6. What is the worldwide marketing experience of the switch candidate?
7. What foreign countries market the candidate OTC? What is its experience in those countries?
8. What do the “use data” show?
9. Has a vigorous risk analysis been performed?
10. Has the efficacy literature been reviewed in a way to support the expected usage and labeling of the switch
candidate?
11. Is there a full understanding of the pharmacy-dynamics of the switch candidate?
12. Is the minimally effective dose for the proposed OTC indication known?
13. Have possible drug interactions for the switch candidate been characterized?
Within the EU, criteria for classifying a medicinal product as subject to a medical pre-
scription or not, according to Articles 71 and 72 of the European Community Code, are
itemized in the European switch guideline (“Guideline on changing the classification for the
supply of a medicinal product for human use”, see Section 3.3).
Yet, despite the above mentioned evolution of definite standard criteria for the eligibility of
drugs to be available without prescription, OTC status is hard to define in an ultimate way.
This allows evaluative regulatory agencies the most freedom of choice, but puts considerable
pressure on the pharmaceutical industry when deciding whether to pursue an OTC switch
or not (Burstein 1994).
3.2.2 Issues to be addressed to fulfill regulatory switch criteria
In order to fulfill the aforementioned switch criteria, both in the US and in Europe, basic
principles of toxicology, clinical pharmacology, and epidemiology have to be applied when pe-
titioning a switch of a certain substance or drug from prescription to nonprescription status.
Specifically, pharmaceutical companies are well-equipped to address the sorts of potential
issues that typically arise in the context of OTC availability. Issues to consider and address
by pharmaceutical companies in their switch application are summarized in Table 3.
Overall, today’s criteria for marketing a product classified as OTC are fairly rigorous on
principle (Gossel 1991), representing a solid regulatory/scientific foundation for the further
evolution of OTC drugs not only to prevent specific life-style conditions but also to treat
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Table 2: Switch principles elaborated by Robert DeLap, MD and Director of the
Office of Drug Evaluation V, at the 1998 CHPA Research and Scientific Develop-
ment Conference (from Soller 2002)
DeLap’s “Switch Principles”
Fundamentals:
1. Can the condition be adequately self-diagnosed?
2. Can the condition be successfully self-treated?
Points to consider:
1. Is there a need for physician evaluation of the condition?
2. What is the nature and severity of adverse effects of consumer misdiagnosis and delay in correct
diagnosis?
3. Regarding effective product use, what is the nature of consumer understanding of product use?
4. What is the consumer understanding of the expected benefit?
5. Does the consumer have the ability to assess treatment effect?
Safe product use:
1. What is the consumer understanding of product directions for safe use?
2. What is the consumer understanding of what to do if the product isn’t working?
3. What is the consumer ability to identify adverse effects and the consumer ability to determine when
adverse events may require professional care?
4. What is the consumer expectation of safety?
(semi-)chronic conditions and diseases. “The broader public health discussions on risk man-
agement of prescription pharmaceuticals will likely impact this process in a positive way,
if the focus of OTC risk management places the consumer at the center of pre- and post-
marketing assessments of drug safety and effectiveness, using a collaborative benefit/risk
co-management approach to self-care” (Soller 2002). Hence, the potential for further self-
care empowerment of consumers is based on a scientific paradigm which defines specific
target populations with readily recognizable conditions, previously diagnosed conditions or
self-diagnosable diseases, and determines which drugs, based on appropriate dosage and
labeling, can provide a reasonable expectation of benefit with a low potential for toxicity.
3.3 Switch procedures
As opposed to the basic switch criteria which generally tend to be the same in every country
(see also Subsection 3.2.1), switching procedures actually vary among different countries not
least due to individual governmental systems and leadership. In general, a case-by-case as-
sessment of a product or ingredient according to benefit/risk considerations, as depicted in
Subsection 3.2.1, should be at the core of the switch assessment process with issues such as
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Table 3: Issues to consider and address by pharmaceutical entrepreneurs when
filing an Rx-to-OTC switch application (based on CHPA 2000)
Fulfillment of regulatory switch criteria: toxicology, clinical pharmacology and epidemiology
1. Potential safety issues:
• toxicity:
– carcinogenicity
– reproductive toxicity
– side effects
• therapeutic hazards:
– misdiagnosis (self-selection, self-diagnosis)
– treatment failure (delayed professional treatment)
– incorrect use (long-term self-monitoring, overdose, misuse)
– drug interactions
2. Potential effectiveness issues, based on nature/severity of condition:
• choice of dose, dose interval, age restrictions, etc.
3. Ability of label to convey core communication objectives
4. Benefit/Risk assessment
reimbursement status or professional monopolies to be left out of a respective evaluation. On
all accounts, a well-grounded, transparent and comprehensible switch procedure is essential
for successful switch regulation (WSMI 2009).
In Europe, depending on the country concerned, different regulatory and/or legal parties as
well as expert groups are involved in a drug’s or ingredient’s, respectively, application for
reclassification.
In Germany, for example, the switch procedure is clearly determined in the German
Medicines Law (AMG): an “Expert Committee for the Classification of Medicines”enunciates
a recommendation while the final decision is incumbent on the legal Federal Ministry of
Health. It is important to note that reclassification processes in Germany, as well as in some
other European countries, usually are “class switches” meaning that they are ingredient-
related thus applying to all eligible products containing the respective ingredient in the
respective dosage for the respective indication. On the other hand, reclassification applica-
tions (e.g., in the UK) are evaluated by the national regulatory authority (Medicines and
Healthcare products Regulatory Agency (MHRA)) with advice from a suitable expert com-
mittee, expert advisory groups or, if applicable, even public consultations. Legal status is
changed based on a successful reclassification proposal. Yet, in contrast to the aforemen-
tioned German class switch, all other theoretically eligible products for reclassification with
the same active substance have to apply separately for a so-called “product switch”(WSMI
2009). At this time the latter procedure seems to be preferred in Europe as in most member
states reclassifications are grounded on a product basis (AESGP 2010).
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On a European level, the European Medicines Agency deals with a growing number of pan-
European switch applications for active ingredients or drugs aiming at a common legal and
regulatory basis for the same legal status in every European country (q.v. Section 3.4). When
assessing a reclassification request, the EMA is supported by the Committee for Medicinal
Products for Human Use (CHMP) which is engaged with benefit/risk assessments.
The main principles and criteria as well as specific data requirements to be delivered by
a marketing authorization holder (MAH) within Europe for an application to change the
classification for the supply of a medicinal product from Rx to OTC are outlined in the EU
“Guideline on changing the classification for the supply of a medicinal product for human
use” (European Commission 2006a). It was adopted in 1998 by the European Commission
for the sake of enhanced transparence and harmonization of switching conditions among Eu-
ropean countries. As an example of a supranational legal framework and political support,
the guideline came into effect on January 1st, 1999, and was last updated and amended in
2006 (WSMI 2009). In total, the guideline consists of five parts dealing with different aspects
to be fulfilled and considered, respectively, when applying for a switch (e.g., switch criteria,
data requirements, name of the medicinal product, etc.).
In particular, part three of the guideline addresses data exclusivity due to the fact that based
on Article 74a, Directive 2004/27/EC, the MAH is awarded one year of data exclusivity pro-
vided that the switch application contains “significant pre-clinical tests or clinical trials”.
However, in effect, information on interpretation and specification in terms of detailed re-
quirements is somewhat imprecise. Against this background, the present thesis focuses on
the substantiation, elaboration, and discussion of distinct criteria, data categories and re-
quirements potentially eligible for the grant of data exclusivity with the intention to make
current legal provisions more concrete and thus practically applicable (see Chapter 4 ff.).
3.4 Regulatory drug approval and switch strategies in Europe
From a strategic point of view, different scenarios for changing a drug’s and/or indication’s
classification status are possible. For example, a completely new authorization may be ap-
plied for if no OTC version has been available in the European Union so far. Alternatively,
the scope of an existing OTC product in a certain dosage and with a certain indication might
be enlarged by switching other/additional dosages or indications to OTC via the variation
of already existing authorizations. In any case, depending on the regulatory pre-conditions
of existing Rx or potentially OTC authorizations, the regulatory process of Rx to OTC re-
classification is often quite complex in nature.
In general, a medicinal product may only be placed on the market in the European
Union3 when a marketing authorization has been issued by the competent authority of a
member state for its own territory (a national authorization) or when an authorization has
been granted for the entire Community (a Community authorization) in accordance with
3 more precisely, in the European Economic Area (EEA) including Norway, Iceland and Liechtenstein
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effective legal requirements (i.e., Article 6, Directive 2001/83/EC, as amended4, and Article
3, Regulation (EC) No 726/2004).
With respect to the approval of a medicinal product5 in the EU, different routes may be
followed depending on the envisaged scope of merchandising: if the focus lays on marketing
and commercialization in one particular EU member state, the national application proce-
dure (as exemplarily briefly described above for Germany and UK, see Section 3.3) is to be
applied. It is reviewed and decided on by national authorities based on national require-
ments and guidelines. If a medicinal product is planned to be marketed under the same
conditions in several, or even all, European countries and hence approval across several or
all EU countries is necessary, three different ways of seeking approval have been established
since the latest review of the pharmaceutical legislation: approval via mutual recognition
procedure (MRP), decentralized procedure (DCP), or centralized procedure (CP) with the
two former being alternatives to the latter if this is not mandatory.
More specifically, the so-called “mutual recognition procedure” is to be followed in case the
medicinal product already possesses a marketing authorization in one EU member state.
“Mutual recognition” implies that EU countries may approve the decision made about the
approval of a medicinal product by another EU country. Hence, the procedure is based on
mutual recognition of national marketing authorizations (Medicines Agencies 2010).
In contrast, the decentralized procedure should be used for products that have not previ-
ously been approved in any member state (i.e., have not yet received authorization in an EU
country (Medicines Agencies 2010)).
An approval for a medicinal product intended for use in every EU member state simulta-
neously may be obtained by applying to the European Medicines Agency via centralized
procedure (q.v. also Section 3.3). Within the EMA, a scientific committee for human medic-
inal products composed of one representative of each member state, the CHMP prepares
an opinion preceding a formal approval by the Commission. The classification adopted by
“Community decision” has to then be followed by the member states to avoid the co-existence
of a central and national marketing authorization. As to eligibility for CP, so called “manda-
tory” and “optional” approval routes have to be differentiated. Article 3(1) and the Annex
of Regulation (EC) No 726/2004 define the mandatory scope of the CP as obligatory for a
selected group of medicinal products and new active substances, respectively (e.g., medicinal
products developed by means of biotechnological processes, medicinal products for human
use containing new substances for the treatment of certain diseases such as cancer, neuro-
degenerative, or auto-immune diseases or medicinal products designated as orphan drugs).
In contrast, the optional scope of the CP may apply in the following situations: according
to Article 3(2)(a) of Regulation (EC) No 726/2004 a medicinal product containing a new
active substance that has not previously been authorized in the Community qualifies for the
central procedure (i.e., will be “first in class”). Moreover, by virtue of Article 3(2)(b) of
Regulation (EC) No 726/2004 the proof that the envisaged medicinal product is innovative
4 i.e. Directive 2004/27/EC
5 either based on a new chemical entity (Rx or OTC) or on a substance with well-established use in a new combi-
nation or with significant innovations providing therapeutic benefit (e.g., new classification, new indication, new
pharmaceutical form, etc.)
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in nature (i.e., significant therapeutic, scientific or technical innovation, for example, intro-
ducing a new administration route or combination) or “in the interest of patients health at
Community level” is at the basis of this optional route. Finally, Recital 9 of Regulation (EC)
No 726/2004 allows for optional access to the CP “in cases where use of a single procedure
produces added value for the patient” thereby underpinning Article 3(2)(b).
As regards the choice of an appropriate Rx-to-OTC switch drug approval strategy, the-
oretically all of the above mentioned approval procedures are available depending on the
envisaged target markets for a certain switch candidate. Up to this point national switch
procedures have comprised the majority of OTC approvals in Europe (Senior 2010), although
with the huge drawback of extended review times and thus a long time until the marketing
authorization is finally issued (e.g., up to two years or even longer for Rx-to-OTC switch
approvals).
In contrast, specific challenges are to be overcome in the case of multinational switches, re-
garding the many different cultural norms and especially the very diverse roles pharmacists
play across Europe. Nevertheless, up to now a number of switches have also been applied on
the basis of a supranational, central procedure with the successful reclassification of orlistat
in 2009 as pioneering example. Within this context, CP comes into consideration automat-
ically (i.e., mandatorily) for a specific Rx-to-OTC switch candidate, if the active substance
of the Rx drug has originally been approved via the prescription drug centralized process
(Senior 2010) as it was the case for orlistat (see also Subsection 4.4.4). Besides, it is the
above mentioned “optional” route of the CP that paves the way for a central Rx-to-OTC
switch application and its eventual approval.
In any event, independent of the route taken into consideration, a switch application primar-
ily based on financial arguments is commonly viewed as “invalid” and therefore not accepted.
In general, switches are scientifically rigorous, case-by-case, weight-of-evidence, data- and
dialogue-driven processes (Pawaskar 2007; Soller 2002). Most of the switch candidates are
more or less “old” substances with well-established use and sometimes even available OTC
in some countries inside or outside the EU such that cumulative safety data can and should
be an integral part of the regulatory assessment report.
3.5 Major switches and re-switches
The following chapters intend to briefly describe examples of fundamental switches and re-
switches over recent years in order to deduce essential learnings and potential caveats for
upcoming switch projects.
3.5.1 Examples of notable switches worldwide
There are a number of switches that are worth mentioning at this point, however, as the
present thesis is limited in scope, only a selection of them will be described somewhat more
in detail. An overview of important switches worldwide over the last twenty years is given
in Table 4.
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Vaginal mycosis/Bacterial candidiasis. Candida vulvovaginitis or vaginal candidiasis, a
vaginal yeast infection, is the second most common diagnosis in women with vaginal symp-
toms (Gurwitz 1995). The condition can be effectively treated with the active imidazole
substance “clotrimazole”. It was the first “azole” compound for the treatment of fungal
infections in humans, introduced in 1973 by the Bayer company (Canesten
®
). In 1990 and
1992 topical clotrimazole was switched for the treatment of external mycosis on a national
basis in the US and the UK, respectively, followed by many other countries (AESGP 2004;
Lipsky 1999). Important for a successful outcome was the fact that vaginal yeast infec-
tions occur frequently and most women do not require medical intervention for a diagnosis.
Warnings on the packaging state that medications are not intended for women with a first
occurrence of symptoms, but for those with a medically supported pre-existing condition.
In this setting, the pharmacist is a key guide and gatekeeper, referring patients not eligible
for OTC treatment to the doctor. In general, compliance is high, side effects are rare, and
most patients effectively respond to treatment. Since its availability for vaginal use in OTC,
no adverse events due to misuse have been reported and concerns regarding an unnecessary
increase in consumption have thus not been substantiated. Patient education includes advice
on how to prevent future infections, and scientific brochures as well as public relations (PR)
activities help to inform about self-medication. As a result of the OTC switch, patients
benefit from quicker and convenient access to an effective treatment option without the need
to consult their doctors for symptoms they are profoundly familiar with. Moreover, multiple
study analyses confirm a reduction in the number of physician visits for vaginitis, leading to
valuable cost savings to public social healthcare budgets (Gurwitz 1995; Lipsky 1999; Lipsky
2000).
Heartburn and acid indigestion. Treatment of heartburn and acid related disorders has
changed radically over the last twenty years with the OTC switch of H2-blockers (or H2-
receptor-antagonists) and proton pump inhibitors (PPIs), respectively. Prior to 1995 noth-
ing but antacids or antirefluxants had been available to medically self-treat symptoms mild
in nature. The market first changed when H2-blockers (e.g., famotidine 10 mg (PepcidAC
®
,
Johnson & Johnson/Merck)) based on a systemic mode of action were introduced in the
early 1990s for treatment and prevention of more severe symptoms. With the introduction
of the first PPI, omeprazole 20 mg (Prilosec OTC
®
, Procter & Gamble) in 2003, the OTC
market changed again. It was then the only product approved for the treatment of frequent
heartburn (≥ 2x/week), the cardinal symptom of the so-called gastroesophageal reflux dis-
ease (GERD) affecting around 30 % of patients. PPIs likewise act systemically providing
lasting, although not immediate, relief from heartburn and are the current medical standard
medication. Treatment algorithms have changed accordingly over time and PPIs have expe-
rienced an explosive growth over recent years, with other PPI substances gradually following
the omeprazole switch. At a global level, PPIs’ retail sales rose dramatically from 2002 to
2004 - highly influenced by the switch in the US.
In June 2009 the EMA approved Nycomed’s OTC application for Pantoloc Control
®
(panto-
prazole 20 mg) as the second centralized pan-European Rx-to-OTC switch in history. In the
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absence of automatic eligibility for the central switch procedure (see Section 3.4), the switch
request was based on a non-automatic approach “in the interest of patients health at Com-
munity level” according to Article 3(2)(b) of (EC) No 726/2004 and was approved following
unanimous votes by 27 member states. On the other hand, the concurrent application for
one year of data exclusivity according to Article 74a of Directive 2004/27/EC was rejected.
A more detailed analysis of the denial will be given in Subsection 4.4.4. Pantoloc Control
®
has since gradually been launched in most EU member states. In contrast to the US, the
switch of PPIs within Europe has not caused significant growth in retail value sales at a
global level so far (Euromonitor International 2010). One possible explanation might be the
pharmacy staff’s reserved position due to a fear of masking underlying serious diseases. An-
other factor influencing pharmacy recommendation might be the ongoing discussion of the
possible interactions of PPIs with other medications and their potential clinical impact. This
situation was probably even worsened in light of the flood of non-consistent informational
and educational material provided by originators and generic manufacturers of OTC PPIs
in respective European countries.
Obesity. Another milestone in the arena of self-medication was the addition of orlistat
(tetrahydrolipstatin) for weight management and treatment of obesity. Its primary function
is to prevent the absorption of fats from human alimentation, thereby reducing caloric in-
take. It is well known that being overweight or obese in the long run increases risk for severe
chronic diseases such as hypertension, coronary heart disease, diabetes, and even prema-
ture death. In general, weight management just like smoking cessation is initially typically
approached as a self-help endeavor without formal medical treatment and requiring radical
behavioral changes (effort and discipline). Just like tobacco dependence obesity is a chronic,
relapsing condition demanding long-term management and treatment.
The OTC switch of orlistat 60 mg (alli
®
, GlaxoSmithKline) in a number of countries for
use in combination with a modified diet has filled an important weight management gap.
In January 2009 orlistat was approved as the first ever centralized switch in Europe by the
EMA to help curtail the increasing prevalence of heart disease, making it the first licensed
weight loss aid suddenly available without prescription throughout Europe. Orlistat 60 mg
was automatically eligible for a switch via the centralized route, as its Rx counterparts have
also been authorized by way of central application (cf. Section 3.4). One year of data exclu-
sivity was equally requested in the application but refused by the evaluating committee (q.v.
Subsection 4.4.4). The switch was accompanied by a heavy media campaign including TV
advertising, as well as consumer and pharmacy support packages. A comprehensive network
via the “myalli” website targeted at consumers committed to behavior change with user fo-
rums, chat rooms, and blogs delivers tailored behavioral support and helps to set up a special
weight management plan (“not just a pill, but a program”). Pharmacies were profoundly
equipped with educational and informational material even prior to the switch (DAZ 2010).
Initial concerns about ab- or misuse were addressed by post-marketing surveillance measures
closely monitoring in-market performance.
In the US, the switch of orlistat was very successful in 2007, yet in 2009 there was a decline
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in use due to the lack of good weight-loss results and gastrointestinal side effects. In May,
2010, the US FDA decided that a warning about potential liver damage had to be added to
the drug facts label6. Moreover, one criticism of OTC obesity drugs is that disease status is
also largely related to psychological and behavioral factors not included in the clinical eval-
uations of weight-loss results and people might consequently only lose weight temporarily
without necessarily rooting out the real cause. New dietary guidelines about to be completed
in many countries place more emphasis on healthy diets instead of pills to achieve weight
loss, and more and more competitors are on the rise in supplements and functional food
(Euromonitor International 2010). Thus, whereas the reclassification of orlistat as the first
approved European centralized switch was groundbreaking in terms of regulatory decision
making, its successful establishment in the market is still to come.
Raised cholesterol levels. An illustrative example of tackling major health problems by
helping people lower their individual risk factors for chronic diseases is the treatment of
raised cholesterol levels with statins. This class of drugs is also termed “HMG-CoA reduc-
tase inhibitors” due to its ability to inhibit the so-called HMG-CoA reductase, an enzyme
with a central role in hepatic cholesterol production. Increased cholesterol levels represent a
major preliminary stage in the development of cardiovascular diseases such as coronary heart
disease, a common cause of death, and statins are used in the prevention of these. The WHO
estimates that more than 50 % of CHD in developed countries is due to high blood cholesterol
levels (AESGP 2004). In a dosage of 10 mg, simvastatin was reclassified from POM to P sta-
tus in 2003 in the UK for treatment of raised cholesterol levels (Zocor Heart-Pro
®
, McNeil).
OTC simvastatin is indicated for individuals at moderate risk (> 15 % (AESGP 2004)) of
a heart attack in the next ten years. Product specific clinical study data have shown that
the product is able to significantly reduce low density lipoprotein (LDL) cholesterol levels
(by around 27 % after four weeks of treatment) thus clearly decreasing – depending on the
starting level - the risk of major coronary events (e.g., death or myocardial infarction) af-
ter continuous treatment (WSMI 2009). Importantly, primary prevention of CHD through
self-care requires a framework of collaborative care with the intervention of specially trained
HCPs, like pharmacists, to assess individual risk factors, give advice, and continually mon-
itor self-treatment (AESGP 2004). From a pharmacy training point of view, the switch of
simvastatin 10 mg in the UK setting has been a model switch: based on a detailed protocol
pharmacists are to guide and advise consumers about their appropriateness for treatment
and to provide information on individual risk factors as well as adequate lifestyle provi-
sions. As opposed to the recommendations of pharmacists associations such as, for example,
the American Society of Health-System Pharmacists (ASHP) (American Society of Health-
System Pharmacists 2005), cholesterol tests before starting OTC simvastatin treatment are
not envisaged in the UK based on the view that the target group will benefit from reducing
cholesterol level irrespective of the starting point. Independent of the unwillingness of certain
pharmacists to sell the product without a full diagnosis by a physician, pharmacovigilance
data collected from nonprescription use in the UK have not yet shown any significant prob-
6 cf. shortened URL: http://goo.gl/Lx4JA linking to www.fda.gov, last accessed 2012-12-29
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lems associated with this switch (WSMI 2009).
However, this switch has been intensively discussed among experts and a similar switch ap-
plication for lovastatin 20 mg (Mevacor
®
, Merck & Co.) has been twice rejected in the US so
far. Critics deem a daily dosage of 10 mg simvastatin, as it is recommended for OTC usage,
as too low for a full beneficial effect (Aronson 2009) and state that beneficial effects have only
been shown in high risk populations (Choudhry 2005). Unrestricted access may encourage
unnecessary use by low-risk patients or OTC statins might just be taken as a substitute
for indispensable behavioral changes (e.g., diet, exercise, smoking cessation). Moreover, as
for the aforementioned NRT or orlistat treatment, medication itself is not sufficient to ob-
tain the desired effects: needed are comprehensive consumer support programs going far
beyond labeling by providing education about the condition treated as well as emphasizing
behavioral modification which emphasize that lifestyle changes are required to achieve the
full benefit of the drug. Such supportive programs are designed voluntarily by the spon-
soring companies and the FDA so far has been reluctant to approve such non-traditional
switch proposals in the absence of a clear legal authority for official assignment (Hemwall
2010). Others still hold the opinion that hypercholesterolemia is a chronic, unremitting, and
asymptomatic condition requiring an accurate diagnosis based on clinical testing as well as
practitioner-directed medical management (Soller 2002). Last but not least, the occurrence
of drug-related adverse events, even though limited from a Rx perspective, gives rise to
concerns. With widespread use, a small excess risk for toxic effects might easily translate
into a large number of adverse events (Choudhry 2005). Muscle injury (myopathy, rhab-
domyolysis) as a well-known example has already been associated with high-dose statin use.
Post-marketing surveillance, epidemiological studies, and adverse drug reaction (ADR) re-
porting are important instruments for the detection of potential side effects related to drug
therapy – after but maybe even more so before a potential Rx-to-OTC switch (American
Society of Health-System Pharmacists 2005).
Central to the FDA’s rejection of the lovastatin 20 mg switch application was the industry-
funded CUSTOM study, a consumer/patient use study of OTC Mevacor. Based on a actual
use study concept having been in practice in the US for several years (see also Subsection
3.2.1), it was designed to observe consumers’ initial and continued statin use to lower LDL
cholesterol in the setting of OTC statin availability in simulated retail pharmacies with
participants recruited by mass-media advertising (Brass 2004; Choudhry 2005). The study
evaluated more than 3,300 subjects’ ability to self-manage high levels of LDL cholesterol
by using a multifaceted cholesterol self-management program (Mevacor Over-the-Counter
Self-Management System (MOTC-SMS)) (Melin 2004). The dataset also included follow-up
information on purchasers for up to six months of self-managed therapy. Results showed
that the majority of study participants appropriately self-selected OTC statin therapy and
acceptably managed ongoing treatment (Melin 2004). However, only 10 % of users of OTC
lovastatin met all of the label eligibility criteria and 10.3 % had a potential contraindication
(Choudhry 2005). 62 % achieved the LDL target goal and interactions with physicians were
common. The authors concluded that MOTC-SMS can effectively guide consumers to make
appropriate decisions with respect to managing their elevated LDL cholesterol levels and in-
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teract with HCPs if necessary (Melin 2004). Nevertheless, despite infrequent in CUSTOM,
the use of OTC statins by consumers needing more intensive statin therapy or facing the
risk of potential drug-drug interactions still holds reasons for concern (Brass 2004). One
major shortcoming of the study was the fact that it was not designed to evaluate clinical
outcomes and therefore not able to demonstrate efficacy/effectiveness (American Society of
Health-System Pharmacists 2005).
Taken together, the benefits of statins in patients at moderate risk are well documented.
Correct self-diagnosis and continued monitoring of treatment effects, however, certainly are
challenges still to deal with (AESGP 2004).
Table 4: Examples of major Rx-to-OTC switches of certain indications and active
ingredients/medicinal products, respectively, in the last twenty years
Indication Active ingredient/Product (manufacturer) Country/
Region
Year
Heartburn Famotidine 10 mg/Pepcid AC® (Johnson & Johnson/Merck),
Cimetidine 100 mg/Tagament HB® (SmithKline Beecham)
US 1995
Smoking cessation Nicotine replacement therapy devices (gums, patches):
Nicorette® (GlaxoSmithKline), Nicotrol® (McNeil)
US 1996 7
Emergency hormonal
contraception
Levonorgestrel/NorLevo® (HRA Pharma) France 1999
Allergic rhinitis Loratadine 10 mg/Claritin® (Schering Plough) US 2002
Frequent heartburn Omeprazole 20 mg/Prilosec OTC® (Procter & Gamble) US 2003
Raised cholesterol
levels
Simvastatin 10 mg/Zocor Heart-Pro® (McNeil) UK 2003
Bacterial conjunctivitis Chloramphenicol 0.5 % eye drops/Optrex infected eyes®
(Optrex)
UK 2005
Migraine Naratriptan 2.5 mg/Formigran® (GlaxoSmithKline),
Sumatriptan 50 mg/Imigran Recovery® (GlaxoSmithKline)
Germany,
UK
2006
Chlamydia infection Azithromycin 500 mg/Clamelle® (Pliva Pharma) UK 2008
Obesity Orlistat 60 mg/alli® (GlaxoSmithKline) US
EU
2007
2009
Reflux symptoms Pantoprazole 20 mg/Pantoloc Control® (Nycomed) EU 2009
Prostate health Tamsulosin hydrochloride 400 mcg/Flomax Relief®
(Boehringer Ingelheim)
EU 2009
7 In some European countries nicotine replacement therapy devices have been available over-the-counter even
earlier – that is, from the beginning of the 1990s (e.g., UK: OTC-switch of nicotine gum in 1991).
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3.5.2 Examples of major re-switches
Whenever a drug is used in an OTC setting, bearing in mind the risk of abuse is of great sig-
nificance. Dramatic harm, public and media attention can result in changing legislation that
reverses liberalized access to effective medication (Rosenau 1994). Although so far a very
rare event due to long-term clinical use of drugs and careful regulatory evaluation (WSMI
2009), there are some examples of drugs switched back from OTC to Rx status (e.g., thalido-
mide as hypnosedative drug in 1961 in some German federal states (Kirk and Friedrich 2001)
before its withdrawal from the market (see also Section 5.1), the antihistamines terfenadine
and astemizole in 1997 in the UK) or even fully withdrawn from the market (e.g., in the US
antimicrobial hexachlorophene in 1977, antihistamine methapyrilene in 1979, and laxative
danthron in 1987) (Bond 2008; CHPA 2010; WSMI 2009).
By way of example, the antihistamine terfenadine was re-switched both in Europe and in
the US (Ward 1999; Wise 1997). In the UK, terfenadine was reclassified from POM to P
status in 1997 (see above). The non-sedating antihistamine ranks among the most widely
used treatments for hay fever in Britain (ca. 2.3 mio. Britons) and has a good safety record
when used as recommended (up to 120 mg/d) (Wise 1997). After intake as a prodrug, it is
converted into its active metabolite fexofenadine and usually completely metabolized in the
liver. However, if liver-metabolization is impaired or overloaded it might reach circulation
and cause serious or even fatal cardiac arrhythmias (“torsade de pointes” arrhythmias). This
may be the case if co-administered with drugs like erythromycin or ketoconazole inhibiting
the Cytochrome (CYP) P450 system in the liver, the main enzyme system in charge of hep-
atic metabolization, or if taken both by people with heart or liver disease and in overdose
(Ward 1999; Wise 1997). The determining factor for re-switch considerations was the dis-
covery of an interaction potential with grapefruit juice which would lead to an increase of
terfenadine concentrations in the blood associated with an enhanced complexity of precau-
tions needed for safe use.
Interestingly, response to these suddenly uncovered risks differed between individuals, that
is, consumers/patients and institutions, such as the Medicines Control Agency (MCA) in
the UK. Although patients experienced greater anxieties and awareness of risks, there was
little evidence of disaffection or disuse of terfenadine. The MCA, however, promptly decided
to reclassify terfenadine to prescription-only status again.
The example above demonstrates that certain - especially serious - adverse events may only
become manifest after many patients have taken a drug and that residual uncertainty always
remains (Ferner 2008). Current drug development programs are generally not large enough
for reliable detection and recognition of very rare, serious AEs and reliable predictions still
cannot be made (Friedman 1999). One major limitation is the fact that many clinical trials
do not take place in a real-life setting and thus specific susceptible patient groups, such as
the elderly or children, who have to be taken into account when it comes to considering the
risks of e.g. non-compliant drug usage etc.
Ab- or misuse of a certain drug or reversed manufacturing of active ingredients is another
driver for potential re-switches. Actual use of a certain medication is not always predictable
based on protocol-driven clinical trials that are designed primarily to demonstrate a prod-
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uct’s effectiveness. The alkaloid and antitussive substance codeine, for example, was switched
back from OTC to Rx status in many countries between 2006 and 2010 due to reasons of
abuse. Similarly, alkaloid and methamphetamine precursor pseudoephedrine and antitussive
dextromethorphan are used for the composition of illegal drugs and therefore included in
drug control enforcement lists or even banned from OTC usage in certain countries.
When evaluating a new drug to become available without prescription, benefits must out-
weigh risks. In the case of drugs for self-medication minor risks may be acceptable, whereas
more serious ones might only be acceptable if drugs are targeted at the treatment of life-
threatening illnesses. However, given the regulatory authorities’ fear of switching drugs in
doses higher than the lowest effective dose, it has to be taken into consideration that the
OTC dosage – if lower than the therapeutic standard dose - might not be optimally ef-
fective (Friedman 1999). Thus, post-marketing surveillance must by all means become an
integral part of drug regulation including the involvement of multiple stakeholders, such as
pharmacy personnel and other HCPs, the pharmaceutical entrepreneur, and not least the
patients themselves.
3.5.3 Key lessons and implications for future Rx-to-OTC switches
As can be concluded from above, there have been a rising number of switches since the
Rx-to-OTC switch movement was started about sixty years ago. Interestingly, it has to be
noted that so far every single switch has been different in nature and there seems to be no
“one-size-fits-all” approach to a successful switch application. Yet, the analysis and eval-
uation of relevant Rx-to-OTC switches, including the case studies depicted above, fosters
further knowledge and enables determination of both key success factors as well as remaining
challenges, which will shortly be discussed in the following.
From an overall perspective, switches have first of all proven successful if they had a bene-
ficial impact on public health as demonstrated by the example of the Rx-to-OTC switch of
NRT which has resulted in both an immense amount of former smokers thereby preventing
premature death as well as in a huge net health economic benefit (Keeler 2002; Shiffman
1997; Shiffman 2008). In particular, with respect to the targeted beneficiaries of a switch
(i.e., patients and also HCPs as their advisers) a distinct added value provided by a specific
switch has to be apparent and visible, such as the rapid relief of acute symptoms or the pre-
vention of severe, (semi-)chronic diseases by successful self-management of associated risk
factors.
Secondly, a drug newly switched to and communicated as self-medication fulfilling a so far un-
met medical need will probably direct patients to pharmacies in order to address complaints
they might not or only insufficiently have treated before (“silent sufferers”). A prominent ex-
ample was the aforementioned reclassification of the antimycotic agent clotrimazole to treat
vaginal mycosis (cf. Subsection 3.5.1 and Chapter 5). Another candidate definitely falling
within this category would be an effective treatment for urge incontinence, for instance.
Thirdly, the availability for self-treatment with emergency hormonal contraception (see Sub-
section 4.4.2) or triptans to treat migraine exemplarily shows the importance of complying
with patients’ demand for increased and timely access as an essential element of a successful
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Rx-to-OTC switch. Direct medical access including, at best, profound pharmacy consulta-
tion enables them to effectively relieve their symptoms in due time and carry on with their
daily-life activities.
In her analysis “Rx-to-OTC switches: trends and factors underlying success”, Mahecha has
identified four specific categories whose variable factors are estimated to have large influ-
ence on the outcome of a switch (cf. Figure 5). These categories are the “product” and its
characteristics in terms of: efficacy, safety, etc., as well as brand recognition; the “company”
and its marketing expertise and strategies; the “market” in terms of consumer/patient need,
entrance time, and price positioning; and last but not least, and maybe most important, the
“regulatory field” including factors like the available (clinical) evidence to support approval
and at best case the provision of data (and market) exclusivity (Mahecha 2006). The role of
data (and market) exclusivity as a general key success factor in the launch of new products
or new indications, etc. and its justification for Rx-to-OTC switches will be dealt with in
Chapter 4 ff.
Product
• Efficacy
• Safety
• Ease of use
• Advantages/Claims
• Brand awareness
Company
• Consumer marketing expertise
• Clear strategy for brand
• Consistent marketing message
• Ability to sustain large-scale advertising and
promotion campaign
• Retail relationships adequate for smooth 
launch and widespread distribution
Rx-to-OTC switch
success
Market
• First to market/Early to market
• Reasonable price point
• Consumer need and demand
• Repeart purchases likely
Scientific affairs/Regulatory
• Sufficient clinical evidence to support
approval
• Lack of political or moral issues to impede
approval
• Clinical evidence to support data/market
exclusivity
Figure 5: Factors contributing to successful and sustainable Rx-to-OTC switches
(based on Mahecha 2006)
Referring to the “product” category, product differentiation certainly displays a critical
determinant for a specific switch candidate to be sustainably established (Francesco Interna-
tional 2009). Other than the fundamental and naturally inherent pharmacological properties
of a molecule that cannot easily be changed, there are various variables that might be added
or modified to differentiate from competitors and provide meaningful benefits and features to
consumers at the same time. Depending on the OTC competition including not only existing
OTC products, but also other Rx products likely to be reclassified, meeting current category
requirements must be standard. “Ideally, a switch should be better than the current OTC
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product advantages with none of their disadvantages” (Francesco International 2009). In
terms of medications, basically three main types of product benefits, namely efficacy, safety,
and ease of use offer starting points for differentiation – OTC appropriateness and commer-
cial feasibility provided.
Furthermore, crucial planning of a switch comprises the setup of adequate measures for
monitoring and managing anticipated risks. Post-marketing surveillance of OTC products
should encompass not only the implementation of a classical, robust, and easily accessible
pharmacovigilance system facilitating (spontaneous) reporting of suspected AEs/ADRs, but
also monitor for “upstream” behaviors that may put consumers at risk (e.g., use by inappro-
priate populations). This form of “behavioral surveillance” might be accomplished through
accurately timed and intensive analyses of test market results, or consumer surveys, and
might then be countered by educational advertising as well as appropriate risk minimization
measures (e.g., restriction of age, pack size, etc.) (Shiffman 2008).
In addition, findings from further analyses allude to the central role of clear and comprehen-
sive product information with regards to the various target groups and their individual risks.
The labeling of OTC (switch) products has been ascribed an educational role and therefore
is estimated to be critical for consumer/patient understanding as well as appropriate and
compliant use in self-medication. In particular, a switch candidate’s safe, effective, conve-
nient, and compliant use based on adequate labeling has to be imputed to regulatory affairs,
on the one hand, and company activities, on the other (Juhl 1998). As depicted in Figure 6,
these should be directed towards patients/consumers and mediated by HCPs including both
doctors and pharmacy staff.
Information has to be presented in a way that patients/consumers can choose the appro-
priate medication on their own and use the medicine safely and effectively (WSMI 2009).
“The hallmark of OTC drugs is not self-diagnosis, it’s self-treatment” (Peter Baron Hutt,
expert on food and drug law) (White and Beall 2001). Labeling as the superordinate means
of communication with the consumer should not only be legible and easily comprehensible.
Accurate information on warnings and directions for use are imperative and self-evident
(Stitching AESGP Foundation 2002). This means, appropriate specifications have to be
worked out on the regulatory side and assiduously implemented by sponsoring companies.
They might conduct so-called “label comprehension studies” (LCS) as well as observational
actual use trials (AUTs) in order to continually improve labeling on the basis of insights in
consumer understanding (Hemwall 2010; McCook 2007). The development of “test market”
concepts as a general form of behavioral research has been suggested elsewhere to address
case-specific (switch-related) questions as well as to affirm the identified target population
and exclude potential risk populations, respectively (White and Beall 2001). In light of more
complex switches being more often seen today, accompanying educational programs, most
suitably personalized, have emerged as useful information and training tools. Prominent ex-
amples of recent switches using this kind of information kits are the aforesaid Prilosec OTC
®
and alli
®
. They provide assistance via mail, toll free phone lines, and/or internet. Apart
from information and training on indication and medication use, such campaigns are designed
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HCP: Doctors/Medical staff
• Encouragement and support of
self- care after initial medical
diagnosis
HCP: Pharmacists/Pharmacy staff
• Product recommendationbased
on treatment protocol/guidance
for patient consultation
• Identification of at risk population
• Improved communication skills
Patients/Consumers
• Disease and brand awareness
• Appropriate self-selection
• Effective and safe use of OTC drug
• Effort regarding behavioral change
Clear OTC labeling, 
comprehensive 
informational and 
educational material
Figure 6: Central role of OTC label, product information, and communication
to minimize individual patient risk
to create disease awareness, on the one hand, and consumers’ action towards tackling their
health problems, on the other. Advertising of NRT, for example, was explicitly targeted to
“committed quitters” ready to quit and campaigns emphasized the importance of consumer
efforts (e.g., Nicorette
®
Gum: “You can do it, Nicorette
®
can help”) (Shiffman 2008). Such
programs are regarded to be a great educational opportunity with as much potential for a
positive public health impact as the drugs themselves by not only informing but also driving
consumers to consult a HCP, if applicable (Fuster and Mearns 2009).
Likewise, adequate information and support of HCPs is considered an essential Rx-to-OTC
prerequisite. Imagining an increase of disease diagnoses initially made by a doctor, discussed
with the patient, and treated by the latter on recurrence of symptoms, the important role
of doctors in encouraging and supporting self-care activities becomes apparent. Stakeholder
consensus about the targeted indication in self-medication has to be taken for granted to
successfully implement such a collaborative care approach that might be necessary for spe-
cific indications switched from Rx to OTC. In the same way, this holds true for pharmacists
as third key-player in this patient-doctor-pharmacist triangle. Pharmacists should not only
receive comprehensive information and training on the product in advance and continuously
during marketing phase, but should also acquire some practically relevant communication
techniques (Stitching AESGP Foundation 2002). Recommendation and advisory procedures
(e.g., of when to seek medical assistance) could be depicted in concrete treatment protocols
or guidelines on how to conduct a consultative dialogue with patients. In this respect, the
UK leads the way by its availability of pharmacy protocols for a number of indications.
Moreover, these kinds of informational campaigns should be integrated into school curricula
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and public education programs in the form of an intensive co-operation between academia,
professional bodies, and manufacturers.
Last but not least, from a strategic point of view a possible reclassification of Rx products
to self-medication should be an integral part of a product’s life-cycle analysis and be initi-
ated along with early stakeholder (regulatory, legal, HCP, etc.) buy in aiming at continued
support and consensus regarding the targeted indication (MISG 2010; Stitching AESGP
Foundation 2002). Within this context “short-term management thinking” is viewed as “en-
emy number one” (Francesco International 2009), as meaningful competitive advantages only
result from well-timed and proactive planning and development of a switch project. Tak-
ing into account different developmental steps like competitive intelligence analysis, market
research, and scientific/regulatory issues (dossier submission, review, and approval) as well
as preparations regarding the switch product itself, the whole switch process is estimated to
require 43-82 months from the managerial “go-decision” until the launch of the final product
with an approved labeling8 (Francesco International 2009).
Regarding the other side of the coin (i.e., concerns and challenges to overcome in terms of
Rx-to-OTC switching) drug safety is, of course, a major issue. Rare adverse events may only
become manifest after many patients have taken the respective drug (MISG 2010). Specif-
ically, in light of changing medication consumption patterns with a trend towards higher
medication related to an ageing population, the problem of AEs including drug interactions
might even get worse (Friedman 1999; Temin 1983). The potential risk of inaccurate self-
diagnosis by patients possibly associated with a delay or even lack of needed therapy is
another crucial element (Brass 2001; MISG 2010).
Additionally, compliance is a major issue referring to both potential mis-/abuse and inap-
propriate use by populations at risk (Shiffman 2008) eventually resulting in severe or even
fatal outcomes and irregular use. Especially in the face of preventive treatments and mainly
asymptomatic conditions, adherence to continuous therapy certainly is to be deemed an issue
to tackle. Innovations in drug delivery systems as well as labeling, promotion, and pharmacy
guidance can theoretically assist with that (Bond 2008; Choudhry 2005). Advances in tech-
nology, widespread availability, and acceptance of reliable, easy-to-use monitoring devices
may equally contribute to a compliant, safe, and effective self-treatment of (semi-)chronic
conditions (Brass 2001). One possible explanation for frequently observed non-compliance
might be the fact that OTC drugs often are considered as ordinary commodity and less effec-
tive than prescription medicines (Bond 2008; White and Beall 2001). Creating and raising
public awareness of the necessity to take OTC medicines with caution and respect is hence
imperative (Bond 2008). Counseling and motivation by physicians has an important share
in this context and should always be kept in the loop as there is justifiable concern that the
loss of their role as prescriber might undermine physician engagement (Shiffman 2008).
Increased resistance as a potential result of inappropriate medication use is another concern
to be raised here, although even more on a public than an individual health level. OTC
8 This is, of course, also depending on the regulatory switch strategy/procedure chosen and the specific lead time
needed by the regulatory body involved.
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approval of acyclovir was denied partly due to this reason (Juhl 1998).
Furthermore, switching the appropriate dosage displays a main challenge. Trying to switch
the lowest dosage possible for self-treatment due to safety reasons always bears the risk
of being not effective, especially, if the switched dosage is below the standard therapeutic
dosage (Euromonitor International 2010; MISG 2010). With people increasingly getting
bigger in size, this issue has become a major concern for the industry, as dosing might not
be as effective. Thus, the challenge of creating a “one-size-fits-all” approach to achieve a
population-based benefit gets even greater, as future switches should rather tend towards
customized dosing for appropriately addressing the effect of people’s different body sizes
(Euromonitor International 2010; Hemwall 2010). Finally, in case of (central) European
switches with the intention to launch the OTC product throughout entire Europe, there
may be hurdles on a regulatory, political, and cultural level regarding the inevitably existing
discrepancy among member states regarding approved indications and recommended OTC
dosages as well as the different roles of pharmacists across Europe (MISG 2010; Stitching
AESGP Foundation 2002).
3.6 Summary and conclusion
The reclassification of a drug and/or associated indication(s) from Rx to OTC status typically
constitutes a scientific data-driven and highly regulated process. For a medicinal product
to be granted OTC status, it must possess both a proven adequate safety margin and ac-
cordant effectiveness. Apart from that, easily understandable, consumer-friendly labeling is
of utmost importance to ensure appropriate self-directed usage in the absence of medical
guidance. Depending on the regulatory switch strategy chosen (i.e., national approval or
approval in some or even all European countries) the process of Rx-to-OTC switch might
take several months or even years.
As demonstrated by previous notable switches, a careful evaluation of the envisaged Rx-
to-OTC switch based on scientific and economic conditions, the potential for explicitly af-
fording added value to patients (backed by HCP recommendation, if applicable), meticulous
planning and preparation including early and continued stakeholder involvement, as well as
post-marketing surveillance and risk management strategies, have proven to be key require-
ments for a positive outcome of a switch approach in a short- and long-term perspective.
Given the above mentioned trend towards more complex switches, correspondent require-
ments associated with the planning, realization, and successful implementation of a certain
Rx-to-OTC switch are constantly growing. In the author’s view, the option of drug reclassi-
fication should thus be integrated in a drug’s life-cycle development as early as possible. As
regards the challenges remaining, companies will have to find creative and viable solutions
enabling them to tackle issues such as, for example, compliance under OTC daily-life condi-
tions or dealing with the diversity of pharmacy systems within Europe. However, according
to the author, the latter will only gain momentum, if an appropriate political, legal, and
regulatory environment is in place. Within this context “data exclusivity” has been set up
as an institutional tool in European legislation to foster and reward compelling and inno-
vative Rx-to-OTC switch approaches. The following chapters will shed a critical light on
Chapter 3 - The Rx-to-OTC switch process 45
the role of data exclusivity provision within the context of Rx-to-OTC switches in Europe
at the present time. Potential issues identified will subsequently be discussed and possible
proposals for solution will be elaborated.
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4 Data exclusivity as important sucess factor for Rx-to-OTC
switches
The following section will begin with the description of data exclusivity within the context of
prescription drugs. Essentials will subsequently be assigned to the situation of Rx-to-OTC
switches (see Section 4.4 ff.).
4.1 Definition of data exclusivity9,10
As the most valuable asset for a research based company is its research data, it is quite
obvious that adequate protection of a company’s research based data is vital to its owner
(Dodds-Smith 1996). In addition to other forms of data protection like patents, data exclu-
sivity represents an important form of intellectual property for innovators providing incentive
to invest in the development and marketing of new product candidates (Grabowski 2008).
Basically, pharmaceutical products can be protected against generic competition in two ways:
by means of patents and/or data exclusivity (Adamini 2009). As overlapping and comple-
mentary forms of intellectual property (Adamini 2009; Grabowski 2008) both are awarded
independently (Junod 2004).
Patents usually are applied for in the pre-clinical or early clinical phase of the development
process and as a rule they are granted for “true” innovative inventions based on the criteria
of novelty, utility, and non-obviousness giving the holder the right to exclude others from
making, using, selling, or importing the protected product for the duration of patent protec-
tion.
In contrast, the instrument of data exclusivity recognizes a research company’s substantial
investments essential for regulatory approval by preventing generics from immediate acceler-
ated market entry (Clift 2008). “Ideally, data exclusivity would delay abbreviated [generic]
filings and patent challenges until innovators have had an opportunity to earn a positive re-
turn on the new therapeutic candidates [. . . ]” (Grabowski 2008). In essential, by definition,
“data exclusivity for a specified period prohibits a regulatory authority from affirming the
9 In fact, the term “data exclusivity” refers to the exclusive right to use proprietary information in support of an
application for a defined period of time whereas the term “market(ing) exclusivity” refers to the exclusive right
to market a product. The exclusivity period based on data exclusivity legislation is thus normally longer than
the one based on market exclusivity legislation due to the necessity that competitive products first have to be
authorized after expiry. Both terms, however, are encompassed by the term “data protection” (WSMI 2009).
10 The terms “marketing exclusivity”, “market exclusivity”, “new product exclusivity”, “Hatch-Waxman exclusiv-
ity”, “sui generic protection”, “data exclusivity” and “data protection” are all found in the relevant US and/or
EU legal literature. The US exclusivity system is mostly referred to as “market(ing) exclusivity” whereas both
the terms “data exclusivity” and “data protection” are more frequently used in the EU system (Friedman 1999;
Sanjuan 2006).
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safety [and efficacy] of a bioequivalent generic by using the pre-clinical and clinical trials
data submitted when a product was initially registered. Central to this approach is the idea
that the initial sponsoring company paid for the trials and thus owns the data, though the
trials were done for a public authority and for a public purpose” (Adamini 2009). Data
exclusivity comes into force with approval once the safe and effective use of the concerned
drug candidate has been proven. Compared with patents, it is generally associated with less
administrative and procedural burden (Junod 2004).
As mentioned above, pharmaceutical companies have the possibility to call upon patent and
data exclusivity in a cumulative way due to the fact that they are granted independently from
each other. Hence, after a drug’s patent expiration the provision of data exclusivity might
ensure further protection difficult to be challenged by reason of its mediation by authorities
(Junod 2004).
4.1.1 The notion of reliance
As depicted above, data exclusivity prevents second applicants for a certain period of time
from relying on original data of the reference drug generated for the sake of demonstrating
safety and efficacy. In the US as well as in Europe, “reliance” is understood as direct or in-
direct “use” of the pioneer’s proprietary data. In practice, a second entrant’s reliance would
be only indirect as it is liberated from generating the same data as the originator in order
to prove safety and efficacy of a similar drug seeking marketing approval (Junod 2004).
As a consequence, unlike patent right protecting the product itself, data exclusivity is not
a right that pioneer firms can invoke directly against generic firms (Sharma 2007). That
is, if during the limited period of data exclusivity a second entrant generates its own data
supporting the safety and efficacy of its own drug, the entrant is not banned by data exclu-
sivity. The entrant is thus able to get marketing approval on the basis of his own data – a
long and highly costly process though which is usually avoided in favor of market entrance
after the period of exclusivity has expired (Gorlin 2000; Junod 2004). Moreover, next to the
mere economic and practical reasons, objections are to be raised from an ethical point of
view, as it is deemed unethical to replicate the testing of drugs both on animals and humans
(Sanjuan 2006).
Of note is, however, that in the case of an abridged so-called “informed consent” application
both the US and the EU entitle a second applicant with the right of referring to and relying
on the originator’s data before the data exclusivity period has expired (Junod 2004).
4.2 Data exclusivity in practice
The protection of regulatory test and study data is considered as a relatively new form of
independent intellectual property rights. In the mid-1990s it was first recognized interna-
tionally and has since been legally required by both the North Atlantic Free Trade Agree-
ment (NAFTA, Article 1711) and Article 39.3 of the World Trade Organization’s (WTO)
Agreement on Trade-Related Aspects of Intellectual Property Rights (“TRIPS Agreement”)
(Pugatch 2004). The provisions intend to protect undisclosed pharmaceutical test data from
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so-called new chemical entities (NCEs) that required “considerable effort” to be generated
against disclosure and “unfair commercial use” in order to provide incentives for the devel-
opment of innovative pharmaceutical products (Gorlin 2000; Sanjuan 2006). Unfortunately,
many countries currently still fail to provide accordant data exclusivity with non-compliance
ranging from total absence to an effective scope which is only limited (Gorlin 2000).
Even if not mandatory based on its correct interpretation (Sharma 2007), industry groups
and certain developed countries, such as the US and the EU, have argued that TRIPS Article
39.3 charges countries with the setup of a data exclusivity regime as a form of time-limited
intellectual property right with both of them having adopted data exclusivity regimes for
medicinal products even prior to the TRIPS Agreement (see Subsections 4.2.1 and 4.2.2)
(Clift 2008; Sharma 2007). Interestingly, these models do not fall under the category of
trade secrets though, as they are rather an inseparable part of the regulations concerning
the approval of pharmaceutical products (Pugatch 2004).
4.2.1 Data exclusivity in the United States
Until 1984, a trade secret protection regime quite limited in scope constituted the only
US protection for an applicant’s unpublished safety and efficacy data (Sanjuan 2006). In
1984, data exclusivity was introduced with the “Drug Price Competition and Patent Term
Restoration Act” amendment – commonly named after its sponsors (i.e., “Hatch-Waxman
Act” (Clift 2008)). It is now codified in FD&C Act Section 505 (i.e., Title 21 U.S. Code
(U.S.C.) § 355 11, respectively (Pugatch 2004)). Related implementing regulations are pro-
vided by § 314 of Title 21 of the Code of Federal Regulations (CFR) (Dickinson 1999).
In principal, there are two main categories of marketing or data exclusivity to be granted
depending on the kind of drug application (Junod 2004):
 a five-year period of data exclusivity can be obtained for drug products based on NCEs,
meaning the drug does not necessarily have to constitute an innovation or represent a
significant therapeutic advance, but must contain an active moiety never approved by
the FDA ever before alone or in combination (Sanjuan 2006).
 a three-year period of marketing exclusivity is awarded for drugs already approved for
which essential clinical test data were submitted to support new or supplemental new
drug applications (e.g., new indications, changes affecting active ingredients, strength,
dosage form, route of administration, etc.). However, an important limitation of this
kind of exclusivity is that it only protects these specific “additions” without the uses
or indications already established.
Specific conditions have to be fulfilled by a pharmaceutical company to benefit from
this three-year market exclusivity, such as, for example, the conduct or sponsoring of
clinical trials essential for the approval of the application (at least 50 % of study costs).
In this regard, the FDA has set up only vague definitions of the kind of data to deliver
11 cf. http://www.gpo.gov/fdsys/pkg/USCODE-2010-title21/pdf/USCODE-2010-title21-chap9-
subchapV-partA-sec355.pdf, last accessed 2013-08-05
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except for the fact that “significant innovations” and clinical investigations “vital to
the application or supplement” are required (Junod 2004; Sanjuan 2006).
In contrast to the five-year exclusivity, during the three-year exclusivity period the FDA is
allowed to receive and review further applications (often in the form of so-called “abridged
applications” implicating that the applicant does not have to replicate the original data but
can refer to these). In case of a positive decision, approval will become effective immediately
after expiry of the three-year exclusivity period offering second applicants the opportunity
to directly enter the market.
Both types of exclusivity often are combined, that is, a five-year data exclusivity is often
followed by a three-year period when it is about to expire. Consequently, the total period
of exclusivity is maximized by this sequential addition. In terms of eligibility, it is the FDA
which autonomously decides whether the conditions for exclusivity are met (Junod 2004).
4.2.2 Data exclusivity within the European Union
Within Europe, the origin of data exclusivity dates back to 1987 and has been a Commu-
nity affair ever since. Before that time, the EU data protection regime basically was made
up of a trade-secret regime considerably varying from country to country (Sanjuan 2006).
Historically, a system of data exclusivity was introduced to allow some form of protection
to research-based pharmaceutical companies in EU member states, such as Spain or Por-
tugal, not endowing pharmaceuticals with any patent protection until 1992 (Junod 2004).
Provisions on data exclusivity were first included in EU Directive 87/21/EEC, affording
six years of data exclusivity to the majority of pharmaceuticals as of the issue of the first
marketing authorization in any EU member state and ten years for biotechnology and high-
technology medicinal products. In 2001, precursor directives were consolidated in a single
Community Code, Directive 2001/83/EC, governing the current EU data exclusivity regime
and amended in 2004 by Directive 2004/27/EC (Adamini 2009; Garland 2007). The 2004
amendments with the objective to strengthen EU competitiveness in the pharmaceutical in-
dustry (CMS 2007) constitute a “compromise package” resulting from lengthy negotiations
among the European Parliament, the Commission, and the Council initiated in 2001 within
the so-called 2001 Pharma Review process (Junod 2004). Data exclusivity was a key topic
of the review with the main objective to harmonize national differences in length among EU
member states (Adamini 2009; Junod 2004) against the background of striking a balance
between the interests of brand-name industry, on the one hand, and generic industry, on
the other (Bogaert 2005). Whereas the latter strove for minimization of the period of data
exclusivity, the brand-name industry – appealing to the US exclusivity system - lobbied for
a harmonized upward-extension as well as a broadening towards secondary uses or other
variations (Junod 2004).
The most significant changes and compromises introduced for implementation include the
following:
 “8+2+1 formula” for new drugs
This term refers to the fact that new drugs approved within the EU either via cen-
Chapter 4 - Data exclusivity as important success factor 51
tralized or decentralized procedures will be able to benefit from eight years of data
exclusivity as of their first marketing authorization with generics prohibited from rely-
ing on corresponding original data until this period has expired. A new term - “market
exclusivity” - was introduced at the same time alluding to the prevention of generic
firms during two additional years from marketing a generic product although their
(abridged) applications may already be processed after expiration of the eight-year pe-
riod of data exclusivity. Hence, generic market entrance is not possible before ten years
of marketing the originator’s drug product have passed, but there is a two-year window
during which bioequivalence testing may be carried out. In case of “new therapeutic
indications” with significant clinical benefit in comparison to existing therapeutic op-
tions, market exclusivity might be extended by one additional year if applied for during
the eight-year period of data-exclusivity (Adamini 2009; Garland 2007; Junod 2004).
Importantly, contrary to the US system, this extension of market exclusivity is to cover
the product as a whole (i.e., both “new” and “old” uses) (Generics Bulletin 2004).
Another crucial distinction from the US system, where a three-year exclusivity may
be granted for new uses/applications, etc. of a drug, is the EU’s 2004 legislative assig-
nation that all variations and line extensions of an initial marketing authorization as
well as any other additional strengths, pharmaceutical forms, administration routes,
etc. granted to the holder of the initial authorization are considered to belong to the
same “global marketing authorization” and, therefore, these changes are not awarded
any data protection (Bogaert 2005; Sanjuan 2006).
 “Bolar Scheme”
Whereas in the US generics are enabled to conduct research before the relevant patent
has expired, this was not possible in the EU until 2004 due to patent infringement.
In order to put the EU system in line with the US regime, the 2004 Directive now
allows for generic makers conducting their own specific studies viewed as necessary
with respect to approval of a certain drug marketing authorization, even during the
lifetime of the relevant patent to enable them to demonstrate bioequivalence prior to
patent expiry (Adamini 2009; CMS 2007; Garland 2007; Junod 2004).
 Definition of “generic medicinal product”
Directive 2004/27/EC for the first time comprises an explicit definition of a generic
medicinal product with respect to the terms “active substance” and “pharmaceutical
form” (Bogaert 2005), as the hitherto valid concept of “essential similarity” raised
important questions due to its vague formulation (Kingham 2000). According to Ar-
ticle 10(2)(b) a generic medicinal product “has the same qualitative and quantitative
composition in active substances and the same pharmaceutical form as the reference
medicinal product, [. . . ] whose bioequivalence [. . . ] has been demonstrated [. . . ]. The
different salts, esters, ethers, isomers, mixtures of isomers, complexes or derivatives of
an active substance shall be considered to be the same active substance, unless they
differ significantly [. . . ] with regard to safety and/or efficacy. [. . . ]”. This definition
offers further, although still not ultimate, clarity (Bogaert 2005; Junod 2004) as to
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when a drug qualifies for the abridged procedure in case of expiration of a pioneer
drug’s exclusivity period (Adamini 2009; Garland 2007).
 “European reference product” and “Historical reference principle”
The new provision of “European reference product” allows generic applications to refer
to products licensed in any other member state (Generics Bulletin 2004). Additionally,
the “Historical reference principle” authorizes generic companies to equally develop
similar products of original pharmaceuticals that had previously been (i.e., had been
approved for at least eight years) but are no longer on the EU market (Adamini 2009;
Bogaert 2005).
However, despite of the effort to bring about further clarification, Bogaert and Michaux
identified major outstanding issues in their analysis of the reviewed legal framework (Bogaert
2005) with one of them being, for example, the lack of clarity if an abridged marketing
authorization can be granted during the aforementioned period of market exclusivity. The
current provisions only state that a generic product is not to enter the market during that
time. Sound reasons are in favor of this authorization to only be valid at the end of the
market exclusivity, yet this issue is not without ambiguity. If it is granted before, control
mechanisms will be required to prevent marketing steps to be taken.
4.3 The rationale of data exclusivity provision
When developing a drug, originator companies often have to cope with high-risk, temporal,
and costly investments in connection with innovations that result in completely new drugs
or the further development of an already existing drug. Research intensive pre-clinical and
clinical study investigations often lasting over several years are needed to generate the data
required by regulatory authorities for first time approval. Additionally, in many cases the
delay between patent filing and final regulatory approval of a marketing authorization cor-
respondingly reduces the number of years of protection remaining for the product to recoup
associated investments (Clift 2008). In contrast, generic pharmaceutical manufacturers can
achieve marketing approval of a certain drug without the need of engaging in similar sig-
nificant research and development expenditures. Innovators, therefore, seek to obtain the
broadest patents for their drug to be protected against generic invasion.
On the other hand, more and more drug products are developed these days without being
eligible for patent protection due to the lack of a “true” innovative character. Many of them
rather represent line extensions or other variations (e.g., fixed dose combinations, etc.) ac-
cording to a product’s life-cycle management. In this case, non-patent data exclusivity plays
an important role for the pharmaceutical industry (Junod 2004), as it constitutes a valuable
alternative means to protect proprietary data and interests against unauthorized use and
disclosure.
The Organization for Economic Co-operation and Development (OECD), among others,
strongly encourages the award of data exclusivity periods due to the following reasoning:
“Data exclusivity recognizes the innovator’s investment in conducting the rigorous pharma-
cological, toxicological and clinical trials necessary to establish the safety and efficacy of new
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drugs before they can be provided to patients” (Garland 2007). “The central justification
for data exclusivity is that, as with patents, the longer an innovator company enjoys protec-
tion from price competition (i.e., market exclusivity), the greater its incentive to innovate”
(Adamini 2009). “Without a data exclusivity period, there would be little incentive to in-
vest in developing and marketing new product candidates with few remaining years of patent
protection or with uncertain forms of protection” (Grabowski 2008).
Data exclusivity nowadays is thus seen as a principal instrument to maintain pharmaceutical
research and development by extending market protection for new indications, pharmaceuti-
cal forms, and other variations12 in order to reward pharmaceutical companies for investments
taken in hand for approval (Junod 2004).
4.4 Data exclusivity for Rx-to-OTC switches
The present chapter will deal with legal conditions for and practical examples of data exclu-
sivity provision for Rx-to-OTC switches.
4.4.1 Legal framework in the US
In the US, based on the provisions deduced from the aforementioned Hatch-Waxman Act and
implemented in § 314 of Title 21 of the Code of Federal Regulations (q.v. 21 CFR 314.108),
switch applications might be eligible for a three-year period of marketing exclusivity (see
also Subsection 4.2.1) provided that new clinical data considered essential by the FDA is
available and investigations are conducted or sponsored by the applicant (Cullen 2007; WSMI
2009). Importantly, as not all data are automatically viewed as essential, these data have
to prove significance for the approval of the switch application either regarding safety and
efficacy/effectiveness of the drug itself, or with respect to diagnostic measures, for example
(Fish 2010). As mentioned before, FDA guidelines - like those of the EU - do not identify or
arrange for a mechanism of how to conform to its quite indefinite requirements (Junod 2004).
However, contrary to the EU, exclusivity has already repeatedly been granted to Rx-to-OTC
switch applications in the US and published switch application documentation might thus
give a clue on the kind of data potentially relevant within the context of exclusivity provision
in the US.
4.4.2 Practical examples of data exclusivity application for Rx-to-OTC switches in the US
The following two case studies will serve to depict the conditions of data exclusivity assign-
ment within the context of Rx-to-OTC reclassification in the US.
Levonorgestrel 0.75 mg (Plan B®, Duramed Research Pharmaceuticals). The supplemental
new drug application (sNDA) for Plan B
®
(levonorgestrel 0.75 mg tablets) was first sub-
mitted to the FDA under Section 505(b)(1) of the Federal Food, Drug and Cosmetic Act in
12 unless coming under an existing “global marketing authorization” within the EU and therefore not eligible for
data protection (see also Subsection 4.2.2)
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April 2003. After rejection of this application by the FDA in May 2004 based on “inade-
quate sampling of women under 16” (Johnson et al. 2006), Plan B
®
was at last successfully
reclassified to OTC on August 24th, 2006, for women of the age of 18 or older after agreement
on certain commitments to be followed by the applicant.
Plan B
®
is an emergency hormonal contraception drug to prevent pregnancy commonly also
known as “morning after pill” containing the active ingredient levonorgestrel, a hormon-
ally active second generation synthetic progestogen (Camp et al. 2003; Trussell and Cleland
2007). Even though any drug product comprising other forms of the same active moiety as
the drug under consideration had already been approved under Section 505 of the FD&C
Act, this particular form of the active moiety for which the application was submitted had
not previously been approved by the FDA. Three years of exclusivity were claimed in line
with the application for changing the drug’s legal status. Due to the list of published studies
demonstrating safety and effectiveness not being sufficient and satisfactory for approval, the
applicant submitted two new clinical investigations deemed essential for approval that had
not been relied upon by the agency before and that did not duplicate the results of other
investigations relied on by the agency to demonstrate the effectiveness of a previously ap-
proved drug product (i.e., did not re-demonstrate something the agency considered to have
been demonstrated in an already approved application). Both studies fall under the defi-
nition of “behavioral studies” with the first one being a label comprehension studytesting
consumers’understanding of the product label (cf. also Subsection 3.5.3) and the second
one demonstrating actual use in a simulated OTC setting (actual use trial) with repeat use,
occurrence of pregnancy and adverse events as secondary objectives. Both studies have been
published in the relevant literature (Raymond 2002; Raymond 2003).
According to the effective legal requirements (q.v. Subsection 4.4.1), the applicant had been
identified as sponsor of the respective studies. Therefore, the FDA granted three years of
exclusivity for the OTC approval of Plan B
®
(levonorgestrel 0.75 mg tablets) based on the
provisions laid down in the Code of Federal Regulation.
Orlistat 60 mg (alli®, GlaxoSmithKline) In June 2005, the pharmaceutical company Glax-
oSmithKline submitted a sNDA for alli
®
(orlistat 60 mg capsules) to the FDA under Section
505(b)(2) of the Federal Food, Drug and Cosmetic Act requesting its nonprescription use for
weight loss in adults of 18 years and older when used with a reduced-calorie, low fat diet,
and an exercise program.
Orlistat, also known as tetrahydrolipstatin, is a lipase inhibitor acting locally in the intestinal
tract. As saturated derivative of lipstatin, a potential natural inhibitor of pancreatic lipase,
it was primarily designed to partially prevent dietary triglycerides from hydrolysis and ab-
sorption by binding to pancreatic lipase in the small intestine (Schwartz et al. 2008). Caloric
intake is thus reduced, especially as orlistat is strongly recommended for use in combination
with a calorie-reduced diet.
The application was approved on February 7, 2007, for use as recommended after commit-
ment to and completion of FDA required actions based on its review of the original submission
(e.g., accomplishment of a label comprehension and self-selection study including subsequent
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adaptation of the labeling, etc.). The study data handed in partly cross-referenced to the
original application of orlistat 120 mg capsules, published literature data, and was comple-
mented by new study data intended to simulate OTC usage.
Within its application, GlaxoSmithKline also requested a period of exclusivity of three years
under 21 CFR 314.108(b)(4)(iv). This claim was based on two clinical investigations con-
sidered essential for approval - a weight loss study in primary care setting of four months
duration and an AUS simulating OTC setting of three months duration. Both investigations
had not been relied upon by the FDA to demonstrate effectiveness of a previously approved
drug product and examinations did not duplicate the results of any investigation previously
referred to by the agency for supporting potency of a formerly approved drug product. In
the actual use trial which was conducted in co-operation with 18 community pharmacies and
which was published in 2008, customers were to decide on the appropriateness of orlistat 60
mg for self-treatment with only very little pharmacist assistance. Consumers gave their con-
sent to participation in the study about the purchase of the product in a “real-world setting”
and were then followed-up during three months by regular telephone interviews being asked
about product use, occurrence of AEs, use of educational material, doctor/pharmacist inter-
action, multivitamin use and satisfaction with the product (Schwartz et al. 2008). Overall,
237 participants purchased and made use of the product. Approximately 80 % of subjects
took account of the educational material placed at their proposal and found it useful. The
same percentage indicated being satisfied with treatment effect. In conclusion, orlistat 60
mg proved to be an appropriate weight loss treatment in OTC environment. The weight loss
study was a double-blind, randomized, placebo controlled, parallel group, phase III clinical
efficacy study in a primary care setting of four months duration. It is unclear why study
duration was limited to four months. Subjects (n = 195 placebo t.i.d.13 vs. n = 196 orlistat
60 mg t.i.d.) were overweight with a body mass index (BMI) of 25-28 kg/m2. Interestingly,
94 % of study participants were female. Average age was about the same in both placebo and
verum groups (46.5 yrs and 45.8 yrs, respectively). Overall, results were not different from
pooled results of other efficacy studies submitted and statistical significance versus placebo
was only given with respect to a 3 % and not to a 5 % weight loss (FDA 2006b).
Nevertheless, the applicant had been identified as sponsor of both studies and was granted
three years of exclusivity for the classification of alli
®
(Orlistat 60 mg capsules) as OTC
drug product based on the aforementioned study data.
4.4.3 Legal framework in the EU
In the EU, a draft version of Directive 2004/27/EC amending Directive 2001/83/EC primar-
ily envisioned a data protection period of three years for marketing authorizations of drug
products envisaging a change of classification, but this was reduced to one year at the final
stage of approval (WSMI 2009). Finally, the following wording has been passed in Article
74a, Directive 2001/83/EC, introduced by Article 54, Directive 2004/27/EC:
“Where a change of classification of a medicinal product has been authorized on the basis
13 t.i.d. = “ter in die” (Lat.) meaning “three times a day”
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of significant pre-clinical tests or clinical trials, the competent authority shall not refer to
the results of those tests or trials when examining an application by another applicant for
or holder of marketing authorization for a change of classification of the same substance for
one year after the initial change was authorized.”
This means that generic versions of the switched product can be marketed if the legal re-
quirements to submit an abridged application are met (q.v. Subsection 4.2.2). However, in
contrast to the reference product it will not be available OTC but prescription-only during
one year after the switch of the originator’s pharmaceutical product (Bogaert 2005).
As is the case for every European legislative directive, the new legislation approved by the
European Commission had to be transposed into national law, namely until October 30,
2005, at the latest. The provision applies in relation to the results of tests or trials which
form the basis of valid applications for reclassification received on or after January 1, 2005,
including both variation applications and applications for new reclassified marketing autho-
rizations.
The one-year data exclusivity period under Article 74a is a stand-alone period of protection.
It can be granted independently from any other periods of data protection (European Com-
mission 2006a). However, in the UK, for example, the MHRA as competent authority has
decided that the principle of additional exclusivity as applied by various exclusivity provi-
sions within the reviewed legislation is affirmed only once per global marketing authorization
(see also Subsection 4.2.2). The one-year period of data protection starts from the date of
the issue of the authorization or variation affecting the reclassification, not the date on which
the pharmaceutical product is first placed on the market. Only one year after the date of
grant of the authorization or variation the competent authority of the concerned member
state is allowed to refer to the originator’s data when examining a reclassification application
by another applicant for the same substance, whereas applications referring to these data
will not be scrutinized during the period of data exclusivity (MHRA 2005).
A so-called “Notice to Applicants” (NTA) has been prepared by the European Commission
in consultation with member states to give some guidance on the procedures related to the
receipt of a reclassified marketing authorization. Correspondingly, “a report justifying that
[the] application includes significant pre-clinical tests or clinical trials which have been car-
ried out in relation to this change of classification” has to be submitted. This report should
be not more than five to ten pages of length and include:
 a summary of the tests and/or trials conducted in relation to the switch of classification
as well as
 a justification why these tests and/or trials should be considered as significant.
Related study reports and literature references should be inserted in the relevant places of
the dossier and cross-referenced to accordingly. A reference to the “Guideline on changing
the classification for the supply of a medicinal product for human use” is equally requested
(European Commission 2008).
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4.4.4 Practical examples of data exclusivity application for Rx-to-OTC switches in Europe
Three recent Rx-to-OTC reclassifications within Europe - two centralized and one national
- will be analyzed below with particular attention regarding eligibility of the data submitted
in order to award protection through data exclusivity.
Orlistat 60 mg (alli®, GlaxoSmithKline) As previously mentioned (cf. Subsection 3.5.1),
the central European Rx-to-OTC switch application of orlistat 60 mg hard capsules indicated
for “weight loss in adults who are overweight (BMI ≥ 28 kg/m2) and should be taken in
conjunction with a mildly hypocaloric, lower-fat diet” under the alli
®
brand was the first to
be approved by the EMA in January 2009 based on a CHMP recommendation after review
of data on quality, safety and efficacy and careful benefit-risk evaluation in the proposed
indication and dosage strength (EMA 2009a).
Before the switch, the product as presented on the European market as a prescription prod-
uct consisting of orlistat 120 mg hard capsules. The active substance used in the requested
60 mg line extension is identical to the one of the already approved alli
®
120 mg capsules
(Xenical
®
). As the latter already had been authorized via central procedure, reclassification
of alli
®
60 mg was automatically eligible for assessment through the central Community
procedure.
Besides quality specifications and details regarding non-clinical aspects (which could be de-
rived from existing Rx data) generally required in the case of (new) drug applications, the
applicant submitted some clinical studies supporting efficacy/effectiveness of the proposed
dosage strength of 60 mg in the target indication. Whereas three pivotal studies originated
from the initial Rx marketing authorization application of orlistat 120 mg in which 60 mg
also had been tested in comparison, two additional supportive studies included data on the
real-life use of orlistat 60 mg. These behavioral studies were conducted in the US, where
orlistat 60 mg already has been OTC since 2007. Based on study data, both refinement of
target indication/population from BMI ≥ 25 kg/m2 to ≥ 28 kg/m2 and labeling changes
had to be carried out by the applicant to ensure a satisfactory effect as well as appropriate
self-selection by the target population. Apart from that, clinical data was considered rele-
vant and sufficient to support the extension of the marketing authorization in the proposed
indication. In terms of safety, five studies were handed in for the initial application of orlistat
120 mg as prescription drug including data regarding the lower strength, as well as three
additional US studies with orlistat 60 mg capsules. Furthermore, post-marketing experience
worldwide was evaluated. Given the cumulative safety experience of orlistat 120 mg and
post-marketing experience of orlistat 60 mg in the US, the CHMP finally agreed upon its
favorable safety profile compared to 120 mg (less withdrawals due to AEs in pivotal studies)
after having suggested some additions to the product information (i.e., amendments in the
section of contraindications and AEs as well as advice with intake). As far as pharmacovig-
ilance is concerned, a detailed so-called risk management plan (RMP) was added including
proposed pharmacovigilance activities (i.e., routine actions and scheduled cumulative review
of AE reports, so-called Periodic Safety Update Reports (PSURs)) as well as risk mini-
mization activities (routine activities, warnings in product information) depending on the
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characteristics of identified risks. No additional risk minimization activities were required
based on consideration by the CHMP. Residual concerns regarding an increased risk of de-
layed diagnosis and treatment of underlying conditions as well as potential for incorrect use
were addressed through demonstration of the results of consumer surveys showing a high rate
of patient physician interaction in the target population and data from the US experience
with alli
®
60 mg as a nonprescription medicine. Finally, after the applicant’s proposal of
further strengthening information on the labeling and package leaflet by incorporation of a
medical reference for a general health check and consultation in the case of co-morbidities,
the CHMP recommended the classification of alli
®
60 mg to “medicinal product not subject
to medical prescription”.
Additional clinical studies (one weight loss, i.e., clinical efficacy study, and one actual use
trial, as well as two consumer surveys from the US and Europe, respectively) were submit-
ted with the intention to claim one year of data exclusivity. The CHMP reviewed the data
taking into account the provisions of Article 74a of Directive 2001/83/EC, as amended, and
concluded it not to be relevant and thus not eligible for one-year data exclusivity. Both
the weight loss and the AUT were identical with those exclusivity had been granted for in
conjunction with the Rx-to-OTC reclassification in the US. According to the CHMP, both
studies were not considered relevant and necessary for demonstration of both efficacy and
safety of the reduced strength. This opinion was based on the inaptness of studies to provide
additional value and insights due to study designs, on the one hand, and already existing
study and post-marketing data, on the other. Original clinical study data from the initial Rx
marketing authorization for orlistat 120 mg had already confirmed the preservation of efficacy
under the reduced strength of 60 mg with at the same time fewer and less severe undesirable
adverse effects recognized. Forthcoming clinical study data as well as post-marketing data
for orlistat 120 mg and 60 mg from the US have further supported the overall safety profile
rendering the generation of new safety/efficacy data for the respective switch application of
orlistat 60 mg superfluous. However, the reason why the submitted consumer surveys were
not eligible to be considered in light of exclusivity provisions was not clarified (EMA 2009a).
Of note, instead, important insights into its “appropriate safe and effective use in a nonpre-
scription setting” obviously were expected from the applicant’s commitment to survey both
EU alli
®
users’ demographic and clinical characteristics as well as their individual usage
patterns (EMA 2009a).
In conclusion, based on a comprehensive review of data on quality, safety, and efficacy, the
CHMP, by majority, considered the benefit-risk balance of alli
®
60 mg favorable for OTC
usage in the proposed indication and therefore recommended an extension of the marketing
authorization. However, taking into account the exclusivity provision of Article 74a, Di-
rective 2001/83/EC, as amended, the CHMP did not consider the clinical data submitted
by the applicant as significant and essential for the respective reclassification, due to their
inability to yield additional relevant findings.
Pantoprazole 20 mg (Pantoloc Control®, Nycomed) The agent pantoprazole belongs to
the pharmacological class of proton pump inhibitors - substituted benzimidazoles which act
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by irreversibly blocking the hydrogen/potassium adenosine triphosphatase enzyme system
(“proton pump”) of the gastric parietal cell. As terminal stage in gastric acid secretion,
inhibition of proton pumps results in effective and lasting reduction of acid production.
Therefore, PPIs are considered the most potent substance class for acid inhibition to date
and have displaced H2-blockers as therapeutic standard medication to treat acid-related dis-
orders including gastro-esophageal reflux disease (cf. Subsection 3.5.1).
The pan-European switch of Pantoloc Control
®
20 mg gastro-resistant tablets with the ac-
tive ingredient pantoprazole 20 mg indicated for “short-term treatment of reflux symptoms
(e.g., heartburn, acid regurgitation) in adults” was the second switch within Europe based
on a central application and was approved in June 2009. Eligibility was grounded on the
demonstration of “interest of patients health at Community level” due to the fact that the
wish for an optimal self-treatment of heartburn is universal and valid for patients across
the whole Community. A harmonized nonprescription pantoprazole product would enable
Community-wide access as well as consumer protection, based on harmonized labeling avoid-
ing diverted markets. The request was based on a so-called “hybrid application” meaning
that it referred to already approved products but that - compared to these - changes in the
therapeutic indication were applied for supported by the results of appropriate non-clinical
and/or clinical trials (EMA 2009b). Overall treatment duration without doctor consultation
was suggested to be limited to four weeks and in case of continuous therapy to two weeks,
respectively. Product quality characteristics were tested and demonstrated satisfactory. Con-
cerning non-clinical aspects, a comprehensive overview of pharmacological, pharmacokinetic,
and toxicological aspects was provided based on published information and data available for
the reference product such that, in accordance with the evaluating committee, no additional
data had to be provided in support of the application. Moreover, no bioequivalence data
were required, as the medicinal product applied for and the reference product are identical
in regards to qualitative and quantitative composition as well as manufacturing itself.
In relation to clinical aspects, however, appropriate clinical data supporting the proposed
change in indication had to be submitted. Heartburn and acid regurgitation are considered
as cardinal symptoms of GERD and 17 clinical studies were filed including the treatment of
symptoms in patients with GERD as primary or secondary endpoint. In these studies the use
of pantoprazole 20 mg, either compared to placebo or another PPI/H2-blocker, within the
first 14 days of symptomatic treatment of GERD at any stage, was investigated. Apart from
showing the superiority of pantoprazole 20 mg to the placebo and the H2-antagonists, and the
non-inferiority to other PPIs as well as pantoprazole 40 mg and 80 mg at most time points,
results demonstrated an onset of clinical effect within seven days (up to 80.6 % symptom re-
lief after day seven) more or less independent of the initial GERD stage. The latter is crucial
with a view towards self-medication, where the severity of GERD is not explicitly determined
as treatment generally is performed prior to medical endoscopic diagnosis. A self-medication
setting was also mimicked by one study which encompassed patients exclusively based on
the presence of reflux symptoms without endoscopic examination. No dose-finding studies
were performed. Likewise, no clinical studies or study analyses were performed in special
populations in support of the application. In response to the CHMP’s request for study data
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of pantoprazole 10 mg as lowest available dosage strength, one accordant study was identified
pointing out to, however, 20 mg as more consistent and satisfactory in terms of symptom
relief. In turn, the CHMP then acknowledged and agreed on the efficacy/effectiveness and
safety of the 20 mg dose as being appropriate for the proposed indication in a nonprescrip-
tion status.
Safety was evaluated based on reviewing the applicant’s worldwide clinical trial database
and post-marketing surveillance data concluding with a benefit-risk consideration for non-
prescription status. As far as safety in special populations is concerned, special safety and
pharmacokinetic studies were performed during Rx drug development reassured that panto-
prazole is safe in elderly and renal- or liver-impaired patients. Neither children nor women
during pregnancy or lactation are included in the target group of the current OTC applica-
tion. In light of the long safety record in Europe since its introduction in 1994, the CHMP
agreed that the nonprescription application of pantoprazole 20 mg does not require a risk
management plan. Moreover, it is based on a reference product which has been widely used
in Rx setting and mandates no additional risk minimization activities in terms of direct dan-
ger. “Indirect danger” of potential masking of underlying serious conditions was considered
minimal in relation with adequate product information. Results from a published actual use
study with OTC omeprazole from the US (Fendrick 2004) were used to show appropriate
self-assessment and self-selection. User-tested package information leaflet and labeling were
judged adequate with respect to the safe and effective use of the medicine including appro-
priate guarding for potential misuse. Overall, the CHMP concluded the documented use of
pantoprazole 20 mg as relevant for the proposed indication and thus considered its supply
as nonprescription medicine appropriate.
Referring to Article 74a of Directive 2001/83/EC, as amended, the applicant requested one
year of data exclusivity on the basis of 6 unpublished studies out of the 17 studies handed
in. Significance of this new study data for assessing a change of classification was ascribed
to the fact that they all recorded reflux-related symptoms at least once during the first 14
days of treatment. The applicant further substantiated the justification by pointing out the
demonstration of efficacy/effectiveness with respect to the proposed indication and posol-
ogy in a nonprescription setting as well as emphasizing selected studies showing early onset
of relief from reflux symptoms (54.0 % - 80.6 % after day seven). Overall, the applicant
considered that the new data from these studies “added significant support to the classifica-
tion as nonprescription product as it provided both effect and relevance to the assessment”
(EMA 2009b). The applicant’s claim on data exclusivity was addressed by the CHMP with
the following observations: overall study results were either comparable to those of already
published studies thus not adding additional significant value to the application or lacked in
effectiveness data after two weeks of treatment, showing only data for day 28 or even after.
In a nonprescription setting, however, patients would be self-referring to their physician, if
no symptomatic relief was obtained after 14 days of therapy, making the study design of
limited value for self-medication issues. Another shortcoming regarding the study design of
the respective studies was the comparison of pantoprazole 20 mg with omeprazole 10 mg
which is usually applied as maintenance and not starting dose in the treatment of reflux
Chapter 4 - Data exclusivity as important success factor 61
disease and therefore not therapeutically equivalent. Additionally, similar results, i.e. non-
inferiority compared to other PPIs, were already shown elsewhere in the published literature.
Therefore, the CHMP concluded that “none of the 6 above-mentioned studies provide data
to support the proposed indication and treatment duration that could not be derived from
the other 11 studies provided with the application” and accorded the studies no genuine
impact on the classification of the product as “medicinal product not subject to medical
prescription” (EMA 2009b).
All in all, after review of data on quality, safety, and efficacy/effectiveness, the CHMP con-
sidered by consensus that benefits of Pantoloc Control
®
outweigh risks in the proposed
indication of short-term treatment of reflux symptoms thus being favorable as nonprescrip-
tion product and that granting of the marketing authorization, therefore, was to recommend.
As for alli
®
though, the CHMP did not judge data submitted by the applicant with refer-
ence to Article 74a, Directive 2001/83/EC, as amended, to be of additional significant value
in support of the change of classification and thus declined its one-year data exclusivity
application.
Tamsulosin hydrochloride 0.4 mg (Flomax Relief® MR, Boehringer Ingelheim) In the UK,
reclassification of the active ingredient tamsulosin from POM to P status was recently ap-
proved for the first time worldwide by the UK’s competent authority MHRA.
Based on a UK national procedure, Boehringer Ingelheim applied for P status of tamsulosin
hydrochloride 0.4 mg under the name Flomax Relief
®
MR, indicated for the treatment of
lower urinary tract symptoms (LUTS) in the common male condition of benign prostatic
hyperplasia (BPH) in men aged 45 to 75. The application was submitted as an abridged
application according to Article 10.1(c) of Directive 2001/83/EC cross-referencing to an al-
ready existing Rx marketing authorization of Flomax
®
MR and combined the application
for a new product license with a reclassification application (MHRA 2009).
Tamsulosin is a selective α1-receptor-antagonist preferentially targeting α1A-adrenoceptors
in the prostate versus α1B-adrenoceptors in the aortic tissue (Wilde and McTavish 1996).
Subsequent relaxation of smooth muscles in the prostate and the urethra result in relieving
obstruction and improving urinary flow rate. Thus, symptomatic relief is usually achieved
within 7-14 days of treatment.
Based on its cross-reference to an already approved product, no new pre-clinical or clinical
data were submitted. During the process of reviewing the application, in addition to a public
consultation, the Commission on Human Medicines (CHM) was asked for advice and finally
argued in favor of the reclassification. The positive vote was based on several arguments.
First of all, the benefit-risk ratio of the respective substance was considered positive due
to its proven satisfactory pre-clinical and clinical safety as well as efficacy profile. Second,
the applicant proposed only symptoms to be assessed and treated in the pharmacy, whereas
the condition itself (i.e., BPH) is to be diagnosed and confirmed at subsequent general
practitioner (GP) review. The applicant had developed a comprehensive pharmacy model
including training materials on lifestyle advice, patient monitoring, etc., revised by relevant
professional pharmacy organizations. A pharmacy questionnaire had been developed for
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patients” symptom assessment (based on an international symptom score) supporting an
adequate treatment choice. Continuation of treatment may only occur on recurrent inter-
action of the patient with the pharmacist and GP encouraging men to sign up with one
specific pharmacy which may thus help monitor treatment success. As mentioned in the
public assessment report, this kind of model was supported by study data “showing that
the in-pharmacy assessment, including a suitable questionnaire, ensures that the supply of a
product is consistent with current guidelines” (MHRA 2009). Third, next to a disease aware-
ness and patient support program, the applicant had developed a so-called “Men’s Health
Pack”. A booklet proposed to be placed in the product packaging in addition to the patient
information leaflet was designed in order to inform about the pharmacy supply scheme, allow
for self-assessment of symptoms (through a copy of the symptoms questionnaire) and educate
on lifestyle measures as well as disease management. Moreover, a medication/registration
card to share with the GP should enhance patients’ linkage to their pharmacy and their
medicating GP. Finally, the applicant proposed to, and was advised by, the CHM to conduct
a “post-authorization compliance program” for follow-up monitoring of men’s compliance
with the pharmacy protocol under real-life conditions as well as registration of potential
adverse events to be reported to the CHM/MHRA every six months within a period of two
years (MHRA 2009).
Furthermore, it is important to note that UK’s switch of tamsulosin for treatment of BPH
symptoms was not only the first of its kind worldwide with respect to the active substance
and indication, but also unique when it comes to the provision of data protection. It was
the first Rx-to-OTC switch in Europe which was granted one year of data exclusivity in
accordance with Article 74a of Directive 2001/83/EC, as amended, for data submitted in
support of the reclassification. Data exclusivity was granted with approval of the Rx-to-OTC
switch on December 3, 2009, and hence officially expired on December 2, 2010. Based on
the fact that according to the public assessment report no new pre-clinical and clinical study
data were handed in and no such data could be detected or traced on the relevant internet
sites of the responsible regulatory authority (MHRA) after expiration of the one year’s data
protection period, the author of the present work postulates that exclusivity presumably was
not granted on grounds of any new pre-clinical or clinical study data available at the time
of reclassification, yet supposedly on the basis of the comprehensive supportive data and
material submitted by the applicant instead. As can be derived from the above, this mainly
includes a complex pharmacy supply model as well as disease awareness and management
programs, next to comprehensive patient and pharmacist education measures. Obviously,
without backing by these collateral measures the switch of tamsulosin for the treatment of
LUTS could not have been approved, as Article 74a rules that data exclusivity must only
be granted based on significant data interpreted as “relevant and necessary for the change
in classification” (European Commission 2006a). Moreover, hypothetically, the applicant’s
commitment to delivering post-authorization data verifying the proposed pharmacy supply
scheme under real-life conditions and concurrently monitoring potential AEs may also have
contributed to this reward of data protection.
From a regulatory perspective, this precedent UK switch of tamsulosin is thus to be seen
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as success in regards to the reclassification request itself, but even more so when with a
view towards it being the first and only positive approval of data exclusivity provision for a
Rx-to-OTC switch within Europe to date.
4.4.5 The rationale of data exclusivity provision for switch products
In principle, the same idea that is fundamental to data exclusivity provision for the devel-
opment of prescription drugs (see Section 4.2) is underlying the one for switch products.
As well, the main intention of this incentive tool is to encourage companies to undertake
necessary investments in essential data generation to successfully pursue and establish new
switches of well-established drugs with a favorable safety and efficacy profile (WSMI 2009).
In particular, when applying for the release of a certain substance or drug from prescription-
only status (especially if “first in class”), a new or modified set of tests and/or trials usually
is necessary to confirm effectiveness and safety of a reduced strength, posology, and/or a
new indication intended for OTC status. For example, the generation of data pointing out
that the significant therapeutic benefit for the target group in its intended use might require
considerable effort and investment from pharmaceutical companies. Most notably, in light
of future switches being increasingly complex in nature, resources to be spent on switch
projects should not be underestimated. As can be derived from reclassification examples
depicted above (cf. Section 4.4 ff.), apart from the demonstration of a product’s safe and
effective use in OTC setting, the development of clear and comprehensive guidance to both
HCPs and consumer/patients as well as comprehensive post-marketing pharmacovigilance
and risk management systems seem to be increasingly relevant prerequisites – depending
on the characteristics of the potential switch candidate and the targeted disease. Against
this background, a certain period of data exclusivity obviously is key to a successful Rx-
to-OTC switch, as it allows the originator company the possibility to accordingly prepare
and settle into the OTC market in the absence of a prompt invasion of “me-too” products
from generic competitors that usually do not engage with similar efforts when entering the
market. Moreover, the development of a brand is generally considered as the main potential
competitive advantage of being first-to-market but is as well accompanied by “substantial
and ongoing investment”. Within this context, the “copying of brand trade dress” (so-called
“passing-off”) by competitors was mentioned as a particular concern where the “protection
of investment” (e.g., by awarding data exclusivity) is likewise of interest (AESGP 2011).
As mentioned before (see Section 2.3), Rx-to-OTC switches may implicate significant public
health benefits and economic savings due to easier and faster access to effective treatment
or preventive therapy options eventually resulting in cost and time savings for health care
systems and society in general. Adequate incentives are needed to motivate pharmaceuti-
cal manufacturers to undertake accordant investments necessary to provide well-established,
safe, and effective therapeutic options to a broader target group whose therapeutic benefit
thereby can be maximized. Since Rx-to-OTC switch products in general are not “novel”
and therefore not eligible for patent protection, data exclusivity represents an alternative
incentive to be afforded to companies initiating and conducting a costly, time-consuming
and often also risky switch project.
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4.5 Summary and conclusion
Just like patent protection, data exclusivity constitutes a fundamental intellectual property
right. It has internationally been acknowledged and legally required since the mid-1990s by
important trade agreements – that is, the North Atlantic Free Trade Agreement and the
World Trade Organization’s TRIPS Agreement.
In essence, data exclusivity is provided independently from patent law and bans regulatory
authorities from relying on proprietary data for assessing an abbreviated generic drug ap-
plication during a specific period of exclusivity (in case of switch products three years in
the US and one year in Europe). Respective provisions are laid down in corresponding legal
frameworks, such as: FD&C Act Section 505 (i.e., more specifically, 21 U.S.C. § 355, imple-
mented in 21 CFR 314.108) and Article 74a, Directive 2001/83/EC, as amended by Directive
2004/27/EC, for Rx-to-OTC switches in the US and in Europe, respectively. Accordingly,
applicants are granted exclusivity based on the submission of “significant” data from pre-
clinical tests (EU) or clinical trials (US, EU) meaning they need to be considered crucial
in regards to a positive reclassification decision. However, in contrast to the US, with the
reclassification of tamsulosin in 2009 in the UK there has been only one precedent example
of successful regulatory appliance of legal provisions within Europe to date.
In general, the rationale behind data and/or market(ing) exclusivity provision is the at-
tempt to stimulate resource intensive development of high value medication in the absence
of eligibility for patent protection by a delay of generic invasion. Most notably in light of
augmenting requirements and investments associated with drug research and development,
the existence of such incentive tools is regarded to be of major importance.
As implicated by a trend to more complex switches and indicated by recent practical ex-
amples, a similar increase in requirements and preconditions is to be asserted with a view
to Rx-to-OTC switch approvals. Therefore, in the author’s opinion adequate incentive tools
likewise need to be in place that foster the accelerated and broader access to safe and effective
switch products targeting patients with unmet medical needs, thereby eventually providing
a significant benefit to public health. Yet, based on the fact that switch products occur only
late in a drug’s life-cycle, they naturally are hardly ever able to come up with criteria to be
fulfilled for patent protection (i.e., novelty, utility, and above all non-obviousness). Against
this background, according to the author, data exclusivity provides a valuable alternative
means of protecting comprehensive proprietary data to be generated within the context of
an Rx-to-OTC switch over a certain period of time after reclassification. More specifically,
depending on the complexity of a specific switch proposal, the author considers it as an
important success factor for originator companies to be motivated to develop and provide
a comprehensive framework (including: e.g., post-marketing surveillance, drug product sup-
ply, risk management, etc.) necessary for successful implementation and establishment in
the market.
However, unfortunately, on the grounds of the hitherto existing all but one negative examples
of data exclusivity application within Europe, the author concludes its current practicability
to be rather limited.
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4.6 Legal framework of data exclusivity provision for Rx-to-OTC switches
in the EU at status quo – a critical analysis
On a European basis, the only basic approach to interpretation of the current legislation
on data exclusivity for switch products is given in part III of the “Guideline on Changing
the Classification for the Supply of a Medicinal Product for Human Use”. According to
this guideline, pre-clinical tests and/or clinical trials are considered “significant” if they are
“relevant and necessary to the change of classification” (European Commission 2006a). As
reflected by the aforementioned examples of data exclusivity application for switch products
in the EU (see Subsection 4.4.4), this interpretation is, however, not at all concrete and does
not provide detailed information on what kind of data might comply with Article 74a and
the switch guideline, respectively. Therefore, from a legal perspective the term “significant”
as it is used in Article 74a of Directive 2004/27/EC, as well as the terms “relevant” and
“necessary” as used in the EU “Guideline on Changing the Classification” constitute so-
called “indeterminate legal terms” lacking a clear, unambiguous interpretation, concretion,
and implementation within this specific context. Moreover, a clear definition and outline of
data requirements regarding “pre-clinical tests”, but especially “clinical trials” is missing.
Requested data categories, criteria, standards, and quality aspects are likewise unmentioned.
In fact, based on the above mentioned, it could even be argued that the current interpretation
of Article 74a of Directive 2004/27/EC is rather a “hindrance” instead of being adjuvant
with a view to the provision of data exclusivity when transferring a drug from prescription
to nonprescription status. Of course, it has to be borne in mind that the provision of
data exclusivity implies both a huge political and economic dimension due to the fact that
exclusivity certainly prevents (generic) competition and thus price erosion for a limited period
of time – a situation which is not always welcomed.
Within this context it is important to note that the legal clarity of the EU Directive and
subsequent amendments have been fairly influenced by political considerations resulting
in the fact that certain issues such as the grant of data exclusivity are still vague and
therefore much debated as many formulations and provisions are incomplete (WSMI 2009).
Experts also state that the award of exclusivity for switch products throughout the world
still is largely insufficient to justify and safeguard further investment within this therapeutic
movement (AESGP 2011).
Based on the aforementioned, the author has developed two main hypotheses regarding the
issue of data exclusivity provision for Rx-to-OTC switch products within Europe which will
be analyzed in detail and discussed below.
4.6.1 Hypothesis 1: The current EU legal framework makes it virtually impossible to reach
data exclusivity for Rx-to-OTC switches based on the given criteria and data categories.
As can be understood from the above, within the context of interpreting Article 74a of Di-
rective 2004/27/EC regarding data exclusivity provision for Rx-to-OTC reclassifications, the
current switch guideline does indeed stress the importance of confirmatory pre-clinical test
or clinical study data with respect to a drug’s safety and efficacy profile in case of any modi-
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fication (i.e., dosage strength, pharmaceutical form, duration, or modalities of treatment, as
well as indication, etc.). Furthermore, “significant” data as a basic requirement for eligibility
for data exclusivity currently is interpreted and defined as “relevant and necessary to the
change of classification”.
However, this interpretation of the respective legal specification implicates all or nothing. Its
concept remains rather indeterminate and no guidance is given with respect to specification
and interpretation of relevant data categories, criteria and requirements. Hence, it is not
astonishing that apart from one precedent case in the UK (switch of tamsulosin), success-
ful Rx-to-OTC switch applications claiming data exclusivity based on the EU’s actual legal
framework and its interpretation are still being awaited.
Against this background and in the author’s opinion, the currently changing nature of Rx-
to-OTC switches in terms of both indications and drug products directing towards an in-
creasingly autonomic self-management of people’s health should definitely be reflected by the
setup of accordant criteria and data categories for the provision of data exclusivity within
future reclassification processes. Besides, requirements for data exclusivity in the context
of Rx-to-OTC switches should finally be in analogy with the general evolution of switch
criteria, described in Section 3.2, where the focus of regulatory assessment obviously was
complemented by or has even shifted from the mere evaluation of substance and product
properties towards the demonstration of a patient’s safe and effective use of a switch product
for the treatment or management of a certain condition.
Moreover, according to the author, the current one-year data exclusivity period for Rx-to-
OTC switches in Europe is to be challenged based on the considerations above. A period
of one year in the author’s opinion seems to be rather short for successfully settling or - de-
pending on the scenario – establishing a new (sub)category in the market.
Thus, in summary, further clarity, transparency, amendment, and adaptation is needed on
the current interpretation of the legal provisions for data exclusivity to be granted to future
switches. Only if there is a common understanding of what set of data, etc. seems to be
appropriate in order to be eligible for data exclusivity, will this “incentive tool” work as such,
leading to the second main hypothesis of the present work which is depicted below.
4.6.2 Hypothesis 2: Available criteria and data categories have to be specified and new ones
have to be developed to enable the provision and receipt of data exclusivity for Rx-to-OTC
switches.
Specific characteristics and trends in the Rx-to-OTC switch movement, the definition and
implication of data exclusivity as well as current European legal provisions and interpreta-
tions within this context were analyzed in the previous chapters. As discussed above, the
present existence of exclusivity criteria and data category requirements for switch products
is rather questionable and incomplete especially with respect to future self-medication with
switched OTC products. Against this background, next to the discussion, interpretation,
and specification of current data categories, further potential eligibility criteria as well as
data categories will have to be elaborated upon, analyzed, and discussed explicitly focus-
ing on appropriateness, feasibility, and applicability aspects with regards to data exclusivity
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provision for Rx-to-OTC switches targeting the setting of self-medication.
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5 Case study analysis: Rx-to-OTC switch of clotrimazole for
the treatment of vaginal candidiasis
For the purpose of verification of the aforementioned hypotheses (cf. Subsections 4.6.1
and 4.6.2), the reclassification of clotrimazole for the treatment of vaginal candidiasis was
retrospectively analyzed comparing pre-clinical and clinical data categories available at its
registration as prescription medicine with those at its subsequent Rx-to-OTC switch. The
primary objective was the identification of potential major gaps in data requirements and
data generation (i.e., availability) for each submission. In theory, if existent these gaps could
then serve as reference points for new data to be generated within the context of an Rx-to-
OTC switch potentially eligible for the provision of data exclusivity.
Clotrimazole is a tritylimidazole derivative (triphenylimidazolylmethane) which was synthe-
sized at the Bayer Research Center in 1967 as the first member of a new class of substances
showing effective antimycotic activity (Clayton 1977; Plempel 1982). It was registered and
marketed in 1973 for the first time primarily on the grounds of treating vaginal and skin
infections caused by yeasts and dermatophytes (Sawyer et al. 1975). In vivo, the drug is
highly effective against the Candida species (Clayton 1977) and seems to have some antibac-
terial property (Sawyer et al. 1975). Products with the active ingredient clotrimazole have
since been marketed by its originator Bayer under the Canesten
®
brand. Many delivery
and therapy forms are available, by now ranging from its application as powder, solution, or
cream to (vaginal) tablets depending on the respective indication it is used for.
Clotrimazole has been available OTC as of 1977 for the treatment of skin infections immedi-
ately after expiration of the automatically triennial obligation to be marketed as prescription
drug effective at that time (according to § 35a, German Medicines Law,1961). In contrast,
after automatically having been available as prescription only for three years, clotrimazole
was classified to stay Rx within the indication of vaginal infections according to § 35, German
Medicines Law, 1961. Hence, it has only been available for self-treatment of vaginal can-
didiasis as of 1993 when it was switched from Rx to OTC status for this indication. Today,
in Germany all Canesten
®
products, aside from the six-day-therapy of vaginal mycosis, are
available without prescription.
5.1 Excursus: overview of the development of the German Medicines Law
As mentioned above (q.v. Chapter 5), in Germany the first Canesten
®
drug products were
registered in 1973 (application submitted in 1971) and switched for the treatment of vaginal
yeast infection in 1993. In order to understand the legislative framework that governed these
processes and its development to present in Germany, a short overview of the development
of the German Medicines Law is depicted in Table 5. An institutional national Medicines
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Law was first introduced in 1961. One major difference from the Medicines Law as it is
effective today is the fact that drug substances, so-called proprietary products (“Arzneis-
pezialita¨ten”), had not to be authorized by a special approval procedure but simply to be
listed on a specific index (“Spezialita¨tenregister”) based on a standard form being filled in
with required details. After several changes and amendments the most important of which
was the “thalidomide amendment” in 1964 as reaction to the well-known thalidomide14 disas-
ter, the German Medicines Law was extensively reformed in 1976. A comprehensive approval
procedure in compliance with existent legal requirements and guidelines has since become
compulsory for the authorization of a new drug. The reformed Medicines Law came into
effect in 1978 and has since formed the fundament of the current German Medicines Law of
which the 16th amendment has become effective in 2012.
14 Thalidomide is a hypnosedative drug introduced in the 1950s and taken as a sleeping aid under the brand
Contergan®. It was withdrawn from the world market (after it had been reclassified to prescription status in
some German federal states, cf. Subsection 3.5.2) in late 1961 due to its potential to cause infant limb defects.
Interestingly, thalidomide was never marketed as sleeping aid in the US, as the FDA had objected to the lack of
chronic toxicity studies (Kirk and Friedrich 2001). However, the active substance thalidomide has since been
selectively reintroduced for use in autoimmune and inflammatory conditions (Tseng et al. 1996) and might play
a potential role in inhibition of tumor angiogenesis (Seitz 2001).
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Table 5: Overview of the development of the German Medicines Law (based on Blasius 2003; Gall 2009)
German
medicines
law
Up to 1961 1961 (introduction) 1976 (reform, effective as of
1978)
Characteristics  No consistent national
Medicines Law
 Some regulations for certain sub-
stances only (e.g., vaccines, etc.)
 Law on the marketing of drugs
 Introduction of manufacturing
permission: requirements regard-
ing development, manufacturing
and marketing
 Introduction of index-listing
of so-called proprietary prod-
ucts, but not of generic prod-
ucts:
– no obligation regarding ef-
ficacy and safety trials
for originator drugs to be
listed
– for substances and for-
mulations not commonly
known a report regarding
kind and amount of po-
tential side effects was re-
quired only
 Definitions and terminologies
 17 changes until drug law reform
in 1976
 New structured and stricter law
on the marketing of drugs and le-
gal basis of the current German
Medicines Law (adapted to Eu-
ropean legislation)
 Introduction of authorization
of drug products and generic
products:
– approval procedure (docu-
ment review) for all except
homeopathic drug prod-
ucts
– proof of quality (GMP), ef-
ficacy, and safety
 Stricter monitoring of drug mar-
keting:
– stricter requirements for
packages and leaflets
– development of an in-
formation system for
documentation, evaluation
and management of ad-
verse events (graduated
plan procedure)
Continued on next page. . .
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Table 5 – Continued
German
medicines
law
Up to 1961 1961 (introduction) 1976 (reform, effective as of
1978)
 Introduction of absolute liabil-
ity of pharmaceutical manufac-
turer and safety regulations for
study participants (e.g., insur-
ance, etc.)
 Further refinement of definitions
and technologies
 Implementation of European
guidelines (European Economic
Community (EEC))
 16 amendments up to date
Continued on next page. . .
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Table 5 – Continued
German
medicines
law
Up to 1961 1961 (introduction) 1976 (reform, effective as of
1978)
Major changes
and amend-
ments
 First drafts for a separate na-
tional Medicines Law in 1928,
1931, 1933, and 1938, yet with-
out implementation
 2nd Amendment 1964 (“Thalido-
mide amendment”):
– requirement to report pre-
clinical and clinical evalua-
tion for substances and for-
mulations not commonly
known according to re-
spective scientific know-
ledge (§ 21, 1a+b)
– general prescription-only
availability of substances
and formulations not
commonly known lasting
for (at least) three years
(§ 35a, 1-4)
 2nd Amendment 1986:
– clinical evaluation imputed
to surveillance by author-
ities under obligation to
submit clinical investiga-
tion plan
 7th Amendment 1998:
– implementation of addi-
tional authorization proce-
dures according to Euro-
pean regulations: CP and
MRP
 12th Amendment 2004:
– implementation of Euro-
pean guidelines: Good
clinical practice (GCP)
regulation replaces require-
ment to disclose towards
authorities by approval
procedure through ethical
review committee
– clinical drug assessment re-
quired in children and ado-
lescents if intended to be
authorized for use in these
patient groups
– Periodic Safety Update
Report (PSUR): re-
quirement to extensively
document and disclose any
(suspected) adverse event
Continued on next page. . .
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Table 5 – Continued
German
medicines
law
Up to 1961 1961 (introduction) 1976 (reform, effective as of
1978)
 14th Amendment 2005:
– implementation of DCP
– omission of § 49, i.e., dis-
continuation of the require-
ment of new substances au-
tomatically being classified
Rx, but also automatic re-
classification to OTC (if
applicable)
– implementation of Eu-
ropean guidelines (e.g.,
“Guideline on traditional
herbal medicines”)
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5.2 Gap analysis: original registration vs. Rx-to-OTC switch of clotrima-
zole (Canesten®) for the treatment of vaginal candidiasis
Based on a short overview of the legislative environment, data categories available at both
the time of its original registration for the therapy of vaginal mycosis and the corresponding
Rx-to-OTC switch of clotrimazole, respectively, will be analyzed below.
5.2.1 Legislative environment
The development of the German Medicines Law has been and is still in large part guided
and influenced by the European legislative environment. On a legal basis, several directives
and regulations have been ground-breaking. Some of them judged to be of major relevance
are listed in Tables 6 (e.g., Directive 65/65/EEC, “Clinical Trials Directive”, or “GCP Di-
rective”) and 7, respectively.
In parallel, big institutions such as the WHO or OECD have developed and released impor-
tant guidelines to be considered in a drug development process. Standard references and
quality requirements, for example, have been established by the European Pharmacopoeia
(Pharm. Eur.). These guidelines as well as the legal requirements mentioned above (e.g.,
“Good Manufacturing Practice” (GMP), “Good Laboratory Practice” (GLP), “Good Clin-
ical Practice” (GCP), etc.) are primarily based on the so-called “Declaration of Helsinki”
of 1964 which was adopted by the 18th General Assembly of the World Medical Association
(WMA)15 and contains ethical principles essential for medical research involving human sub-
jects.
The biggest guideline compilation with respect to drug authorization requirements is by now
represented by the so-called ICH Guidelines (“International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceuticals for Human Use”). Its evolution
is mainly due to the effort of harmonizing guidelines and requirements for the registration
of pharmaceuticals against the background of the establishment of one single (European)
market for pharmaceuticals. Based on independent discussions about harmonization pos-
sibilities, Japan and the US joined the initiative and shortly thereafter the ICH was born
(April 1990)16. Today, more than eighty guidelines are provided in four main categories,
namely: efficacy, safety, quality, and multidisciplinary guidelines. Major ICH guidelines
have also been implemented in national and international legislation.
Table 8 gives an overview of selected relevant guidelines which have been developed over
the years. As Canesten
®
for the treatment of vulvovaginitis (in the following discussion its
actual brand name “Canesten
®
GYN” will be used) is analyzed in the present work, the
date of its original registration in 1963, its switch from prescription to nonprescription status
in 1993, and the situation today (2012) were used as time frames for the tabular overview.
15 cf. http://www.wma.net/en/30publications/10policies/b3/, last accessed 2013-01-06
16 cf. http://www.ich.org/about/history.html, last accessed 2013-01-06
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Table 6: European legislative framework (as amended) relevant for the autho-
rization process of medicinal products for humans in 1973 (original registration
of Canesten®), 1993 (Rx-to-OTC switch of Canesten®), and at present (selec-
tion)
1973 1993 2012
• Directive 65/65/EEC 17 • Directive 75/318/EEC 18
• Directive 75/319/EEC
• Directive 92/26/EC
(“Classification Directive”)19
• Directive 93/41/EEC
• Directive 2001/20/EC
(“Clinical Trials Directive”)
• Directive 2001/83/EC
• Directive 2003/94/EC (“GMP
Directive”)20
• Directive 2005/28/EC (“GCP
Directive”)21
• Regulation (EEC) No 2309/93 • Regulation (EC) No 726/2004
17 first European pharmaceutical directive providing quality guidelines for the development and manufacturing of
drugs, pharmacovigilance guidelines and three criteria for the registration of new drugs – safety, quality, and
therapeutic efficacy (Schmucker 2006)
18 approximation of the laws of member states relating to analytical, pharmaco-toxicological, and clinical standards
and protocols in respect of the testing of proprietary medicinal products
19 Cranz 1999
20 GMP = “Good Manufacturing Practice” relates to international regulatory requirements regarding the manufac-
turing and control of products in health care, food, and cosmetic sectors (Bliem 2004)
21 GCP = “Good Clinical Practice” represents an international ethical and scientific quality standard with respect to
the design, conduct, record, and reporting of trials with participation of human subjects (EMA 2002)
22 “Richtlinie u¨ber die Pru¨fung von Arzneimitteln” announced by German Federal Health Minister Ka¨te Strobel
– first directive in Germany for the assessment of drugs on the basis of European legislation and guidelines,
respectively
23 “Arzneimittelpru¨frichtlinien”
24 “Grundsa¨tze fu¨r die ordnungsgema¨ße Durchfu¨hrung der klinischen Pru¨fung”
25 “Verordnung u¨ber die Anwendung der guten klinischen Praxis bei der Durchfu¨hrung von klinischen Pru¨fungen
mit Arzneimitteln zur Anwendung am Menschen”
26 “Bekanntmachung zur klinischen Pru¨fung von Arzneimitteln am Menschen”
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Table 7: German national legislative framework (based on EU provisions) rel-
evant for the authorization process of medicinal products for humans in 1973
(original registration of Canesten®), 1993 (Rx-to-OTC switch of Canesten®),
and at present (selection)
1973 1993 2012
• German Medicines Law 1961
including amendments until
1973
• Directive regarding the
evaluation of drugs (1971)22
• German Medicines Law 1976
including amendments until
1990
• Drug evaluation directives (cf.
§ 26 German Medicines Law)23
• Principles on the Conduct of
Clinical Trials (1987)24
• German Medicines Law
including amendments until
2012
• Drug evaluation directives
(1995)
• Regulation regarding GCP with
respect to the Conduct of
Clinical Trials with drugs
intended for human use (GCP
Regulation 2004) 25
• Announcement regarding the
clinical evaluation of drugs in
humans (2006)26
Table 8: Relevant guidelines with respect to the authorization process of medic-
inal products for humans in 1973 (original registration of Canesten®), 1993
(Rx-to-OTC switch of Canesten®), and at present (selection)
1973 1993 2012
• Declaration of Helsinki
(1964)27
• EC Guidelines (various)28
• WHO GMP Guidelines
(endorsed 1969)29
• European Pharmacopoeia (Ph.
Eur., 1st edition)30
• EC GMP Guideline (first
published 1989)
• EC GCP Guideline (operational
as of 1991)
• OECD GLP principles (first
published 1992)
• European Pharmacopoeia (Ph.
Eur., 2nd edition)
• EMA (CPMP/CHMP)
Scientific Guidelines
• ICH Tripartite Guidelines31, 32
• WHO GCP Guidelines (first
published 1995)
• OECD GLP principles
(updated 1997)
• European Pharmacopoeia (Ph.
Eur., 7th edition)
• ISPE GPP Guidelines33
• IEA GEP Guidelines 34
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5.2.2 Overview of data (categories) required for and available at original registration and
Rx-to-OTC switch
Against the legislative background illustrated above, data requirements and data available,
respectively, at the time of the original registration of Canesten
®
and at the time of its Rx-
to-OTC switch for the treatment of vaginal mycosis were analyzed and compared in order
to identify potential disparities and gaps.
For comparability reasons the different data categories of the so-called Common Technical
Document (CTD) provided by the ICH as a standard set of specifications for (new) drug
application dossiers and consisting of five different modules35 were used as basic guidance
to structure this gap analysis. Furthermore, as specific preconditions have to be fulfilled
before a substance and/or indication will be allowed to be switched to self-medication, OTC
specific requirements and data categories were equally included in the analysis.
In order to check the availability of different data categories according to the requirements
at the respective time points of Canesten
®
’s original registration and its reclassification to
OTC, all relevant documentation (i.e., dossiers, pre-clinical test and clinical study reports,
publications, etc.) still retrievable and either published or unpublished was screened and
27 a set of ethical principles for medical research with the participation of human subjects which was developed
by the World Medical Association and adopted in 1964 in Helsinki, Finland (cf. http://www.wma.net/
en/30publications/10policies/b3/17c.pdf, last accessed 2013-01-20) and is “the most widely accepted
guidance worldwide on medical research involving human subjects” today (Christie 2000)
28 later published by the EMA which was founded in 1995
29 GMP guidelines recommended and issued by the World Health Organization (WHO) since 1969 to support
quality assurance of pharmaceutical products
30 based on the Convention developed by the Council of Europe on the Elaboration of a European Pharmacopoeia
in 1964 (Convention on the Elaboration of a European Pharmacopoeia, 1964, cf. http://conventions.
coe.int/Treaty/Commun/QueVoulezVous.asp?NT=050&CL=ENG, last accessed 2013-01-24); single refer-
ence work for the signatory states of the Convention on its elaboration, providing a legal and scientific basis
for standard quality control during the development, production, and marketing processes of medicines (q.v.
http://www.edqm.eu/site/background-50.html, last accessed 2013-01-24)
31 ICH = “International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuti-
cals for Human Use”, unique initiative that has brought together since 1990 the drug regulatory authorities and
the pharmaceutical industry of Europe, Japan and the United States initially focusing on the development of
harmonized ICH Tripartite Guidelines regarding criteria and documents required for approval and authorization
of new medicinal products intended for use in ICH regions (cf. http://www.ich.org/about/vision.html,
last accessed 2013-01-21), > eighty guidelines and annexes in the four categories efficacy, safety, quality and
multidisciplinary guidelines (Kuhnert 2011); implemented in European legislation as well as EMEA scientific
guidelines
32 including the EU switch guideline (European Commission 2006a) which has been adopted in 1998 (cf. Section
3.3)
33 International Society for Pharmacoepidemiology (ISPE). Guidelines for Good Pharmacoepidemiology Practice
(GPP), issued 1996, revised August 2004 & April 2007 (q.v. http://www.pharmacoepi.org/resources/
guidelines_08027.cfm, last accessed 2012-07-21)
34 International Epidemiological Association (IEA) European Federation. Good Epidemiological Practice (GEP) –
IEA Guidelines for proper conduct of epidemiological research. November 2007
35 module 1= administrative and prescribing information; module 2 = overview and summary of modules 3 to 5;
module 3 = quality (pharmaceutical documentation); module 4 = safety (toxicology studies); module 5 = efficacy
(clinical studies)
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evaluated according to its classification based on the different data categories. A summary
of the analysis is provided in Table 9.
As can be derived from this tabular overview, in principle the main data categories of pre-
clinical, but also clinical drug development phases were in existence back in 1973. The main
differences between then, 1993 (i.e., the time of the Rx-to-OTC switch of Canesten
®
GYN),
and today are in scientific and technological progress, on the one hand, and the advancement
of ethical principles and considerations, on the other.
To give an example with respect to pre-clinical data, genotoxicity testing has among others
been added to the range of toxicological evaluation due to increasing scientific knowledge
and the development of newer and increasingly sensitive analytical and diagnostic tests. Be-
sides, on the grounds of a growing pool of drug substances aimed at widely varying target
molecules associated with more and more different metabolic pathways, naturally more ex-
tensive evaluation of drug interaction potential has been required and performed over the
years and has set a high standard for current drug evaluation.
When it comes to ethical aspects, based on a continued evolution of existent guidelines and
the addition of new ones (e.g., regarding GLP, GMP, GCP, ICH guidelines, etc.), require-
ments regarding the conduct of clinical studies, for example, have constantly risen. Provisions
regarding study population, size, design, documentation, etc. are clearly specified and not
least determined by the legislative environment. However, back in 1973, basic principles of
randomization control, blinding, and comparison with existing therapeutic alternatives were
already valid and required by legislation - even though not yet that formalized (cf. Tables
6, 7, 8 and 9).
Due to the availability of comprehensive data generated for Canesten
®
’s registration as a
prescription drug and during its post-marketing phase meeting the basic requirements for
drug application as effective in 1973 and still valid in 1993 in its kind, the Rx-to-OTC switch
of Canesten
®
GYN was primarily a bibliographic one (i.e., referencing existing pre-clinical
test and clinical study data). Thus, based on 1993 general data requirements for both the
application of a new drug as well as an Rx-to-OTC switch of an existing drug (the European
Commission’s switch guideline was yet not in place), no additional pre-clinical or clinical data
had to be or were, respectively, generated. Instead, existing data was reviewed, analyzed,
evaluated, and summarized by a scientific expert according to current scientific knowledge.
In view of a substance and/or indication to be registered OTC or to be switched from pre-
scription status to nonprescription safety, efficacy/effectiveness, and self-assessment under
OTC conditions deserve special attention and evaluation. Whereas none of these categories
were relevant at the time of the original Canesten
®
registration as prescription drug, it has
become important for its Rx-to-OTC switch. For this purpose and in the absence of a specific
guideline (like today’s EU switch guideline) existent (post-marketing) Rx data were evaluated
with respect to conditions relevant for intended OTC usage. Market research instruments
were employed to collect patient data regarding knowledge, attitudes, and behavior as well
as treatment options used in association with vaginal candidiasis and to judge the ability of
self-diagnosis as well as the potential for mis– or abuse. A two-step survey design provided
qualitative insight through a small pilot study, whereas quantitative information was gained
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via questionnaires sent to a representative study population of women from all over Germany
who had had a preceding vaginal infection (data on file). This kind of enquiry was probably
able to provide decision makers with an anticipated “feeling” of how the disease would be
diagnosed and treated under daily conditions of OTC usage. The fact that it demonstrated
that women suffering from repeated infection seem to self-diagnose correctly due to familiar
symptoms and that most of them do not consult their doctor right away (mainly not until
after one week) was certainly pivotal to the decision of switching Canesten
®
GYN to OTC so
as to offer the possibility of immediate access to treatment. Therefore, from a retrospective
point of view, the basic idea behind this kind of data might have been able to qualify for
data exclusivity, if it had been existent at that time, and might be seen as seminal (at least
with regards to content) to the definition of respective data categories today.
Aside from market research instruments specific study designs are available nowadays, such
as “actual use” or “self-selection” studies in order to investigate correct self-diagnosis, com-
pliance, effectiveness, and safety, etc. in a nonprescription setting and anticipate actual OTC
usage (q.v. Subsection 9.3.3). However, as these study designs – at least the way they are
conducted in the US - do not represent clinical trials in a classical sense (like phase I-III stud-
ies) and study objectives are different from typical post-marketing surveillance studies (phase
IV) generally required throughout pharmaceutical development (Bradford et al. 2010), ac-
ceptance of such “real-world data” by regulatory authorities still significantly varies. One
reason might be that the validity of observational research study data (cf. Chapter 7) con-
siderably differs as definite standards regarding study design and statistical evaluation have
not yet been determined. In contrast, as label comprehension is an important prerequisite
for correct and compliant self-medication in general, “label comprehension” or “readability”
tests have been recommended for several years, though not yet common at the time of the
Rx-to-OTC switch of Canesten
®
GYN.
5.3 Summary and conclusion
The case study of Canesten
®
GYN was retrospectively analyzed in order to determine po-
tential differences between data requirements and data available at the time of its original
registration as prescription drug in 1973 compared with the situation of its reclassification
to OTC in 1993. To this end, the concomitant development of relevant legislations and
guidelines both at a national and European level was taken into account disclosing that the
main advancements over time are to be found in scientific and technological progress as well
as ethical aspects, yet that fundamental principles in the main data categories of pre-clinical
and clinical drug development phases were already existent back in 1973.
In conclusion, the showcase of Canesten
®
GYN demonstrates that unless the term “sig-
nificant” is further substantiated and “pre-clinical tests” as well as “clinical trials” in the
absence of precise specification are interpreted other than in a conservative (i.e., classical)
way, the availability of usually extensive pre-clinical and clinical data from a drug’s original
Rx registration in practice virtually leaves no room for novel data generation eligible for the
award of data exclusivity to a certain Rx-to-OTC switch. Moreover, it can be postulated
that this holds even true for older substances (such as clotrimazole in the example used
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here) which for the most part already comply with basic scientific and ethical demands in
pre-clinical and clinical research.
Instead, market research data that had been generated for the support of a change of classifi-
cation of Canesten
®
GYN provided valuable insight into patients’ ability to self-diagnose and
presumably constituted a crucial component in the final reclassification decision. Besides,
epidemiological study data demonstrating patients’ ability to correctly self-select and/or self-
medicate in an OTC setting could possibly have further complemented the existing Rx data
pool in the Canesten
®
GYN case with respect to self-medication issues. Yet, if such data
could have qualified for data exclusivity from the (retrospective) perspective of the current
legislation is not clear on the basis of its insufficient specification and indistinct, or rather
absent, interpretation at present.
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Table 9: Overview of data requirements and data availability at the time of the original registra-
tion and the Rx-to-OTC switch of Canesten® for the treatment of vaginal mycosis (actual brand
name “Canesten® GYN”) compared to current requirements
1973
Canesten® original 
registration
1993
Canesten® GYN
Rx-to-OTC switch 
(bibliographic)
Now (2012)
Preclinical requirements
Pharmacology
Primary  pharmacodynamics x x x ø (Ref. to existent Rx data) x
Secondary pharmacodynamics 
(not required for core safety assessment)
ø ø ø ø (Ref. to existent Rx data) (x)
Safety pharmacology x x x ø (Ref. to existent Rx data) x
Pharmacodynamic interactions (x) ø x ø (Ref. to existent Rx data) x
Pharmacokinetics
Analytical methods and validity reports 
(if available)
x x x ø (Ref. to existent Rx data) x
Resorption, distribution, metabolism, elimination x Only single dose x ø (Ref. to existent Rx data) x
Pharmacokinetic drug interactions x x x ø (Ref. to existent Rx data) x
Other preclinical studies ø ø (x) ø (Ref. to existent Rx data) (x)
Toxicology
Single dose Acute Acute x ø (Ref. to existent Rx data) x
Repeated dose
(depending on duration of clinical investigation)
Subacute, chronic Subacute, chronic x ø (Ref. to existent Rx data) x
Genotoxicity 
(in vitro , in vivo  incl. toxicokinetic evaluation)
ø ø ? ø (Ref. to existent Rx data) x
Carcinogenicity 
(long-, short-, or medium-term studies, other studies)
x x x ø (Ref. to existent Rx data) x
Reproductive and developmental toxicity 
(fertility and embryonic development, embryo/fetal development, 
pre- and postnatal development (with offspring dosed/evaluated))
x x x ø (Ref. to existent Rx data) x
Local tolerance studies x x x ø (Ref. to existent Rx data) x
Other toxicity studies 
(antigenicity, phototoxicity, metabolites, dependence, impurities, 
etc.)
ø ø ? ø (Ref. to existent Rx data) x
Documentation
(Tabulatory) summary of preclinical study results 
including description of test systems and methods 
used
x x x
Short (bibliographic) summary/
overview of pharmacological 
properties -> monograph?!
x
Discussion and conclusion of all relevant preclinical 
study data regarding safety of drug under investigation 
to evaluate benefit-risk ratio for human clinical testing 
in intended indication(s)
x x x
x 
(Discussion with respect to 
self-medication)
x
Continued on next page. . .
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Table 9 – Continued
General
Evaluations based on current scientific knowledge 
regarding methodology, biometrics, and ethical 
requirements
Basic x x x
Advanced 
(max. validity, min. 
bias/confounders)
Relevant guidelines: GLP, etc. ø ø x ø x
Use of different animal species (males and females) x x x ø (Ref. to existent Rx data) x
Examination of different (inteded) forms 
of administration
x x x ø (Ref. to existent Rx data) x
Additional
Discussion of advantages against therapeutic 
alternatives
x x x ø
Clinical requirements
Clinical phase I + II
Healthy subjects/patients Primary  pharmacodynamics x x x ø (Ref. to existent Rx data) x
Secondary pharmacodynamics 
(not required for core safety assessment)
ø ø ø ø (Ref. to existent Rx data) x
Pharmacodynamic interactions (x) ø x ø (Ref. to existent Rx data) x
Healthy subjects/patients
Resorption, distribution, elimination, metabolism, 
excretion
x x x ø (Ref. to existent Rx data) x
Bioavailability/Bioequivalence x x x ø (Ref. to existent Rx data) x
Pharmacokinetics of active metabolites x x x ø (Ref. to existent Rx data) x
Pharmacokinetic interactions x x x ø (Ref. to existent Rx data) x
In vitro  - in vivo  correlation studies x x x ø (Ref. to existent Rx data) x
Dose-response (dose finding) studies x x x ø (Ref. to existent Rx data) x
Dose dependency and time course of 
pharmacokinetics
x x x ø (Ref. to existent Rx data) x
Initial tolerability x x x ø (Ref. to existent Rx data) x
Human pharmacodynamic studies
Human pharmacokinetic  studies
Continued on next page. . .
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Table 9 – Continued
Clinical phase III + IV
Efficacy and safety 
Controlled clinical trials pertinent to the claimed 
indication, including special (at risk) populations, 
comparison with therapeutic alternatives
RCTs 
recommended
 (no specific study 
protocol  regarding 
size/kind of study 
population, etc.)
x x ø (Ref. to existent Rx data)
Detailed study 
protocol required 
(based on Clinical Trials 
Directive/ICH/
GCP)
Uncontrolled clinical trials Not recommended x x ø (Ref. to existent Rx data) x
Post-marketing experience ø ø x x (Ref. to existent Rx data) x
Documentation
Background and overview x x x x x
(Tabulatory) summary of clinical study results x x x x (Ref. to existent Rx data) x
Comparison and analyses of results across studies, also 
regarding sub-populations
x x x x (Ref. to existent Rx data.) x
Persistence of efficacy and/or tolerance effects x x x x
Analysis of clinical information relevant to 
dosing recommendations
x x x x x
Drug exposure: overall safety evaluation plan, 
narratives of safety studies, overall extent of 
exposure
ø ø ? x (Ref. to existent Rx data) x
Adverse event analysis by organ system x x x x x
Clinical laboratory evaluations of vital signs,
physical findings, etc. related to safety
x x x x x
Safety in special population groups and situations
(e.g., drug interactions, pregnancy, overdose, abuse, effect on ability 
to drive, withdrawal/rebound)
x x x x x
Inclusion/exclusion/discontinuation criteria x x x x (Ref. to existent Rx data) x
Description of methodology, study design etc.
(e.g., statistics:  level of significance, study subject selection, 
management of missing data, etc.)
x x x x (Ref. to existent Rx data) x
Case report forms and individual patient listings x x x ø (N/A)
General
Submission of complete documentation and all results 
(on request)
x x x ø (N/A) x
Evaluations based on current scientific knowledge 
regarding methodology, biometrics, and ethical 
requirements
Basic x x x
Advanced 
(max. validity, min. 
bias/confounders)
Relevant guidelines/legal requirements: Clinical Trials 
Directive, GCP Directive, ICH guidelines
ø ø ø ø x
Examination of different (intended) forms 
of administration
x x x x x
Continued on next page. . .
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Table 9 – Continued
Quality information
Technical details and specifications regarding drug 
substance, excipients and drug product (e.g., reference 
standards / materials, stability, etc.), and manufacture
x x x x (Ref. to existent Rx data) x
Relevant guidelines: GMP 
(x) Not yet in 
legislation
(x) x ø (N/A) x
Administrative information
Product information: Summary of Product 
Characteristics (SPC), labeling, and package leaflet
x (w/o SPC) x (w/o SPC) x ø x
Results of readability tests ø ø ø ø x
Information about experts used for review/
evaluation 
x x x x x
Environmental risk assessment ø ø ø ø x
Pharmacovigilance: risk management plan (RMP), etc. ø ø ø ø x
OTC specific requirements
Efficacy and safety 
Ability of self-diagnosis ø (N/A) ø (N/A) x
x
(Market research data)
x
Efficacy and safety of dosage form(s) intended 
for OTC usage (e.g., evaluation of strength, indication, 
route of administration), comparison with therapeutic 
options already available OTC
ø (N/A) ø (N/A) x
x 
(Ref. to existent Rx data: RCTs, 
epidemiological studies)
x
Risk of masking underlying serious diseases ø (N/A) ø (N/A) x
x
(Market research data, etc.)
x
Potential of overdose/abuse ø (N/A)) ø (N/A) x
x
(Clinical expert review)
x
Clinical expert review on potential OTC usage ø (N/A) ø (N/A) x x x
OTC drug exposure/post marketing experience 
(if available, e.g., from other countries)
ø (N/A) ø (N/A) x
(x)
Only overview of classification 
status worldwide
x
(Sales, patient 
exposure, PSUR 
data, etc.)
Label comprehension: readability test ø (N/A) ø (N/A) ø  ø x
Self-selection ø (N/A) ø (N/A) ø ø (x)
Actual use: efficacy, safety, compliance, 
overdose/abuse
ø (N/A) ø (N/A) ø ø (x)
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6 Qualitative research: expert opinions at a glace
The primary insight gained from the aforesaid Canesten
®
GYN case study is an obviously
quite limited practicability of the existent indefinite legal framework regarding data exclu-
sivity provision for Rx-to-OTC switches based on conservative interpretation. The following
chapters are therefore dedicated to the specification of existing and elaboration of, respec-
tively, potential new criteria and/or data categories with the intention to further substantiate
(data) requirements for the grant of data exclusivity for Rx-to-OTC switch products. Within
this context national (i.e., German) and international experts as well as stakeholders within
the field of self-medication, and in particular the Rx-to-OTC switch process, were selected
and interviewed on the basis of a qualitative written questionnaire. The present chapter
will focus on the analysis and discussion of qualitative research results gathered from these
interviews.
The questionnaire was developed in order to get information about and insight into various
experts’ opinions on the kind of data categories and criteria they would consider relevant for
the provision of data exclusivity within the context of an Rx-to-OTC switch of a drug and/or
indication formerly only available by prescription. It was comprised of 24 questions (multiple
choice and open format) and was subdivided into six main parts: a short introduction, a
general part related to the topic, and four more or less specific parts comprised of questions
which basically reflected the ideas emerging from the evaluation of relevant literature and
case study analyses.
Of note, potential weaknesses of the interview questionnaire have to be kept in mind: the
questionnaire was developed for the purpose of collecting qualitative interview data from se-
lected stakeholders in the field of self-medication with regards to their knowledge and opinion
on the provision of data exclusivity for Rx-to-OTC switches in Europe and hence no statisti-
cally significant outcomes can be drawn. The majority of questions were composed based on
the author’s preliminary thoughts and considerations related to the definition and relevance
of specific data sets potentially qualifying for data exclusivity. Against this background, the
fact that some questions might be of a slightly suggestive nature has to be considered as
a potential limitation. Moreover, the rather individual nature of Rx-to-OTC switch cases,
which was attempted to account for by differentiating at least three possible scenarios36
illustrated by either real or fictive examples, displays another potential drawback in this
investigation, as some questions and answers might be better applied to one scenario than
to another. The need of specific questions to be discussed on a case-by-case basis has thus
to be kept in mind with regards to data analysis and interpretation. Last but not least, the
author acknowledges potential bias due to some advocacy groups being “overrepresented”
36 scenario A: new OTC substance, known OTC indication; scenario B: new OTC substance, new OTC indication;
scenario C; known OTC substance, new OTC indication
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in terms of interview partners as compared to others. Nonetheless, expert interviews were
conducted with at least one representative of each stakeholder group in some way involved
in the process of Rx-to-OTC switching (i.e., regulatory authorities, patients, pharmacists,
physicians, the pharmaceutical industry as well as third party payers).
6.1 Interview results
In a first step, national and international experts well-known in the arena of self-medication
and Rx-to-OTC switch were contacted by mail, phone, or at congresses and asked for their
willingness to act as interview partner. Further contact persons were subsequently recom-
mended or identified via desk research. Altogether, 13 experts were interviewed and ten of
them filled in the written questionnaire they had been provided with regarding the issue of
“Rx-to-OTC switches and data exclusivity provision”.
Overall, most expert interviews confirmed and highlighted the fact that data exclusivity,
which usually actually affords a temporary market exclusivity, is getting increasingly impor-
tant for not only the growth of self-medication in general, but also the expansion in new
therapeutic areas not yet established within self-medication. However, many experts also
pointed out a probably indispensable conflict of interests between industry and political de-
cision makers rendering the tool of data exclusivity less attractive and desirable. Moreover,
probably most important as regards the potential value and impact of the present work,
individual expert discussions as well as questionnaire results clearly show that there is no
common opinion with respect to the interpretation and implementation of Article 74a of
Directive 2004/27/EC among experts representing the different interest groups involved in
Rx-to-OTC switches. Instead, notwithstanding the high interest they expressed, the topic
seems to be rather new to many experts and corresponding views and opinions currently are,
if at all existent, rather rudimental and diverse. Altogether, conversation partners frequently
alluded to the multiple political considerations influencing an individual Rx-to-OTC switch
decision. This is also reflected by individual answers and a lower response rate regarding
particular questions given in the questionnaire. More specifically, as to the substantiation
of the legislation (i.e., its interpretation and specification) feedback for the most part was
only limited mainly due to lacking knowledge and associated self-effacement in providing
substantial input.
The main results are depicted in the following: first of all, when asked about comprehen-
sibility, precision and relevance with a view towards requirements or criteria, respectively,
for data generation, the existing legal framework regarding the provision of data exclusivity
for Rx-to-OTC switches (i.e., Article 74a, Directive 2004/27/EC) was mostly judged to be
in the range of 2-3 within a 6 point scale (1 = very good, 6 = very bad) or no opinion was
expressed. With respect to the current duration of the exclusivity period, one year was re-
garded as “too short” by the majority of respondents (cf. Figures 7 and 8). On the contrary,
the period was considered as “too long” by one survey participant.
In the next section the legal postulation of pre-clinical test data as potential data category
for the generation of data with a claim on data exclusivity had to be assessed under the
aspect of appropriateness for Rx-to-OTC switching. Figure 9 shows a slight majority in
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Comprehensible Precise Relevant
40 %
30 %
20 %
10 %
0 %
50 %
Figure 7: Judgment of the existent legal provisions regarding data exclusivity
(Article 74a, Directive 2004/27/EC); 1 = very good, 6 = very bad (n = 10)
67 %
22 %
11 %
Too short
Just appropriate
Too long
Figure 8: Assessment of the length of the exclusivity period currently granted for
Rx-to-OTC switches within Europe (n = 9)
terms of pre-clinical test data being “not necessary” and/or “not appropriate”, respectively.
However, almost two thirds of the experts asked could imagine a re-analysis of already
existing pre-clinical Rx data that had been generated for Rx authorization with respect
to OTC critical aspects as potentially relevant (meaning at least supportive) with a view
towards data generation eligible for exclusivity (cf. Figure 10). Among positive judgments,
the following aspects were named for pre-clinical investigation on the grounds of potential
OTC relevance:
 drug interactions with both Rx and OTC drugs,
 overdosing,
 acute/chronic toxicity,
 pharmacokinetics,
 new fixed combinations,
 new routes of administration,
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20 %27%
26 %27%
Figure 9: Evaluation of the appropriateness of pre-clinical test data for a claim
on data exclusivity within the context of Rx-to-OTC switches (n = 12 entries)
60 %
10 %
30 %
Figure 10: Potential relevance of the re-analysis of existent pre-clinical Rx data
under OTC pertinent aspects for the provision of data exclusivity in case of Rx-
to-OTC switches (n = 10)
 new excipients,
 cancerogenicity.
The idea of a potential re-analysis of already existing clinical Rx data under OTC pertinent
aspects for anticipation of self-medication practice found even more encouragement when it
comes to clinical data as basis for the provision of data exclusivity for Rx-to-OTC switches
and experts showed more or less mutual consent in this case (see Figure 13). Against the
background of such a data re-analysis, safety/pharmacovigilance, size and kind of study
population were judged as most significant design and outcome parameters, respectively,
and were thus rated with “1” (on a 6 point scale with 1 = very important and 6 = not
important at all) by most of the experts, followed by the analysis of special patient groups
and compliance parameters as shown in Figure 11.
Another concept that was integrated into the expert questionnaire and suggested as a further
potential category that the provision of data exclusivity for Rx-to-OTC switches could be
built on is the generation of data by conducting actual use studies, self-selection studies,
and/or label comprehension studies as subcategories of the former. The study concept has
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Compliance
Efficacy
Safety/Pharmacovigilance
Study duration
Monitoring (kind, amount)
Quality of studies evaluated
Number of studies evaluated
Special patient groups
Sort of study population
Size of study population
Figure 11: Assessment of the significance of different design and outcome pa-
rameters within the context of a potential re-analysis of existing clinical Rx data
under OTC relevant aspects; 1 = very important, 6 = not important at all (n =
10)
been widely used in the US in a mainly simulated OTC setting providing OTC-like data
to support the Rx-to-OTC switch or OTC registration of respective medications and/or
indications. Figure 12 shows that this kind of study concept was ascribed a comparable
relevance within Europe (large majority of positive votes) when it comes to the generation
of data of informative value regarding potential OTC usage.
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90 %
10 %
Figure 12: Estimated relevance of the generation of OTC-like data for an envis-
aged Rx-to-OTC switch for the provision of data exclusivity within Europe (n =
10)
Among supporters of such a study concept, data referring to “label comprehension”
and especially “actual use” were assessed as most significant against the background of
entitlement to exclusivity (see Figure 14).
90 %
10 %
Figure 13: Potential relevance of the re-analysis of existent clinical Rx data
under OTC pertinent aspects for the provision of data exclusivity in the case of
Rx-to-OTC switches (n = 10)
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Figure 14: Generation of OTC-mimicking data: evaluation of different subtypes
in the context of their potential significance for the provision of data exclusivity
for Rx-to-OTC switches (n = 9)
Furthermore, experts were asked to rate different study parameters (depicted in Figure
15) according to their significance for the design of such studies depending on the switch
scenario to be considered; that is, Rx-to-OTC reclassification of a substance (scenario A),
an indication (scenario B), or both (scenario C). Out of all parameters, “representativeness”
was judged to be of highest importance particularly in the case of a new OTC indication (B),
but also for a new OTC substance in a known OTC indication (A), and to a lesser extent for
both a new OTC substance and OTC indication (C). Furthermore, the “selection of study
population” as well seems to play a major role for a new OTC indication treated with a
known OTC substance (B). “Randomization” is another feature in study design obviously
highly appreciated, even more for scenarios A and B than for C. This is followed by the
parameters “special patient groups” to a little larger extent in scenario B than in A and C
as well as “follow-up”, judged more important for scenario C than for A and B. Residual
assessments can be derived from Figure 15 below.
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Figure 15: Assessment of different study (design) parameters against the back-
ground of the generation of relevant data for a claim on data exclusivity in the
case of Rx-to-OTC switches; scenario A: new OTC substance, known OTC indi-
cation, scenario B: known OTC substance, new OTC indication, scenario C: new
OTC substance, new OTC indication (n = 9)
The next part of the questionnaire focused on the concept of so-called “collaborative
care”. As has already been discussed above, apart from classical switches (i.e., the reclas-
sification of easily self-diagnosable diseases and potential treatment options) the removal of
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indications within the scope of prevention or therapy of (semi-)chronic conditions initially
requiring medical diagnosis and subsequently managed by patients independently is another
model conceivable within the context of the evolution of the self-medication sector includ-
ing Rx-to-OTC switch movement. Survey participants were asked if they considered data
demonstrating self-diagnosis ability and autonomous therapy management by patients after
an initial doctoral diagnosis as basically appropriate to qualify for data exclusivity. As de-
picted in Figure 16 below, the majority of experts questioned could – where appropriate –
imagine data demonstrating the functioning of collaborative care under OTC conditions to
qualify for the grant of data exclusivity.
60 %
20 %
20 %
Figure 16: Expert opinions on the possibility of the general qualification of data
verifying so-called “collaborative care” under OTC conditions (n = 10)
Within this context the development of an adequate method or algorithm, respectively,
that enables patients to correctly self-assess and subsequently self-treat their symptoms was
rated best and preferred by the majority of experts in terms of its potential significance for
data exclusivity, followed by the development of a measurement device easily operated by
patients themselves (see Figure 17).
More specifically, data from actual use studies either with or without specialized personnel
demonstrating patients’ correct self-assessment and effective therapeutic self-management of
their conditions or disease prevention were estimated to potentially be able to contribute to
data exclusivity provision for a respective Rx-to-OTC switch. Besides, data investigating and
showing increased compliance due to measurement devices or activities developed to assist
patients in therapeutic self-management based on the specific Rx-to-OTC switch of either a
certain drug substance, indication, or both were partly attributed exclusivity potential (cf.
Figure 19).
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Figure 17: Evaluation of different therapy management aspects regarding their
appropriateness in contributing to data exclusivity; 1 = very good, 6 = very bad
(n = 8)
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Figure 18: Relevance of a comparison with therapeutic alternatives already
available OTC by means of a clinical study or the like (e.g., phase IV) in ref-
erence to a potential claim on data exclusivity (n = 10)
Another important aspect to investigate within the context of an envisaged Rx-to-OTC
switch might be the comparison with existing OTC therapy alternatives in terms of, for
example, a clinical safety/efficacy study. As shown in Figure 18, this opinion is at least
held by the plural among experts who consider safety/pharmacovigilance and the kind of
study population as the most important parameters in such a setting, succeeded by the size
of study population, including special patient groups, as well as efficacy and compliance as
downstream parameters (cf. Figure 20).
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Figure 19: Assessment of (partial) exclusivity potential of different data cat-
egories demonstrating patients’ diagnostic self-assessment and/or therapeutic
self-management of (potential) OTC conditions or disease prevention, respec-
tively; 1 = extremely relevant, 6 = not relevant at all (n = 8)
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Figure 20: Role of different study parameters of a comparative (clinical) study
with a switch candidate and an existing therapeutic alternative regarding a po-
tential demand for data exclusivity for the respective Rx-to-OTC switch; 1 = very
important, 6 = not important at all (n = 9)
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Additionally, the generation of non-interventional study (NIS) data in the sense of a
classical AUS, but under specific constraints (so-called “conditional release”) was suggested
to experts in order to be assessed for possible eligibility for exclusivity. This means, that
study details including design, outcome measures, etc. could be discussed and agreed upon
with the accordant decision making bodies ante switch to be then put into practice post
switch in order to collect data and insights concerning efficacy/effectiveness, safety, usage
pattern, as well as patient satisfaction, etc. under daily-life conditions of self-medication.
Most experts could imagine such a situation and presumably would accept this kind of study
data as adjuvant in a claim on data exclusivity, although one third of them opposed this
possibility or did not have an opinion on this issue (see Figure 21).
60 %
10 %
30 %
Figure 21: Expert opinions on a so-called “conditional release” concept as po-
tential data basis for data exclusivity with the requirement of actual use (i.e.,
real-life) data generation (non-interventional study) post switch (n = 10)
Without doubt, comprehensive and detailed educational measures including specific
training programs for HCPs and patients, brochures, interactive information services, etc.
play a key element during the establishing phase of a Rx-to-OTC switch, especially in case of
more complex and intensive conditions in terms of management as well as monitoring. Ex-
perts were thus asked to judge “informational and educational measures” as another possible
data category at least partly accounting for the provision of data exclusivity. As depicted in
Figure 22, more than half of the experts interrogated estimated comprehensive educational
material and activities for target groups involved in a certain switch as valuable in regards
to a claim on data exclusivity. Informational and educational material got the highest rating
in this regard, followed by a demand for elaborated training programs and regular quality
checks (q.v. Figure 23).
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Figure 22: Experts’ judgment of comprehensive informational and educational
material within the context of a Rx-to-OTC switch as possible basis for data
exclusivity provision (n = 10)
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Figure 23: Estimation of the potential relevance of different aspects related to
information and education for a potential claim on data exclusivity (n = 24 en-
tries)
The last section of the questionnaire consisted of two questions regarding pharmacoeco-
nomic aspects in terms of a potential increase in public health value associated with a specific
Rx-to-OTC switch. Again more than half of the experts could imagine pharmacoeconomic
analyses preferably investigating non-monetary parameters such as improvement of quality
of life, for example, as partly suitable for a demand for data exclusivity, whereas the remain-
der mainly does not believe such data being adequate in order to be accepted by regulatory
authorities (see Figures 24 and 25).
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Figure 24: Respondents’ opinion on the appropriateness of pharmacoeconomic
data with regards to entitlement to data exclusivity (n = 10)
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Figure 25: Rating of monetary/non-monetary pharmacoeconomic analyses ac-
cording to their potential to be used within a claim on data exclusivity for Rx-to-
OTC switches (n = 6)
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6.2 Summary and conclusion
In order to specify and substantiate the currently rather indefinite legal framework related to
data exclusivity provision for Rx-to-OTC switch products, national (i.e., German) and inter-
national experts regarding the reclassification of medicines had been selected for participa-
tion in qualitative interviews based on a written questionnaire. From an overall perspective,
knowledge of and insight in corresponding legal provisions was rather scarce. Nevertheless,
the tool of data exclusivity was highly appreciated with a view to the future evolution of the
self-medication sector.
More specifically, as can be derived from interview results, the relevance of the existent
data category of “pre-clinical tests” with a view towards appropriateness for data exclusivity
provision for switch products is considered to be rather low by the majority of experts, if
not explicitly focusing on OTC critical aspects. OTC relevant design and analysis param-
eters (study population, safety/pharmacovigilance, representativeness, etc.) were similarly
stressed when referred to the second data category currently available for a claim on data
exclusivity (i.e., clinical trial data) at best newly generated or otherwise re-analyzed from
Rx. Particular importance was thereby ascribed to data emanating from studies conducted
in either a real or in an OTC-like setting to investigate label comprehension, self-selection,
and overall actual use (e.g., if applicable) compared to therapeutic alternatives available.
Moreover, informational and educational material as well as devices facilitating self-
management, such as drug monitoring and compliance within the context of more complex
drug therapies potentially to be reclassified OTC were judged to (at least partly) be ac-
counted for (e.g., as additional data category) with respect to eligibility for data exclusivity
provision.
Based on the aforementioned, the author concludes that the generation of any kind of data
mimicking, as much as possible, conditions of the targeted OTC setting and/or supporting
safe and effective OTC usage is of the utmost importance in regards to potential eligibility
for data exclusivity provision. Of note, according to the nature of self-medication (i.e., no
medical intervention), the generation of OTC-like data is inevitably linked with a merely ob-
servational, non-interventional study design. The quality and validity of this kind of study
data are, however, often challenged by the medical community rendering its potential with
respect to data exclusivity qualification rather arguable.
Thus, in addition to the expert input gained regarding the potential significance of different
study parameters in terms of revaluation of respective parmacoepidemiological study data
and associated eligibility for data exclusivity, statistical approaches to enhance the validity
of observational study data were identified via literature research. These will be briefly pre-
sented and one of them will be subsequently applied to a practical example in the following
Chapter 7.
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7 Data validity in observational research: a statistical ap-
proach to reduce potential biases
As can be concluded from the qualitative interview results depicted above (q.v. Chapter 6),
an important role regarding data exclusivity provision, in the context of Rx-to-OTC switches,
is attributed to the generation of observational OTC-like study data in the case of adequate
quality provided. However, as to the latter, there is a continuous discussion among experts
with the validity of non-randomized observational study data often being doubted.
Based on a short overview of the characteristics and advantages/disadvantages of both ran-
domized controlled trial as well as non-randomized observational study research, the present
chapter is, therefore, dedicated to the discussion of the possibilities to enhance the validity of
observational study data. On the grounds of a potential role regarding eligibility for data ex-
clusivity provision within the context of Rx-to-OTC switches, applicability will subsequently
be demonstrated through a practical example.
7.1 Randomized vs. observational (non-randomized) study research
Several principal methods of study research are available with an important distinction be-
tween so-called randomized controlled trials (RCTs), mainly conducted in a more or less
experimental setting and non-randomized studies including quasi-experiments, natural ex-
periments and non-interventional observational studies (i.e., prospective or retrospective
cohort or case-control studies) (Britton 1998).
“Evidence-based medicine” (EBM) classifies studies into grades of evidence based on re-
search architecture with internal validity (i.e., correctness of the results) as the criterion for
hierarchical rankings (Concato 2000; Concato 2004). According to this approach, RCTs are
considered as the gold-standard (Britton 1998; Schaefer 2007) providing the highest grade of
evidence and quality information, most often serving as the foundation to regulatory deci-
sion making on drug approval or labeling, etc. (Brass 2010). On the contrary, observational
studies usually fall into intermediate levels (Concato 2000; Concato 2004). Over the past
years there were recurrent debates about the merit of observational versus randomized stud-
ies with criticisms primarily aiming at a claimed overestimation of intended (i.e., treatment
effects) (Benson 2000; Britton 1998; Ray 2003). Instead, successes are attributed to “the
study of unintended effects – adverse effects of environmental factors, of behavior, and of
constitutional characteristics” (Miettinen 1983). Recent systematic review analyses, how-
ever, have come to the conclusion that neither RCTs nor non-randomized studies seem to
give larger or smaller treatment effects and that variation in results occurs equally within
both RCTs and non-randomized studies each mainly reflecting a high variability in study
design and analysis (Benson 2000; Britton 1998; Concato 2000; Concato 2004).
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In fact, both research designs have their own benefits and limitations when it comes to in-
ternal and external validity of study results. “The difference goes back to the respective
core problems in these two types of studies – confounding in non-experimental research and
ethics in experimentation” (Miettinen 1983).
As to internal validity, the absence of any type of bias due to potential confounders, all
observational studies have a fundamental deficit with their design not being an experimental
one. Within this setting, any differences in outcome between treatment and control groups
may possibly be due rather to systemic differences in baseline characteristics of the two
comparison groups instead of resulting from the effectiveness of the therapeutic intervention
(Britton 1998). By contrast, randomized treatment assignment in experimental RCTs pro-
vides the basis for reliably unbiased causal estimates of treatment effects (Pocock 2000), as
subjects compared should, at best, only differ in their exposure to the intervention under
evaluation. The main benefit of randomization is, thus, that it is able to balance known and,
in particular, unknown potential confounders (Concato 2004). This allows for high internal
validity of study results and renders RCTs indispensable in drug development with respect
to the elementary study of intended therapeutic effects.
On the other hand, external validity indicating generalizability of results is often comprised
in RCTs due to strict eligibility criteria for study participants and high levels of exclu-
sion (e.g., special patient populations such as elderly, women, ethnic minorities, etc.). This
restriction in study population may lead to a lack of representativeness impairing the gen-
eralizability of treatment results to the target population (Britton 1998; Concato 2004). A
much broader range of patients, also generally containing representatives of populations at
risk, is often included in non-randomized studies (Concato 2000), thus much better repre-
senting the “real-world conditions” of medical practice (Rubin 1997). Hence, although on
the expense of the power to detect drug effects, such a naturalistic study setting allows for
better generalizability of study results (Brass 2010).
The criterion of large patient populations is also one of the rationales underlying the usage
of observational data to monitor for drug toxicity, including rare serious adverse events, or to
study risk factors for disease and prognostic indications, which are all hard to detect within a
small population. Moreover, observational studies generally are more or less easy and cheap
to conduct while at the same time offering timeliness of data. In situations where RCTs are
impossible or unethical, they constitute the only alternative for gathering important study
data (Benson 2000; Pocock 2000).
In general, all types of studies are located on a continuum ranging from irrelevant to relevant
with respect to answering specific research questions. Real-world studies typically lie some-
where in the middle, whereas representativeness is more probable within non-experimental,
observational studies and control over existing, potentially confounding variables usually is
easier and higher within randomized experimental studies (Brass 2010; Rubin 1974).
7.2 Observational research and the estimation of causal treatment effects
In theory, referring to clinical and therapeutic research, the provision of evidence of efficacy
requires: a study (= experimental conditions), in a cohort (= repeated observations of many
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patients), with a control cohort (= comparison), and a randomly generated assignment of
patients to test or control cohort (= randomization) independent of all the other factors.
Against this background the concept of a randomized controlled clinical trial seems to be
the only reliable study research design (Kiene 1998).
However, within the wider context of “therapeutic causality” it is concluded elsewhere that
non-experimental studies apart from investigating unintended (e.g., safety) effects (see Sec-
tion 7.1 above) are likewise able to provide evidence of efficacy37 and infer causal treatment
effects (Concato 2000; Kiene 1998; Rubin 1974). For example, Concato even holds the opin-
ion that well-designed observational studies are able to “produce results similar to those of
RCTs when similar criteria are used to select study subjects” and that “the popular belief
that only randomized, controlled trials produce trustworthy results and that all observa-
tional studies are misleading does a disservice to patient care, clinical investigation, and the
education of health care professionals” (Concato 2000).
7.2.1 Potential biases and confounders in observational research
As mentioned before, the major disadvantage and limitation regarding the validity of study
results from non-randomized, observational study research is the inevitable presence of con-
founding factors that make these studies prone to bias. “Confounding” generally occurs,
when a variable is related to both exposure and outcome variables for the association of
interest with the exposure variable depicting the confounding variable, rather than actually
causing the outcome (Concato 2004).
By far most cited and most obvious is a systematic effect called “selection bias” which
encompasses many subtypes of potential biases some of which are mentioned exemplarily
below. The term generally refers to the distortion of a statistical data analysis due to the
method of collecting samples. Without controlling for this kind of bias, any conclusions
drawn from the study may be kind of false. Selection bias might occur, if a patient’s partic-
ular treatment is deliberately chosen rather than randomly assigned. Consequently, the risk
of systematic differences in outcomes not to be due to the treatment itself is high (Pocock
2000), as selection bias may confound real differences causal to treatment. To give a prac-
tical example, selection bias can be introduced when the base where study participants are
sampled from indirectly depends on exposure variables in an unknown way. If study control
subjects are selected by telephone, for instance, potential candidates not having a phone are
automaticallyexcluded irrespective of their eligibility (Wacholder 1992a). Selection bias may
also be introduced by practitioners or even patients themselves when deciding on treatment
(treatment preference). If treatment assignment is dependent on the indication, an effect
called “confounding by indication” might occur. Hence, in a non-randomized study design,
selection or treatment allocation bias will complicate the assessment of drug therapy as there
might be definite prognostic reasons for favoring one treatment over another, which will be
deceptive in the comparison of coarse outcomes (Britton 1998).
37 i.e., rather “effectiveness”, as studies observing real-world conditions are concerned in this case (see Section
2.1)
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“Chronology bias” comes into play if risk associated with a certain treatment varies with
time. For example, time dependent risk may be a consequence of physiologic adaptation
during prolonged treatment periods or may be associated with medications that display
both beneficial and adverse effects with different induction periods (Ray 2003). This effect
is closely linked to the risk of “prevalent user bias” indicating that prevalent users of chronic
medication (who already took the type of medication under evaluation prior to study entry)
can introduce two types of bias – first of all a potential underestimation of events occurring
early in treatment phase and secondly the inability to account for disease risk factors that
may be changed by the study drugs (Concato 2004; Ray 2003). Study analyses including
prevalent users are also more susceptible to influences of “adherence bias”, as long-term users
obviously seem to be more adherent to therapy. “Even for drugs whose physiologic effects
do not vary with duration of therapy, including prevalent users may amplify adherence bias.
This bias is thought to underlie the findings from analyses of data from several randomized
controlled trials in which better adherence to placebo has been associated with a 30-60 per-
cent reduced risk of death from cardiovascular disease and fewer episodes of fever or infection
in cancer patients [. . . ]. It is thought that adherence is a marker for a constellation of un-
measured factors, some of which may be time dependent, associated with better prognosis”
(Ray 2003).
A scenario that holds true for many medications and in particular those used for prevention
is known by the term “healthy user effect”. As individuals willing to participate in pre-
ventive studies tend to be healthier and also more health conscious, more affluent, better
educated, and demonstrate higher treatment compliance, treatment benefits might be over-
estimated in this patient population. Therefore, these factors potentially interacting with
treatment intervention must be adequately measured and controlled for with study analysis
so as to eliminate systematic differences between the study group and the remainder popu-
lation (Britton 1998; Concato 2004; Ray 2003).
Several other biases are addressed elsewhere, e.g., by Wacholder in his analysis of selection
of controls in case-control studies (Wacholder 1992a; Wacholder 1992b; Wacholder 1992c).
7.2.2 Dealing with biases and confounders in observational research
Some of the most relevant biases are depicted in Subsection 7.2.1 above. In theory, an indef-
inite number of confounders is existent in observational research, possibly leading to biased
research results. In effect, it is impossible to actually control every single variable, especially,
if confounding covariates are unobserved and unmeasured.
Nevertheless, if observed, major systematic bias and confounding effects can be taken into
account and reduced or even eliminated. Of note, however, as a general requirement to this,
some essential assumptions are to be adopted. These are based on the theoretical framework
of the counterfactual account of causality which was first formalized and extended to non-
experimental study designs in the 1970s by Donald B. Rubin (Holland 1986; Rubin 1974).
Key to this framework is the definition of causal effects through potential outcomes (Tsiatis
2006). It theorizes that individuals assigned to either treatment or control group have a
potential outcome in all states (i.e., both the observed and the unobserved state). Each
Chapter 7 - Data validity in observational research 107
subject in the treatment group has an observable outcome in the treatment state and an un-
observable counterfactual outcome in the control state. The contrary holds true for subjects
in the control group (Winship and Morgan 1999). These potential outcomes are also referred
to as counterfactual random variables, as it is impossible to observe them simultaneously
(Tsiatis 2006). Within this context, in theory, the causal treatment effect for each subject is
defined as the difference between the two potential outcomes in the treatment and control
states. Yet as pointed out above, it is impossible to observe and hence to directly calculate
the causal treatment effect at a subject-specific level.
Notwithstanding the aforementioned, the estimation of the average causal treatment effect at
the population-level, which equals the expected value of the subject-specific causal treatment
effect, may be feasible under certain assumptions (Tsiatis 2006; Winship and Morgan 1999).
The first assumption is the so-called “Stable Unit Treatment Value Assumption” (SUTVA)
meaning that “the observed response for [a certain] individual in the sample should not be
affected by the response of the other individuals in the sample” (Tsiatis 2006). The second
assumption refers to the so-called “strongly ignorable treatment assignment” implicating
that any assignment to either treatment or control group is unconfounded conditional on
the observed covariates (i.e., there are no unmeasured confounders) (Yanovitzky 2005). If
so, the assumption that treatment assignment is independent of potential outcomes given
the observed pre-treatment variables may be reasonable. Of note, although not testable, the
latter is key to being able to estimate the average causal treatment effect in observational
study research (Tsiatis 2006). The third assumption is that the probability of being assigned
to either treatment or control is unlikely to be zero or one for all subjects conditional on the
observed confounders. That is, confounders have to relate to potential outcomes and thus
have to be selected accordingly (Tsiatis 2006; Yanovitzky 2005).
Based on the aforementioned assumptions, the relevant literature describes various method-
ologies and techniques with a view towards practical application and dealing with potential
confounders in observational research. Examples are: covariance adjustments based on mul-
tivariate regression, stratification (subclassification), or matching (D’Agostino 1998; Qin
2008; Rosenbaum 1983; Rubin 1973; Rubin 1979; Zanutto 2006).
Another technique which has become increasingly popular within recent years is based on
the estimation of so-called propensity scores (Glynn 2006; Seifert 2009). Propensity score
methodology was introduced by Rosenbaum and Rubin who define a subject’s propensity
score as “conditional probability of assignment to a particular treatment given a vector of
observed covariates” (Rosenbaum 1983). More specifically, as depicted in Figure 26 on the
right, the propensity score is a single-number summary of the set of observed covariates from
which it was estimated with a value always between 0 and 1 (Qin 2008; Yanovitzky 2005).
Importantly, if treatment is strongly ignorable given a specific set of observed covariates
as described above, it is also strongly ignorable given the propensity score as conditional
function of these covariates. Therefore, at any value of the propensity score “the difference
between the treatment and control means is an unbiased estimate of the average treatment
effect” at that particular value of the propensity score (Rosenbaum 1983).
In conclusion, if respective assumptions are acknowledged, it is thus possible to limit calcula-
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Figure 26: Basic idea underlying standard multivariable and propensity score
analysis, respectively. As demonstrated by the continuous line, known con-
founders in contrast to unknown confounders (dotted line) can be adjusted for
(from Biondi-Zoccai et al. 2011)
tion to the use of propensity scores when estimating average causal treatment effects within
observational study research.
7.2.3 Practical illustration of the theory
Based on the above mentioned property of propensity scores theoretically being adequate to
estimate causal treatment effects in non-randomized observational studies, propensity score
methodology will now be applied to a practical example.
The example is about the comparison of two therapeutic options for the therapy of vaginal
mycosis, with one option considered as “treatment” and the other one as “control”. Thereto
the following outcome variables were investigated:
 pruritus, burning sensation, redness, swelling, increased discharge, pain at urination,
pain at sexual intercourse (multiple selections possible)
as well as
 duration until considerable improvement of these symptoms.
The latter was measured in days and/or minutes. Symptom intensity was measured before
treatment and one, two, three, and seven days thereafter on a scale ranging from 0 to 3 with
0 = none, 1 = little, 2 = modest, and 3 = severe.
Additionally, the following 13 covariates were determined as potentially outcome-relevant
pre-treatment characteristics:
 age, body weight, body size, duration of symptoms before treatment (days), impair-
ment of daily activities prior to treatment, impairment of quality of life prior to treat-
ment, predispositions (stress/mental strain, (post)antibiotic therapy, cortisone therapy,
diabetes mellitus, immunosuppression, adolescence, menopause, and others), previous
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vaginal infection, pregnancy, acute status, previous therapy, macroscopic status, and
microscopic status.
The most frequently reported symptom was pruritus. Taking this as an example, the
following outcome variables were considered:
 duration until symptom improvement
 difference between intensity of pruritus on day one of therapy and intensity at baseline
before beginning of the therapy
 difference between intensity of pruritus on day three of therapy and intensity at baseline
before beginning of the therapy
i.e., for pruritus, the outcome variable was “symptom score on day one (day three) after
applying one of the options (i.e. treatment or control, respectively) – symptom score before
applying one of the options”. Small values therefore denote good performance.
The first step in employing a covariate adjustment in an observational study is to select a
set of potential confounders. The 13 variables listed above were assumed to have a possible
relation to both outcomes and treatment assignment and were thought to cover all or at
least the major part of such covariates. Furthermore, since patients were assigned to the
treatment or control group independently of each other and since they reported the results
independently of each other at the end of the study, it seemed reasonable to assume that
the individual response of one patient was not affected by the response of any other patient
and that therefore the SUTVA held. Thirdly, the common support was checked and taken
into account in the computations.
The estimators used in the example can be described as follows: let T be an indicator
of observed treatment exposure (T = 1 if treated, T = 0 if control), let Y be an outcome
variable, and X be a vector of covariates. Let n1 be the number of treated objects, n0 the
number of controls, and n = n1 + n0. Let pi = 1, 2, ..., n be the propensity scores.
The unconditional (“naive”) average treatment effect (ATE) is
ATEuncond = E(Y |T = 1)− E(Y |T = 0), (i)
where E(.) denotes expectation (average), which for observational studies in general is biased.
The unbiased, covariate-adjusted average treatment effect is
ATEcovadj = EX [E(Y |T = 1, X)− E(Y |T = 0, X)] . (ii)
Expression (i) was estimated by
ÂTEuncond =
1
n1
n∑
i=1
TiYi − 1
n0
n∑
i=1
(1− Ti)Yi. (iii)
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As mentioned above (see Subsection 7.2.2), there are several ways to estimate (ii). In the
example study inverse probability weighting with estimator
ÂTEcovadj =
∑n
i=1
TiYi
pi∑n
i=1
Ti
pi
−
∑n
i=0
(1−Ti)Yi
1−pi∑n
i=0
1−Ti
1−pi
(iv)
was used. Lunceford and Davidian compared some commonly used estimators of the average
treatment effect and found that (iv) performed well (Lunceford and Davidian 2004).
In the example study there were 461 patients with complete data for the covariates, of
whom n1 = 204 were treated and n0 = 257 were controls. The propensity scores were esti-
mated for these 461 patients on the basis of a logistic model and kept fixed.
An available case analysis was conducted with respect to the outcome variables. De-
pending on the outcome variable, the proportion of available cases laid between 83.3 % and
94.1 % for the treated and 87.2 % and 95.7 % for the controls. The computations were
conducted both for the “naive” estimator (iii) and for the covariate-adjusted estimator (iv).
Results are depicted in Table 10.
The main reason for presenting these data is to give a viable real-life example that bias
in observational studies can be reduced with the application of appropriate methods. Math-
ematically, the bias of an estimator of a population parameter θ is the difference of the
expectation of the estimator and the true value of the parameter in the population, i.e.,
bias of an estimator of θ = expectation of the estimator – θ.
Here θ corresponds to the average treatment effect. The values of the unconditional
(naive) ATE-estimators for the three outcome variables (formula (iii) above) are displayed
in column six of Table 10. The bootstrap was used to assess the bias of these estimators as
described below (Efron and Tibshirani 1993).
The covariate-adjusted average treatment effects presented in column three of Table 10
corresponding to formula (iv) above are (approximately) unbiased if the fundamental as-
sumptions (SUTVA, no unmeasured confounders) are fulfilled. They can therefore be con-
sidered as the “true” values of the ATE. It remains to determine the expectation of the
ATE-estimators in column six of Table 10.
For this purpose 10,000 independent bootstrap samples were drawn from the data. For
each such sample the average treatment effect was evaluated according to formula (iii).
Finally, the bootstrap expectation of these estimators was approximated by the average of
the 10,000 ATE-values. Results are shown in column seven of Table 10, the corresponding
bias values in column eight. Column nine contains the bias in percent of the true value given
by the formula
Bias % =
|bias|
|true value of parameter| ∗ 100, (v)
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where |.| means absolute value, which gives a better impression of the size of the bias. It
can be seen that the naive estimators were biased between 5.7 % and 23.4 %. Without
adjustment, the naive values could therefore lead to wrong decisions.
7.3 Summary and conclusion
Randomized controlled trials are considered as gold standard within evidence-based
medicine. They mainly differ from non-randomized observational studies by generally ex-
hibiting high internal validity (i.e., the presence of potential confounders being minimal due
to randomized study design). In contrast, non-randomized observational studies often are
exposed to known and unknown biases, yet on the other hand, exhibit high external validity
(i.e., generalizability of results). Moreover, observational study research is of relevance when
it comes to the investigation of “real-world” conditions in prescription and particular nonpre-
scription setting. However, within this context its appropriateness to study intended effects
and draw causal inferences (i.e., therapeutic effectiveness) has been the subject of debate
for many years. Whereas opponents claim the control of potential confounders and biases
to be rather impossible, proponents hold the opinion that well-designed and well-analyzed
observational trials are able to bring about results essentially similar to those of RCTs.
As to the presence of observable confounders, statistical techniques are available which are
able to minimize their biasing impact under certain assumptions. One method being in-
creasingly used in observational study research is the so-called propensity score technique.
By definition, a propensity score represents a person’s probability of being allocated either
to treatment or control group depending on his or her observed covariates. According to the
theoretical framework of the counterfactual account of causality, the average causal treat-
ment effect can be determined based on estimated propensity scores, thereby reducing any
correlation between treatment and outcome which is not due to the treatment itself, thus,
enhancing the validity of the data.
In order to demonstrate the practicability of this theoretical approach, propensity score
technique was retroactively applied to an exemplary set of observational non-interventional
study data.
In conclusion, non-randomized observational study research is regarded indispensable in com-
plementing randomized controlled trial results by delivering important real-world data. This
holds particularly true for the assessment of therapeutic safety, effectiveness and practice
within the setting of self-medication typically lacking close medical supervision. According
to the author, the approach to enhance the validity of such data by applying appropriate
statistical techniques, such as - in particular - propensity score analysis should therefore be
considered as crucial quality criterion within its assessment of eligibility for data exclusivity
as part of an Rx-to-OTC switch application.
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Table 10: Example of the comparison of two therapeutic options (i.e., treatment
and control) for the therapy of vaginal mycosis: average treatment effect (ATE)
for selected variables based on estimated values and bias. (*) Bootstrap estima-
tor on the basis of 10,000 resamples; (**) symptom intensity measured on the
scale 0, 1, 2, 3 with 0 = none, 1 = little, 2 = modest, and 3 = severe
Outcome variable Covariate-adjusted Unconditional (naive)
Group-specific mean ATE Group-specific mean ATE
Treatment Control Treatment Control Estimated
value
Expected
value (*)
Bias Bias % of
(3)
1 2 3 4 5 6 7 8 9
= (1) - (2) = (4) - (5) = (7) - (3)
Time to improvement
(hh:mm, any ailment)
36:10 42:08 -05:58 35:13 41:54 -06:25 -06:26 -00:28 7.76
Pruritus:
decrease of
symptom
intensity
(**)
one day af-
ter medica-
tion
-1.0190 -0.8020 -0.2170 -1.0339 -0.8297 -0.2042 -0.2046 0.0124 5.71
three days
after medi-
cation
-2.2809 -2.0756 -0.2053 -2.2765 -2.1205 -0.1560 -0.1573 0.0480 23.38
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8 Results
Major findings and conclusions from the literature and qualitative interview research, as well
as the Canesten
®
GYN case study analysis, referring to the applicability of the existent EU
legal framework in regards to the data exclusivity provision for Rx-to-OTC switches (Article
74a, Directive 2004/27/EC) will be depicted in the following in conjunction with Hypotheses
1 and 2 initially developed within the present work (see Section 4.6).
8.1 Confirmation of Hypothesis 1
Based on a critical analysis of the European legal framework at present regarding the provi-
sion of data exclusivity within the context of the transfer of pharmaceuticals from prescrip-
tion to nonprescription status, it was hypothesized that there is rather little chance to receive
data exclusivity for a certain Rx-to-OTC switch with given the unspecific legal requirements
(i.e., Article 74a, Directive 2001/83/EC, as amended, and its interpretation in the “Guide-
line on changing the classification for the supply of a medicinal product for human use”)
currently prevailing throughout Europe (cf. Hypothesis 1, Section 4.6). Both a retrospective
case study analysis of the Rx-to-OTC switch of Canesten
®
GYN (see Chapter 5) as well
as the results of personal interviews with experts from different interest groups involved in
Rx-to-OTC switching (cf. Chapter 6) contribute to the confirmation of this assumption (i.e.,
to the adoption of Hypothesis 1), respectively, due to the following reasons:
 absence of a concrete definition, substantiation, and interpretation of the terms “sig-
nificant” as well as “relevant” and “necessary” found in the legal text (Article 74a)
and its correspondent guideline (European Commission 2006a),
 availability of extensive pre-clinical test and clinical trial data from Rx-registration of
even also older substances which in their majority meet basic scientific and ethical data
requirements still valid for drug applications today,
 no detailed definition of “pre-clinical tests” and “clinical trials” as data categories (i.e.,
standard/quality requirements, etc.).
As to the first issue mentioned, the insufficient specification of the relevant terms referring
to eligibility of data for data exclusivity (i.e., “significant”, etc.) for Rx-to-OTC switches
was acknowledged by the majority of experts interviewed and is at least to some extent also
reflected by the results of the respective survey. None of the attributes “comprehensible”,
“precise”, or “relevant” was rated “very good” (c.f. Section 6.1, Figure 7).
Second, with respect to the point of “availability of extensive pre-clinical test and clinical
trial data” the Canesten
®
GYN example shows that even for old substances like clotrimazole
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in this case, which was registered for the first time several decades ago, the original data
submitted for registration seems fairly complete. Although ethical requirements and scientific
knowledge as well as technological methods have certainly arisen and developed over time,
demanding increasingly complex and intricate study research, both ethical research principles
and scientific criteria and requirements have already existed for many years (in Germany
as of the beginning of the 1970s, cf. Section 5.1). Therefore, comprehensive pre-clinical
tests and clinical trials had already been necessary for the registration of older substances
such as clotrimazole, as was illustrated by the exemplary gap analysis of Canesten
®
GYN
documentation (which is of course only an example and not representative by force, yet
might still hold true for other substances as well). Moreover, as large parts of the tests and
trials conducted have been available to the scientific public for a long time, they mostly have
no news value and thus do not contribute to eligibility for data exclusivity as such.
Another hurdle to overcome in the generation of new data within this context is obviously
the deficient specification of the terms “pre-clinical tests” and especially “clinical trials”. If,
for example, “clinical trials” are to be interpreted in the “classical” sense (phase I-III or
post-marketing phase IV), similar studies certainly had to already have been carried out for
and during Rx registration as demonstrated by the retrospective analysis of the Canesten
®
GYN case. However, contrary to the setting of self-medication, studies up to phase III
are of interventional character (i.e., conducted according to a predefined study protocol),
whereas phase IV studies need participants to be insured. Thus, in general the execution
of such studies is rather complex and complicated and, hence, hardly to be realized under
OTC-like conditions. The latter was though determined as an important characteristic in
Rx-to-OTC switch data generation for the application of data exclusivity by most of the
experts interrogated.
In consequence, as largely confirmed by the qualitative interview results, the scope for the
generation of novel data eligible for data exclusivity within an Rx-to-OTC switch is rather
limited taking the current European legal framework as an orientation guide. The potential
success of a certain data exclusivity request seems to be unique to a restricted number of
cases (see also Subsection 9.3.1) and in the current situation (i.e., the absence of distinct
and rigorous criteria applied to data submitted) a positive judgment seems to fairly depend
on regulatory arbitrariness.
8.2 Confirmation of Hypothesis 2
Likewise, Hypothesis 2 which was developed on the grounds of Hypothesis 1 (q.v. Subsection
4.6.2) and refers to the demand for specification of existent and the precise definition of new
criteria and data categories potentially qualifying for data exclusivity, is accepted based on
the following reasons:
 guidance on Article 74a included in the current “Guideline on Changing the Classifica-
tion for the Supply of a Medicinal Product for Human Use” published by the European
Commission in the sense of a detailed interpretation and definition of specific require-
ments is rather limited,
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 accordingly, precise information on Article 74a is equally missing on EU national levels
(except for formal implementation in national law),
 usefulness and meaningfulness of “pre-clinical tests” currently named as potential data
category for a claim on data exclusivity for Rx-to-OTC switch candidates, i.e. drugs
very late in their life-cycle, is questionable.
As mentioned earlier (see Section 4.6), when looking at the current European switch guideline
only a small section (part III) is dedicated to interpreting and specifying the legal provisions
of Article 74a (European Commission 2006a). Although some categorical aspects with the
potential for data exclusivity qualification are named here, crucial hints cannot be found on
how to reach “significance” of data as pre-requisition for the provision of data exclusivity
acceptable for evaluating authorities. The section concludes with the apparent key message:
“To be considered ‘significant’, the pre-clinical tests and/or clinical trials must be relevant
and necessary to the change in classification” (European Commission 2006a). Yet, this
statement rather leaves too much room for interpretation than really providing substantial
information for applicants, thereby all the more generating the impression of an arbitrary
decision to be taken by competent authorities.
Presumably, more or less as a result of the imprecise definition of requirements on a Euro-
pean level (i.e., within Article 74a of Directive 2004/27/EC) virtually no detailed definition
is available (besides technical implementation in national law) in the various EU member
states with the UK as the only exemption. The MHRA as competent regulatory authority
in the UK has issued a “Guidance on the Application for Exclusivity for Change in Legal
Status of a Medicine” (MHRA 2005) (cf. Section 4.6). Unfortunately, this guidance equally
lacks a precise concretion of how data claiming exclusivity should look like in detail, yet while
focusing on clinical trial data at least it points out to some outcome parameters and study
designs, respectively, that might be beneficial with regards to exclusivity (MHRA 2005).
Interestingly, an expanded version is announced in this guidance “with further examples of
‘tests’ or ‘trials’ that may justify exclusivity following agreement of European guidance and
in the light of experience gained [. . . ]”. But no update has been released so far, probably
not least due to a deficient number of precedent cases.
As regards the inclusion of “pre-clinical tests” as a potential data category currently men-
tioned in Article 74a and its interpretation towards the possibility of demanding exclusivity,
the eligibility of such data for Rx-to-OTC switches is to be questioned with respect to their
relevance being rather moderate for switch candidates usually very late in their life-cycle
and used in a setting of self-medication (see Section 9.2). Even though few ideas referring to
pre-clinical tests are mentioned in the respective section of the European switch guideline,
no further specification is given on what they should be like (European Commission 2006a).
Correspondingly, as demonstrated by expert interview results, controversial views or “no
opinion at all” are held by experts on this issue with the majority considering this data
category as less useful and reasonable for Rx-to-OTC switches. Nevertheless, some scenarios
potentially coming under this category were hypothesized and discussed (see Section 6.1,
Figure 9 and Subsection 9.2.2).
Yet, overall, in regards to a possible entitlement to exclusivity the tenor of nearly every
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expert interviewed irrespective of the relative advocacy group, was to focus on clinical trial
data ideally gathered under OTC real-world conditions (e.g., including educational measures,
etc.) rather than pre-clinical test data. At the same time, a detailed definition of clinical
trials to be conducted for this purpose was affirmed to be missing and thus was postulated
in unison.
8.3 Summary and conclusion
As a result of both literature review, as well as qualitative interview research, both hypothe-
ses 1 and 2 can be confirmed to be valid.
In particular, as the applicability of the current legal framework regarding the provision of
data exclusivity for Rx-to-OTC switches (i.e., Article 74a, Directive 2004/27/EC and its
corresponding switch guideline) was demonstrated to be rather limited; they have to be sub-
stantiated by both the concretion of existing and the elaboration of potential new criteria
and/or data categories serving as a sound and realistic basis for the provision of data exclu-
sivity to future Rx-to-OTC switches.
Within this context the generation of OTC relevant data such as, for example, non-
interventional, observational study data in an OTC-like setting is concluded to be crucial
from the qualitative research results of the present work. Respective proposals and concep-
tions with a view towards eligibility criteria and data category specification will therefore be
analyzed and discussed in the following.
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9 Discussion of results
Both Hypothesis 1 and Hypothesis 2 presented in the present work (i.e., the need to further
specify existent and possibly elaborate on new criteria and data categories in regards to data
exclusivity provision for Rx-to-OTC switches due to inadequate precision and thus limited
applicability of Article 74a of Directive 2004/27/EC) could be confirmed in the previous
chapters. Against this background, apart from the discussion and clarification of existent
data categories, the possible introduction of new data (sub)categories and criteria will be
analyzed and debated in the following discussion. At the same time, qualitative results gath-
ered from individual expert interviews based on the questionnaire developed and depicted
in Section 6.1 will add to the discussion.
First of all, it has to be pointed out that within this process the objective to bring about
acceptable, realizable, and transparent proposals that deserve the grant of data exclusivity
as an incentive instrument based on a common understanding is of the utmost importance.
Future reclassifications from prescription to nonprescription status will inevitably take place
and stakeholders, in particular regulatory authorities and political decision makers, will be
confronted with the task to get on with and eventually support this movement, provided
that a clear public health gain argues for it.
Many of the qualitative interview respondents confirmed the assumption that the applica-
tion of “data exclusivity” as incentive instrument currently does not seem to be appreci-
ated/supported from a political point of view – at least in Germany, but presumably in
other EU countries as well. The fact that, as discussed earlier (cf. Section 4.6 and Chapter
8), information and further guidance on specification, interpretation, and implementation
of legal provisions in Article 74a, Directive 2004/27/EC, are missing, is indicative of this
supposition. Thus, in order to ensure the application of “data exclusivity provision” as an
instrument to foster innovative and enlarged self-medication to cope with people’s aspiration
towards increased autonomous health-management and easier access to adequate therapy op-
tions, a precise guidance referring to the generation of data of informative and essential value
within the context of Rx-to-OTC switches has to be elaborated. In particular, subcategories
and definite criteria have to be set up with attention paid to the aptitude of potential new
data categories and/or criteria being acceptable for all stakeholders as well as being accom-
plishable under “real-world” conditions. In particular, it has to be kept in mind that as
pointed out to by William Soller, member of the Self Care Collaboration38, in his recently
published guiding principles addressing Rx-to-OTC switches, new self-medication options
based on Rx-to-OTC switches have to be “driven by a principle of simplicity of design” with
complexity of risk minimization activities, etc. reduced to a minimum (Soller 2012a).
38 “A group of academic-based health professionals with interests in Rx-to-Nonprescription switch and related
conditions of use” (Soller 2012b).
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9.1 Definitions and interpretation of terminology
Based on the aforementioned, in the first instance it is considered essential to define, specify,
and interpret the indefinite legal terms used in Article 74a in order to be able to provide a
basis for the setup of specific data exclusivity criteria and data categories within the context
of Rx-to-OTC switches.
Apart from the unspecific categorical terms “pre-clinical tests” and “clinical trials” which
will be discussed below (see Sections 9.2 and 9.3), as noted before the associated term
“significant” is also devoid of further specification as well, albeit considered as an evident
“key word” (cf. Section 4.6 and Chapter 8). Against this background, an attempt to define
and interpret “significant” within the context of data exclusivity for Rx-to-OTC switches
follows, which is based on the author’s individual judgment and considerations. The basic
meaning of “significant” as an adjective is defined in Oxford dictionary as follows39:
 “sufficiently great or important to be worthy of attention; noteworthy,
 having a particular meaning; indicative of something,
 statistics relating to or having significance”.
Within the context of statistics the latter refers to a mere mathematical definition, which
is not expected to be intended in Article 74a, as “significance” would then only depend
on a certain mathematical value (e.g., a specific p-value40), regardless of study objectives,
outcome parameters etc. Therefore, referring to the former definitions which are more likely
within the context of Rx-to-OTC switches, in the author’s opinion any data might be “sig-
nificant”, if it is able to demonstrate that treatment with a former Rx-only drug in either
a former Rx or an already established OTC indication can be associated with obvious safe
and effective use under OTC conditions implying a positive benefit-risk ratio. Moreover,
the element of “novelty” is another factor that most presumably will have to be accounted
for in this interpretation of “significant”. More specifically, as demonstrated by practical
examples of data exclusivity applications within the context of recent European Rx-to-OTC
switches (see Subsection 4.4.4), a genuine and possibly relevant impact of data eligible for
exclusivity will only be given if not evident from study results which are at the basis of the
general switch application and most often are already disclosed. Furthermore, according to
the author’s view, switch-specific data should be regarded as “relevant” if above all - with
respect to a broad and usually less or even uncontrolled self-medication – generalizability
of data is possible and appropriate. Thus, efficacy/effectiveness and safety data should not
only be convincing from the perspective of controlled, experimental study conditions, but
also from utilization under real-world conditions anticipating the envisaged OTC-setting.
More specifically, the latter might comprise different data categories ranging from actual use
data to health education or risk minimization measures. Hence, as also reflected by expert
39 cf. http://oxforddictionaries.com/definition/english/significant?q=significant0, last ac-
cessed 2012-10-27
40 The so-called p-value determines the probability of obtaining a result at least as extreme as the one that was
actually observed, assuming that the null hypothesis is true (Goodman 1999).
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interview results (q.v. Section 6.1, Figure 15), next to standard quality requirements (e.g.,
methodology, data analysis, etc.) representativeness with a view to the target population,
indication, dosage, and setting should play a major role within data’s “significance” and
“relevance” evaluation.
9.2 Pre-clinical test data
The relevance of pre-clinical test data as one possible data category currently anchored in
the European legal framework with respect to data exclusivity for Rx-to-OTC switches will
be reflected on and discussed below.
9.2.1 Practical relevance up-to-date
By definition, pre-clinical development is a stage of research the purpose of which is to taper
candidate selection for subsequent clinical evaluation in humans. Pre-clinical test data as
a kind of “basic” data usually are generated on a large scale at an early stage in a drug’s
life-cycle in vitro and in animal models. Investigations on drug metabolism, pharmacokinet-
ics, toxicokinetics, drug action, drug targets, and drug-disease interactions help to generate
exposure-response relationships for efficacy and safety which can eventually be extrapolated
to humans (Lesko et al. 2000).
It might be hypothesized that the term “pre-clinical test data” has been deliberately included
in the legislation by legislative bodies for the purpose of providing applicants with a broad
range of possible data to be supplied for a claim on data exclusivity and not to categorically
rule out pre-clinical data as an important data category in drug development in general.
However, based on the aforementioned (cf. Section 8.2), the author holds the opinion that
the category of pre-clinical test data by classical definition seems to be of rather limited value
with respect to eligibility for data exclusivity within the context of the transfer of medicines
from prescription to nonprescription status. Most substances suitable for Rx-to-OTC re-
classification are of long-standing in the Rx market having undergone several assessments in
regards to completeness of data. The general availability of plenty of pre-clinical data orig-
inating from a drug’s Rx-application, most of them available to the scientific community,
and an adequate safety record accumulated during Rx-marketing minimize the practical
relevance of another set of similar pre-clinical data for OTC usage. As the transfer of a
substance from Rx to OTC generally does not include a basic modification of a substance’s
pharmacological properties, no additional value for a drug’s application in nonprescription
setting will be generated by pre-clinical tests unless taking into account OTC relevant as-
pects. Moreover, from an economic, but even more so from an ethical point of view, further
pre-clinical (i.e., in particular animal, but also in vitro) testing would be rather unjustifiable
bearing in mind that these tests in the majority of cases only provide general information
on the drug substance itself less specific for its application in an OTC environment.
Thus, above all, confirmed by qualitative interview results (see Section 6.1), the author con-
siders the likelihood of being able to generate new significant data in this category as rather
low. In fact, a similar attitude is adopted by the UK’s regulatory authority (MHRA) in its
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“Guidance on the application for exclusivity for change in legal status of a medicine” from
2005. The only national interpretation and guidance on the issue of data exclusivity for Rx-
to-OTC switches as addressed by Article 74a of Directive 2004/27/EC known to date states:
“Additional pre-clinical i.e. animal toxicology or in vitro studies for products late in their
life-cycle, may not have much practical relevance on a switch application, but the applicant
is invited to give this due consideration” (MHRA 2005). In the US, to qualify for three years
of Hatch-Waxman exclusivity, an application or supplement must contain “reports of new
clinical investigations (other than bioavailability studies) essential to the approval of the ap-
plication and conducted or sponsored by the applicant”. Thus, by regulation, exclusivity is
provided solely on the basis of clinical, but not pre-clinical, study data and the FDA thereby
clearly interprets clinical investigations as investigations conducted on humans other than
bioavailability studies (cf. FDA 2006a; FDA 2007).
9.2.2 Pre-clinical scenarios with potential relevance to Rx-to-OTC switching
Nevertheless, although not specified in the current legal provision, pre-clinical evaluation
is estimated to be reasonable and required for OTC switches under specific circumstances,
such as the investigation of interaction profiles with newly available drug substances having
not yet been available during pre-clinical test phases of a switch candidate prior to its Rx
registration. Moreover, as suggested in the current EU switch guideline, certain Rx-to-OTC
switch scenarios could benefit from pre-clinical investigations, such as: the pharmacoki-
netic/pharmacodynamic and associated toxicity and efficacy profile of a switch candidate’s
new delivery forms, new fixed dose combinations, or new route of administration. Details
on specific parameters potentially relevant for exclusivity approval, however, are missing.
A proposition of pre-clinical test evaluation/outcome measures based on experts’ opinions
on potential scenarios that they could imagine to contribute to data exclusivity eligibility
is shown in Table 11. The focus on safety and especially toxicity aspects thereby seems
to account for possible remaining concerns related to switch candidates encountering less
medical control in an OTC setting.
Besides, the retrospective analysis of existing pre-clinical test data under OTC relevant
aspects was propounded as a data (sub-)category potentially eligible for exclusivity. Yet,
even though estimated as possibly relevant by two-thirds of the experts interviewed (see
Figure 10), the discussion with these experts revealed that this kind of data analysis could
only (if at all) be of a supportive nature and would definitely have to be complemented by
adequate clinical trial data before being able to be considered significant and thus eligible
for data exclusivity. Therefore, the wording of the interpretive EU switch guideline obvi-
ously equally allowing for submission of combined pre-clinical and clinical data (“and/or”)
is reasonable and important41. The concern about retrospective definition, identification,
and derivation of respective outcome parameters in the pre-clinical assessment relevant for a
specific Rx-to-OTC switch being intricate and disputable in terms of regulatory acceptance
41 In contrast, strictly speaking, the original legislative text (i.e., Article 74a, Directive 2004/27/EC) only allows for
either data category: “Where a change of classification of a medicinal product has been authorised on the basis
of significant pre-clinical tests or clinical trials, [. . . ].”
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Table 11: Scenarios and associated pre-clinical tests suggested by experts inter-
viewed as possibly contributing to data exclusivity eligibility
Scenario Pre-clinical Evaluation
New delivery form Pharmacokinetics/Bioequivalence/Superiority
New route of administration Pharmacokinetics/Bioequivalence/ Superiority
New strength/posology Pharmacokinetics/Pharmacodynamics/Toxicity/
Efficacy
New fixed dose combination Pharmacokinetics/Pharmacodynamics/Toxicity/
Efficacy
New excipients Pharmacokinetics/Pharmacodynamics/Toxicity
Drug-drug interactions with new Rx-/OTC-substances Pharmacokinetics/Pharmacodynamics
If applicable (e.g., old substance, etc.): Re-evaluation
of cancerogenity/genotoxicity
Toxicity (using current standard methods)
might be at the bottom of this assumption.
Overall, in the author’s opinion, pre-clinical test data are essential and relevant when it
comes to the safety and usability of a certain drug substance, delivery form, route of ad-
ministration, etc. and should therefore be required for and precede any clinical development
and registration in both prescription and nonprescription settings. However, apart from the
fact that most pre-clinical data is most often already available (and often published) to a
large extent, according to the author’s view this data, in the classical sense, cannot be con-
sidered appropriate to exclusively qualify for the data exclusivity provision, as it might be
interpreted from the wording of the current legal text of Article 74a. This is due to the belief
that this kind of data is indeed able to cover “basic” safety parameters (e.g., pharmacokinet-
ics/pharmacodynamics/toxicity), but does not take into account specific OTC parameters
which are of at least equal or even higher importance in light of unsupervised “real-life
application” (e.g., patient behavior, etc.) within the setting of self-medication. Instead, if
applicable, new or quasi-new (i.e., re-analyzed) pre-clinical data should on an individual basis
rather be seen as an important, but not sole contributor to eligibility for data exclusivity.
9.3 Clinical trial data
“Clinical trial data” is the second largest data category mentioned in the EU’s current
legal framework (Article 74a, Directive 2004/27/EC) with respect to qualification for data
exclusivity for Rx-to-OTC switches. As with the pre-clinical test data category presented
above, the significance and applicability of the clinical trial data will be debated in the
following.
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9.3.1 Practical relevance at present
By conservative definition, clinical trials are at best to be conducted according to a detailed
study plan in a randomized, controlled way throughout different phases of drug development
(i.e., phases I-IV). More specifically, phase I-III trials are designed to investigate efficacy and
safety in a controlled setting and given indication, whereas phase IV trials including several
thousands of patients aim at the investigation of adverse events after market approval (i.e.,
post-marketing surveillance). Hence, taken as such this commonly used term comprises a
number of subcategories which often differ (e.g., in terms of study design, data quality, etc.).
In any event, clinical studies based on the aforementioned definition always imply the in-
volvement of a physician for treatment decision thus minimizing their potential significance
and relevance for Rx-to-OTC switches targeting self-medication, as results do not fully allow
an evaluation about how treatment would be managed by patients themselves under OTC
usage conditions (i.e., without a physician’s intervention).
In general, clinical study evaluation includes testing of multiple dosages and dosage regimes
of a specific drug finally resulting in the authorization and establishment of a so-called “ther-
apeutic standard dosage”. This is usually the one with the best benefit-risk ratio referring
to a specific indication and patient population under defined circumstances (e.g., prescrip-
tion environment). If proven safe and effective, other than the therapeutic standard dose
might also be available. When it comes to the application of as yet to be approved (e.g.,
reduced strength/posology) of course, confirmation of efficacy/effectiveness and safety in the
targeted indication and patient population appears to be essential. However, as described
before, these data often may already be available or at least derivable from studies con-
ducted for and during a drug’s prescription authorization. As demonstrated by the alli
®
and Pantozol Control
®
cases (cf. Subsection 4.4.2), additional confirmatory study data with
a lower dosage strength/posology may, therefore, not be regarded as significant as long as
safety and efficac/effectiveness data merely are reproduced and - compared to already ex-
isting Rx data – are not investigated in light of additional criteria essential for its targeted
application in a self-medication environment.
Unfortunately, as already depicted above (q.v. Section 8.1), within the context of an Rx-to-
OTC switch no precise specification and interpretation of the term “clinical trials” is given in
the respective legal framework apart from the switch guideline quoting confirmatory clinical
trial data with respect to another (e.g., lower) dose or a new or widened indication in terms
of safety, efficacy, and actual use.
Two double-blind placebo-controlled multiple-dose phase III studies were identified via in-
ternet search on http://www.clinicaltrials.gov investigating efficacy and safety of an
extended release formulation of ibuprofen 600 mg within a typical OTC indication (i.e., den-
tal pain after extraction of third molar teeth) 42,43. Study medication was dosed at 0, 12, 24,
and 36 hours. Apart from AE tracking, primary and secondary outcome parameters mainly
42 cf. http://www.clinicaltrials.gov/ct2/show/NCT01266161?term=ibuprofen+extended+
release&rank=1, last accessed 2013-03-10
43 cf. http://www.clinicaltrials.gov/ct2/show/NCT00707057?term=ibuprofen+extended+
release&rank=2, last accessed 2013-03-10
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included onset, intensity, and duration of analgesic treatment efficacy. Without knowing the
specific background of these studies, according to the author, Rx-to-OTC switch efforts and
considerations claiming data exclusivity on the specific pharmaceutical form as indicated
above might be hypothesized.
However, if study design and results will ultimately qualify for data exclusivity is not pre-
dictable, as no information is provided in the EU switch guideline with regards to study
details such as quality requirements (design, analysis, etc.) for a certain study to be judged
as relevant and significant within the context of a certain Rx-to-OTC switch.
As can be derived from the aforementioned, the author holds the view that a merely
conservative definition and interpretation of the legally indefinite, superordinate term “clin-
ical trials” is not conducive in the context of Rx-to-OTC switches and should therefore be
extended to take the characteristics of the target setting, namely OTC setting, into consid-
eration (in terms of study design, population, endpoints, etc.). Against this background,
different criteria and categories estimated to be relevant for the targeted OTC setting were
suggested and discussed with selected national and international experts and stakeholders
within self-medication (see Section 6.1). Correspondent proposals will be analyzed and dis-
cussed in detail in the following.
9.3.2 Re-analysis of existent data with respect to OTC usage
Actually, all qualitative interview respondents could imagine the re-analysis of clinical data
already available from a drug’s registration as prescription therapy under OTC pertinent
viewpoints. Yet, this is not really astonishing: the Canesten
®
GYN case (see Chapter 5)
shows exemplarily that from a drug’s prescription history there are plenty of pre-clinical and
clinical data available – not only generated for registration purposes, but also during Rx mar-
keting. Therefore, a huge data base comprised of pre-clinical and clinical data related to a
potential switch candidate usually is available at its originator. Especially data gathered after
a drug’s Rx authorization throughout the post-marketing phase, such as non-interventional
study data (cf. Subsection 9.3.3) are thinkable to be re-analyzed and re-structured under
OTC relevant aspects (e.g., utilization patterns, effectiveness and safety profiles, etc.). When
asked about the relevance of various design and outcome parameters with respect to the ex-
trapolation of Rx data to potential future OTC usage, size and kind of study population
were named as the most important design parameters along with safety/pharmacovigilance
as the most significant outcome parameters (cf. Figure 11). The distinct analysis of data
referring to special patient groups (e.g., elderly, patients with comorbidities, etc.) was also
judged valuable in light of potential precautions to be taken within less supervised OTC
usage. As each and every potential switch candidate might differ a lot regarding indication,
target population as well as complexity, for example, specific analysis parameters as well as
inclusion and exclusion criteria (e.g., the exact definition of special populations, etc.) will
probably have to be determined on an individual basis (and are recommended to be also
discussed with authorities). To be considered significant, data should in any account be
analyzed and summarized according to current scientific and especially statistical knowledge
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(i.e., be of adequate statistical power). If available, suitable OTC data with regards to the
same or a similar indication might be integrated into the analysis as well. Corresponding Rx
data could then be analyzed and discussed in light of anticipated OTC utilization patterns
and characteristics.
Aside from the above mentioned, in the author’s opinion the re-analysis of data typically com-
prehensively available from a drug’s history as a prescription drug might also be estimable,
if appropriate, with a view towards ethical considerations and efforts to avoid redundancy
by duplication of data.
After all, however, it is of note that – between the lines - many experts expressed their doubts
that this kind of data might exclusively yield data exclusivity for a certain Rx-to-OTC switch.
Thus, in summary, the criterion of re-analyzing pre-clinical and/or clinical data was indeed
largely considered as supportive, yet not exclusively sufficient. Instead, the necessity of data
generation under daily-life conditions in the target setting of self-medication was more or less
concordantly stressed by experts asked (cf. Figure 12). The following chapter will therefore
deal with so-called behavioral study data as data (sub)category with high potential for data
exclusivity eligibility in Rx-to-OTC switches.
9.3.3 Switch candidate under daily-life conditions: behavioral study data as potential “clin-
ical” data category
“Over the last years, behavioral study research has become an integral part of OTC drug de-
velopment programs as it provides essential insight in and helps predict consumer behavior”
(Leonard-Segal 2009).
One of the most important questions of interest before making a new drug available in a
new OTC indication is how the respective drug candidate will actually be used by patients
in the absence of the more or less close medical supervision mostly found in an Rx setting.
Safety parameters are without doubt at the forefront of important parameters to be analyzed
within this context, followed by effectiveness. Besides pharmacy recommendation and pa-
tient utilization patterns (such as self-selection, label comprehension), actual use (including
potential mis- or abuse, as well as compliance) will have to be evaluated in order to put
the aforementioned outcome parameters into context. Determination of a new OTC drug’s
potential impact on patients’ QoL could as well be worth a downstream evaluation.
In order to investigate a drug’s utilization, safety, and effectiveness under real-world con-
ditions, the study setting obviously has to be as naturalistic as possible (i.e., ideally of
non-interventional and only observational character). Hence, an epidemiological rather than
a conventional clinical randomized study design approach seems to be appropriate in case of
behavior and actual use evaluation. Actual use trials – that is, “anticipatory observational
trials in which designed operations are implemented to create a setting for use that does not
currently exist (OTC sale of a current Rx drug)” and in which only the observation of sub-
jects should more or less provide the forecast of behavior, could help in answering “what are
the public health implications of removing HCP from the process of diagnosing the problem,
prescribing the drug, and monitoring its use” (Bradford et al. 2010). By assessing the safety
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of Rx drugs under usage conditions mimicking OTC, such studies could or rather should
play a key role in the Rx-to-OTC switch application process. The ability of OTC consumers
and/or patients to responsibly and correctly perform functions previously managed by a
physician (i.e., self-diagnosis, self-selection, AE monitoring, etc.), as well as potential ben-
efits and risks to public health are among key regulatory questions when considering the
reclassification of a drug from prescription to nonprescription setting and should be able to
be assessed by properly designed, conducted and analyzed non-interventional AUTs.
As to traditional research models commonly applied in Rx drug development, such as effi-
cacy trials, phase IV studies, passive surveillance systems, etc., Bradford argues that they
typically only answer part of or other questions than those relevant with respect to OTC
usage and, thus, offer only limited data about the suitability of a certain switch proposal.
Efficacy trials are carried out according to a predefined study protocol in a risk controlled
environment and usually investigate a carefully selected population not taking the decision
to self-medicate itself and thus presumably differing from the self-treating OTC population.
In brief, experimental conditions complicate generalization. Passive surveillance systems
(e.g., registries) and epidemiological studies might deliver useful signal detection, yet are
less suited for determination of parameters, such as non-compliance due to only broad ques-
tions and long duration of adequate data collection. In contrast, phase IV post-marketing
surveillance trials might come closest to the generation of data potentially relevant to Rx-
to-OTC switches as they monitor actual drug use, however, with the disadvantage of being
focused on real-life data in the prescription setting only. Yet, despite its anticipatory value
for OTC setting being comprised, this data might possibly serve as a comparative database.
In summary, whereas clinical research in the classical sense mainly provides insight into how
a drug reacts physiologically in a person, observational (consumer) research helps elucidate
how a person reacts behaviorally with the drug (Aker 2006). Against this background and
based on the fact that a successful Rx-to-OTC switch from a scientific point of view mainly
depends on a well-functioning patient behavior in a much less controlled self-medication
setting, the author comes to the conclusion that the interpretation of the term or category
“clinical trials” mentioned in Article 74a, Directive 2004/27/EC, should definitely encompass
appropriate forms of non-interventional behavioral research data (provided that accordant
quality criteria are fulfilled – see below).
As a consequence of the aforementioned, Bradford calls for specific design elements to be
used in actual use trials which he considers to be “significantly different from efficacy trials”
(Bradford et al. 2010). The following chapters deal with the discussion of such design ele-
ments within the context of legal considerations, general principles, and quality criteria to
be adhered to within the context of observational research studies.
Excursus: non-interventional studies (NIS) – short overview of definition, classification, and
quality criteria to date By definition, observational studies are conducted post-marketing
and without external intervention. They are therefore also termed “non-interventional”. In
contrast to randomized, controlled clinical trials, no specific investigational requirements
such as a detailed protocol referring to a distinct investigation and/or therapy procedure
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need to be predefined, as the idea is to conform to normal practice reflecting daily-life con-
ditions (Gu¨nther 2001).
In general, observational studies intend to prospectively or retrospectively collect data re-
garding a certain drug and/or indication over a certain period of time (Kori-Lindner and
Eberhardt 2010). There are different types of observational study designs which can be
classified as either descriptive (e.g., case studies, cross-sectional studies (surveys), non-
interventional studies, drug utilization studies, and ante/post comparisons) or analytical
(e.g., epidemiological cohort studies, case-control studies, and registries) (Ha¨cker 2010; Kori-
Lindner and Eberhardt 2010).
The focus of the present work will be laid on characteristics and requirements of non-
interventional studies as a commonly used instrument to investigate and monitor drugs and
drug usage during the post-authorization stage. Within Europe, the “non-interventional
study” has been legally and regulatory defined by the EU’s so-called “Clinical Trials Di-
rective” (Directive 2001/20/EC)44 referring to the application of “Good Clinical Practice”
when conducting clinical trials. According to EudraLex Volume 10, Chapter 5 (status July
2009), however, the Directive itself in fact does not apply to non-interventional studies, as
the individual risk for study participants should be much less than in interventional clini-
cal studies. Moreover, medical activities representing routine practice are part of patients’
general medical surveillance measures and thus do not come under the Directive’s scope of
application.
In Germany, the above mentioned EU Directive was implemented into national law in 2004.
Section § 4(23) of the German Medicines Law gives a precise definition of the respective
term “non-interventional study”45. Interestingly, as discussed by Ha¨cker, the German legal
definition and interpretation differs from the European one in that not only treatment mea-
sures, but any specifications regarding treatment, diagnosis, and monitoring are interpreted
as “interventional” and thus excluded. On the contrary, the epidemiological interpretation
which is at the basis of the European definition of “non-interventional” includes specifica-
tions regarding data generation, documentation, and control for the sake of data quality
assurance (Ha¨cker 2010).
In 1998 the German regulatory authority (Bundesinstitut fu¨r Arzneimittel und Mediz-
inprodukte (BfArM)) published quality recommendations regarding the conduct of non-
interventional studies which are based on recommendations of the German Association of
Medical Informatics, Biometry, and Epidemiology (GMDS). These recommendations were
updated in collaboration with the Paul-Ehrlich Institute (PEI) and a final version has been
44 “A study where the medicinal product(s) is (are) prescribed in the usual manner in accordance with the terms
of the marketing authorization. The assignment of the patient to a particular therapeutic strategy is not decided
in advance by a trial protocol but falls within current practice and the prescription of the medicine is clearly
separated from the decision to include the patient in the study. No additional diagnostic or monitoring procedures
shall be applied to the patients and epidemiological methods shall be used for the analysis of collected data”
(Article 2c, Directive 2001/20/EC).
45 A study where “findings from the treatment of persons with drugs according to the terms of the marketing
authorization are analyzed with epidemiological methods; thereby treatment, including diagnosis and control,
does not follow any predefined study plan but only the medical practice” (§ 4 (23) German Medicines Law).
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available since 2010 (BfArM & PEI 2010). Another set of practice-oriented recommenda-
tions was published in 2007 by the German Association of Research-based Pharmaceutical
Companies (VfA 2007b) in order to enhance NIS transparency and quality (Ha¨cker 2010).
Besides, with respect to the epidemiological definition of non-interventional study research,
the German national “Guidelines and Recommendations for the assurance of Good Epi-
demiological Practice (GEP)” of the German Working Group Epidemiology46 (DAE 2000)
as well as the “Guidelines for Good Pharmacoepidemiological Practices” of the International
Society for Pharmacoepidemiology (ISPE 2007), and the “Strengthening the reporting of ob-
servational studies in epidemiology (STROBE) Guidelines” are to be noted (Ha¨cker 2010;
Schnetzler and Hayward 2011).
In summary, Table 12 provides an overview of basic quality criteria and recommendations
propounded by the various groups as to the conduct of NIS. Representing a synopsis of the
current scientific state of knowledge and practice they should serve as guidelines for planning
and conducting an accordant NIS.
46 now German Society for Epidemiology (DGEpi)
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Table 12: Actual basic criteria and recommendations referring to the conduct of
non-interventional studies in Europe and Germany, respectively
Study characteristics Quality requirements
General • Marketed and commercial drugs or medical devices
• Diagnostic measures and procedures as well as treatment within current practice,
i.e., no rules for HCPs and patients involved (non-interventional)
• Ethics committee advice recommended
• If applicable: informed patient information and consent (in case of data not treated
anonymously)
• If applicable: reward/reimbursement
Objectives Medical/Scientific objectives:
• safety,
• effectiveness,
• drug utilization, etc.
Planning, conduct,
evaluation
• Based on current scientific knowledge and practice as well as respective quality
standards
• Design and methods used have to be appropriate in responding to study questions
• Design: epidemiological (if applicable: based on appropriate data (registries,
etc.)), prospective (mostly) or retrospective, non-interventional
• Representativeness to be provided and assured
• Study plans: observational and analysis plan including study aim(s), investigated
parameters/ questions, rationale for number of cases needed, patient collective
(selection criteria), upfront identification and description of adequate analytical
methods, determination of bias minimization strategies
• Data management: adequate quality assurance, documentation, storing, protection,
and publication
Disclosure duty • EU: varies by country from full submission to simple notification
• Germany (according to § 67(6) German Medicines Law): general disclosure duty
(apart from studies with nonprescription products) for pharmaceutical companies
regarding study site, time, objective(s), and study plan to the National Association
of Statutory Health Insurance Physicians (Kassena¨rtztliche Bundesvereinigung
(KVB)), the national confederations of health insurance funds (Spitzenverband
Bund der Krankenkassen), and the assigned higher federal authority
(Bundesoberbeho¨rde)
• AEs observed during study period or follow-up to be included in PSUR
Observational study research in the context of Rx-to-OTC switches: behavioral studies –
principles and proposals As discussed above (cf. Subsection 9.3.3), behavioral studies rep-
resenting a subtype of observational, non-interventional study research, have become an
essential means of studying outcome parameters referring to the setting of self-medication
with the US pioneering this kind of study concept. Basically, as shown in Table 13 three
different forms and levels of behavioral studies are to be distinguished depending on their
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complexity.
Table 13: Overview of different kinds of behavioral study designs (adapted from
Leonard-Segal 2009)
Label comprehension
study (LCS)
Self-selection study
(SSS)
Actual Use Study
(AUS)
Characteristics  Development of OTC
label
 Readability testing
 Questionnaire – based
 Trial without drug in-
take
 Determination of cor-
rect self-diagnosis and
product selection by
patients after reading
product label based
on individual medical
history
 Minimal assistance
 Trial without drug in-
take (unless part of an
AUS
 Simulation of OTC
drug use (drug is pur-
chased and then taken
at home for intake
 Relationship between
self-selection decision
and purchase decision
 Assessment of drug uti-
lization, e.g., compli-
ance/adherence
 Safety documentation
(tracking of adverse
events
 Evaluation of effective-
ness (occasionally)
 Used label should have
tested well in LCS
 Considered as clinical
trial ( author’s note: at
least in the US!)
Target popula-
tion
 Representative, demo-
graphically diverse
 Including subgroups of
special interest
 Including low literacy
cohort (selected based
on validated literacy
test)
 Representative, demo-
graphically diverse
 Including subgroups of
special interest
 Potential users and
non-users
 Representative, demo-
graphically diverse
 Including subgroups of
special interest
 Potential users and
non-users
Relevance  If drug is first in class in
OTC setting
 If targeting new OTC
population
 In case of a new OTC
indication
 In case of an extensive
label change
 Data mostly collected
in the context of LCS or
AUS
 In case of a new OTC
indication
 In case of new direc-
tions of use
 In case of new OTC
warnings
 In case of new OTC
medical follow-up re-
quirements or recom-
mendations
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In contrast to the US where this kind of data often is used in assessing either the approval
of new OTC or Rx-to-OTC switch applications, acceptance has virtually been absent among
European authorities until today with a view towards comparable approval processes. Solely
a so-called “readability test of patient information leaflet (PIL)”(i.e., a kind of label compre-
hension study) was decided mandatory for respective authorization processes (or in cases of
significant changes of the PIL) according to corresponding European guidelines (European
Commission 2006b; European Commission 2009) as of November 2005.
Interestingly, when asked about their estimation of the potential relevance of such study
data for the provision of data exclusivity for switch products in Europe, a large majority of
experts asked voted in favor of data resulting from behavioral study research with AUS data
being rated the highest, followed by LCS data (see Figure 14).
However, several issues were raised within this context. In particular, some of the concerns
expressed relate to timing, practicability, quality, and legal/regulatory basis for the conduct
of AUS with Rx drugs in a setting mimicking OTC conditions of use. Moreover, the lack
of definitions, standards, and guidelines referring to the design and analysis aspects of such
studies was also critically pointed out. Indeed, many issues and challenges have already
been recognized and were discussed among expert groups in the US. For instance, in 2006
the FDA Nonprescription Drugs Advisory Committee (NDAC) already discussed essential
questions in study design and data analysis, such as the definition of objectively tolerable
failure and success rates that should also take into consideration associated risks and poten-
tial individual patient reasons for incorrect responses and behaviors. If limited degrees of
failure to heed warnings pose a non-substantial health risk and therefore might be medically
acceptable, respective rates should not be overly restrictive. The multiplicity of independent
endpoints makes the construction of a data analysis plan as it is utilized in clinical trials,
with primary and secondary outcomes assessing a drug’s proposed clinical benefit by prede-
fined statistical tests, rather difficult in patient/consumer behavioral research. Traditional
end points might be difficult to designate in behavioral research and performance against
a comparator is usually either not available or not relevant. A prospective, iterative, hier-
archical approach to endpoint definition and pre-specification of targeted correct response
rates was suggested by different researchers who advocate for the need to pre-specify targets
for acceptable performance and response rates in a study’s analysis plan analogous to the
pre-definition of the α significance level in RCTs (Brass et al. 2009; D’Agostino 2006; Wood
2006). As generally not all messages are of equivalent clinical importance, targets might dif-
fer between endpoints resulting in a “hierarchy” or “pyramid” of endpoints (see Figure 27)
(Brass et al. 2009). Beyond that, benchmarking the results of patient behavior studies, such
as compliance, etc. against that of other OTC domains or prescription setting might help
to put them into perspective. Available information on actual Rx or OTC usage abroad as
well as use of similar OTCs or data from post-marketing surveillance should be integrated
in an extrapolating analysis helping to predict OTC usage patterns (Aker 2006).
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Figure 27: Hierarchy of study endpoints in terms of key messages and related
patient behavior based on their clinical relevance: the pyramid bottom including
the many label messages that are useful, yet normally without major clinical
consequences in case of not heeding; the messages and behaviors at the upper
pyramid levels to be endued with the highest performance targets due to potential
severe clinical consequences if disregarded by patients (adapted from Brass et al.
2009)
The optimal duration of actual use studies might be another aspect of discussion, as the
use of many OTC drugs, in general, is at most intermittent and only limited. No “stan-
dard” recommendations are known hitherto in this regard. However, results of the expert
consultation show that the relevance of these aspects (i.e., study duration and duration of
follow-up (if applicable)) must not be underestimated – both were rated in the range of
1-3 on a 6-point scale (1 = extremely relevant, 6 = not relevant at all). In the author’s
opinion, as these are parameters definitely depending on the individual switch scenario in
terms of a drug substance’s inherent characteristics (e.g., mode and onset of action, effi-
cacy/effectiveness, safety, etc.), the associated indication (acute, recurrent, (semi-)chronic),
already existing OTC options, etc., related decisions should be taken on a case-by-case basis.
In acute, self-limiting conditions, for example, a study duration at least according with the
proposed period of intake (similar to that of already available therapeutic options (if any))
and an adequate period of follow-up should in either case be postulated. The length of the
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follow-up phase should be decided based on elements of the label that need testing, such as
recommended duration of usage, dose adjustment, requirement to consult a HCP, etc. In
general, for a short-term use drug, a study period of one or two weeks longer than the labeled
duration of use has been proposed as adequate “risk-window” to determine, for instance, any
“carry-over safety issues” (Leonard-Segal 2006; MacDonald 2002). In (semi-)chronic condi-
tions study duration is supposed to be longer and might be determined based on experiences
from the prescription setting. Since the “naturalistic” character of an observational study
might get lost at the expense of a long-term scientific follow-up, the evaluation of such trends
and patterns was proposed to be shifted to OTC post-approval as one possible solution (Aker
2006).
For recurrent indications that initially need to be diagnosed by a doctor and the subsequent
or anew treatment/management of which is proposed to be switched to OTC, the concept
of “collaborative care” could be implemented in the corresponding behavioral study design.
This scenario has come true, by way of example, for the aforementioned switch of clotri-
mazole (Canesten
®
GYN) for the treatment of vaginal candidiasis (cf. Chapter 5), yet no
observational data had been generated or available at that time. In such cases patients
could be recruited before or at medical consultations and subsequently be followed-up for
continued management of the respective condition to check their ability to re-diagnose and
self-medicate. Likewise, in indications where a physician’s visit becomes obligatory at a
certain point in time, as it is required for the treatment of benign prostate hyperplasia in
the UK (see Subsection 4.4.4), the attendance of physicians could be included in the study
concept.
Another challenge within behavioral study research refers to the question of implementing
a second or even more groups for the purpose of control (e.g., when a multiple-arm study
should be preferred to the “classical” single-arm study most often used in patient/consumer
behavioral studies). According to their questionnaire assessments experts seem to highly
value “randomization” and consequently the inclusion of a “control group” as one of the
main quality features used in experimental clinical trials (see Figure 15). By definition, this
would ultimately imply for behavioral studies to consist of two arms, at minimum. However,
due to the more or less naturalistic, non-interventional setting of behavioral studies, “ran-
domization” in a conservative sense (i.e., double-blind treatment allocation at best) will not
be feasible, as there should be as little intervention as possible. On the other hand though,
this does in general not rule out multiple-arm studies including a control group. For example,
educational materials and/or therapy monitoring/management devices could be provided to
certain arm(s) of a behavioral study investigating an Rx-to-OTC switch candidate in its
associated indication whereas it will not be provided to the control group. Subsequent anal-
ysis and comparison of results (e.g., referring to safety, effectiveness, compliance, QoL, etc.)
could be essential for a positive outcome of a certain switch decision, if adjuvant measures
prove to favor the respective benefit-risk profile (see also Subsection 9.3.4). In case of an
indication already established OTC, a possible multiple-arm scenario could be the compar-
ison of a potential Rx-to-OTC switch candidate with an existing OTC alternative therapy
in terms of actual use, QoL, etc. – an approach which was equally voted for by the large
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majority of experts interviewed (see Figure 18).
One major problem inherent to behavioral research, however, is the existence of different
forms of bias, as discussed in detail in Subsection 7.2.1. Moreover, “missing data” is another
huge issue in observational research with no simple handling strategies available to date.
These kinds of statistical issues may often result in poor data quality and validity (Brass
and Lyons 2006). Authenticity, completeness, and validity of data, as well as identification
and resolution of deficiencies at an early stage should therefore be of highest interest.
Of course, every switch will be linked with its own challenges and complexities to be ac-
counted for in the respective study design and analysis. However, different factors and
strategies are available that might help contribute to an improvement in data quality and
validity: first of all, basic quality criteria and recommendations for NIS listed above (see
Subsection 9.3.3) should be fulfilled. Second, appropriate study design and adequate data
analysis as depicted in Chapter 7 and supplemented by practical considerations below should
help minimize potential confounding factors.
In spite of the non-interventional study character, observations have to be made implement-
ing a set of operations to conduct research. The scientific challenge is to conceive of and
implement these conditions in a way that the findings of the study can forecast actual OTC
usage. Sampling from a not yet existing, but defined population constitutes a fundamental
task in this process. There are some general principles and suggestions assisting to keep
the observational study process (including recruitment and enrollment) as naturalistic as
possible, even if there are set limitations such as procedures for conducting science and the
protection of subjects’ rights (e.g., informed consent, data collection, etc.) (Bradford et al.
2010). For example, frequency of data collection should be minimized to reduce the potential
of “patient reactivity”. With respect to the target setting, self-selection into the (compara-
tive) trial should mimic the anticipated OTC situation – that is, subjects should obtain their
drug where they normally get it and decide whether the drug is appropriate for them based on
information available (equal to envisaged label and communication strategy). Data related
to non-enrollers in comparison to enrollers might also be critical in order to check sample
representativeness (Ha¨cker 2010) which was considered extremely important by experts in
case of a new OTC substance and indication. Depending on study complexity enhanced
quality of data may be as well achieved by the use of pretested, standardized case report
forms (CRFs) including source data verification47 performed in randomly selected study cen-
ters as it is mandatory for clinical trials and was propounded for NIS in prescription setting
(Theobald et al. 2009). Also, sufficiently large samples tend to be more diverse with respect
to relevant factors or potential contraindications (medical history, concomitant medications,
etc.) and may allow some powerful comparisons among sample subgroups (Bradford et al.
2010). In the author’s opinion, the study size should be more precisely defined by authori-
ties (e.g., by a specific range of patients to be included, taking into consideration, of course,
several influencing factors such as kind and incidence of the condition, associated risks, kind
of study population, quantitative objectives, etc.). This should preferably be subclassified
47 Source data verification refers to the evaluation of the conformity of data from CRFs with source data in order to
assure reliability of data collected (Khosla et al. 2000).
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by study type and serve as orientation guide for the conduct of any observational trial.
With a view towards study data analysis, applied methodology, and techniques should be of
current scientific standard and appropriate to encounter overt or potentially upcoming statis-
tical issues. The so-called “propensity score technique” was presented above (cf. Chapter 7),
as it displays a relatively robust method increasingly used in observational study research
to balance existing known confounders and draw the right conclusions. As demonstrated
by the literature available as well as the practical example at hand (cf. Subsections 7.2.2
and 7.2.3), the employment of propensity score methodology in multiple-arm studies might
be one way to enhance study data validity by contributing to achieve results which are as
realistic and unbiased as possible. Examples are the comparison of study groups with and
without a comprehensive education and training program (q.v. Subsection 9.3.4) as well as
the comparison of a switch candidate with either its counterpart in a prescription setting or
therapeutic alternatives already available OTC.
As to the latter, possible approaches including essential design features were suggested by
an expert group in its 2002 consensus paper (MacDonald 2002): the main focus was thereby
laid on the demonstration of safety equivalence (in terms of “non-inferiority”) using the ex-
ample of low-dose non-steroidal inflammatory drugs. According to this consensus paper, “a
summary approach towards evaluating the safety of a new OTC drug against an appropri-
ately chosen OTC comparator is a multinational, multicenter, pharmacy-based, randomized,
double-masked, two-armed study sized to demonstrate equivalence” which should comply
with GEP guidelines.
The author of the present work agrees with the proposed multinational study design in
particular in case of a switch product to be marketed in several EU countries in light of
differing pharmacy systems and practices as well as user populations and risk factors among
various countries. However, against this background, depending on the switch candidate
in question, feasibility of this approach might be rather challenging. Notwithstanding the
aforementioned, if applicable, the investigation of therapeutically equivalent comparators
will certainly enhance the quality of study results. With respect to randomization, in the
author’s mind the most reasonable strategy would be to randomize center-wise (i.e., one
pharmacy providing only one of the treatment options to be compared). A similar approach
has been promoted by Kori-Lindner and Eberhardt equally suggesting the randomization
of study centers but not study participants (Kori-Lindner and Eberhardt 2010). Moreover,
the author holds the opinion that contrary to expert recommendations in order to retain
the naturalistic character of an observational study as well as possible; blinding of study
medication in theory would only make sense, if similar substances with the same mechanism
and conditions of use were to be compared, but would not be feasible in practice on the basis
of a non-interventional study concept.
Finally, as far as timing as well as legal and regulatory aspects of conducting such a com-
parative study are concerned, the expert group stated that “such a utilization study can
only be done with drugs that already have an OTC license or in countries where the study
drug is already OTC”. Basically, the timing will depend on the individual switch scenario.
By way of example, a switch candidate representing a new therapeutic option in an already
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established OTC indication might be more easily compared with existing OTC alternatives
within the context of a behavioral study conducted post-switch as then both study drugs
are equivalent regarding their legal status and regulatory framework.
Nevertheless, the author deems a comparison of an Rx-only switch candidate with an OTC
therapy option likewise conceivable provided that a comparable supply and data collection
model can be defined and implemented in the respective country of study. In Germany,
for example, depending on the target indication, both Rx and OTC medications could be
handed out by pharmacists together with accordant questionnaires, patient diaries, etc. for
data collection. Appropriately designed data collection instruments could be used to gather
data regarding safe and effective use as well as compliance, but also with respect to patient
centered questions such as non-monetary determination of QoL improvement, patient satis-
faction with treatment, convenience, etc.
In summary, the submission of behavioral study data referring to a certain Rx-to-OTC switch
scenario is proposed as a necessary and relevant criterion regarding the possibility of data
exclusivity provision based on Article 74a, Directive 2001/83/EC, as amended. Even if there
is no one switch scenario like another, some basic requirements should be fulfilled, such as
the consideration of current guidelines and quality recommendations, an appropriate study
design (depending on substance and indication) mimicking OTC conditions at its best and
including an adequate study sample as well as the application of statistical methods ensur-
ing the highest quality and validity of data possible. Of utmost importance, however, with
respect to the anticipated real-life behavior of future OTC patients is the maxim that “the
more the research can stay out of the way of subject behavior, the more likely it is that
the findings will reflect the way consumers will behave once the drug is made available for
nonprescription use” (Bradford et al. 2010). That is, last but not least it has to be kept in
mind that behavioral studies should be kept as simple as possible to preserve predictability
and that it is not feasible to cover every eventuality.
Legal and regulatory strategy considerations for the conduct of a behavioral study within the
context of an Rx-to-OTC switch Based on the quality requirements and recommendations
mentioned above, various aspects regarding legal and regulatory basis as well as strategic
aspects (timing, etc.) for the performance of an observational behavioral study for a certain
Rx-to-OTC switch will be discussed below.
As mentioned above, the scientific conduct of a non-interventional behavioral study in a way
that its “naturalistic character” is conserved to a maximum in order for study findings to
match as much as possible with the anticipated OTC reality is a major challenge. The iden-
tification and definition of an appropriate regulatory strategy complying with the current
legal framework, however, is not less intricate with respect to the fact that the aim of such
a behavioral study is to investigate drug utilization under nonprescription conditions even
though the drug and/or corresponding indication has the legal status “prescription-only”.
Furthermore, the variety of legal settings in the different EU member states complicates this
issue even further, especially in case of multinational study approaches.
Based on their definition, data from classical phase IV clinical studies or NIS - both per-
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formed post-approval (i.e., in-label) in a more or less observational fashion (obligatory in case
of NIS) - theoretically come closest to the data needed with a view towards prospective OTC
usage. In order to gain relevant data with regards to anticipated OTC usage, the challenge
thus is to create and legitimate a setting similar to the envisaged OTC environment. From a
legal point of view, phase IV studies are less flexible due to constraints in terms of associated
commitment to insure patients’ integrity. Hence, the generation of NIS data seems to be the
most promising way.
In principle, different scenarios for the conduct of an OTC-like behavioral study are conceiv-
able mainly depending on their timing. That is, non-interventional behavioral data could
theoretically either be collected in a simulated OTC setting ante-switch or in a real OTC
setting after its approval as a nonprescription drug (i.e., post-switch). The legal background
and potential advantages and disadvantages of both scenarios will be discussed in the fol-
lowing.
In both cases, the generation of OTC-like non-interventional, observational study data could
and should be discussed between switch applicants and the responsible authority in the pe-
riod prior to submission. For this reason the possibility of a so-called “scientific advice”
is offered and highly recommended by EU regulatory bodies. In the case of a study to be
completed post-switch, the approval of the proposed switch candidate would be ultimately
connected with specific requirements agreed upon in the forefront of the switch decision.
This approach would therefore come under the term “conditional release” or “conditional
switch”. If the arranged conditions were not fulfilled, the respective authority would be
entitled to officially reverse its positive decision about the switch. The legal basis for such
a concept can be seen in the European legal framework provided by Articles 21a (b), 22a
(1a+1b) and 22b of Directive 2010/84/EC, amending Directive 2001/83/EC.
In Germany, with the 16th amendment to the German Medicines Law that came into force
in October 2012, respective European provisions were implemented in § 28(3). This para-
graph enables responsible authorities to mandate (e.g., further safety testing or the collec-
tion of pharmacovigilance or effectiveness data) either with approval (§ 28(3a)) or afterwards
(§ 28(3b)). Importantly, the term “safety testing” has been conferred a more or less novel
definition in § 4(34) saying that it adheres to any investigation regarding an approved drug
conducted to determine or quantify a safety risk, confirm a drug’s safety profile, or to evalu-
ate drug associated risk management measures. On a European level, this definition traces
back to Article 1(15), Directive 2001/83/EC, which defines a so-called post-authorization
study (PASS) as “a pharmacoepidemiological study or a clinical trial carried out in accor-
dance with the terms of the marketing authorization, conducted with the aim of identifying
or quantifying a safety hazard relating to an authorized medicinal product”48. Correspond-
ingly, as long as the determination of safety parameters has been appointed as a primary
study objective, the definition of PASS comprises both non-interventional epidemiological
observational studies and interventional clinical GCP-conform phase IV studies (Niedziolka
48 In contrast, post-authorization efficacy studies (PAES) lack a specific official European and/or German national
definition, though they can equally be required according to Articles 21a, and 22a+b, respectively, Directive
2010/84/EC as well as § 28(3a+b), German Medicines Law (Stra¨ter 2011).
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2012; VfA 2007a). Detailed information on the various study types and effective guidelines
and directives is given in the current pharmacovigilance guidelines released by the European
Commission (EudraLex Volume 9)49. Of note, PASS are independent from any associated
regulatory authorization strategy and therefrom can be realized within the context of every
application procedure; that is, CP, MRP/DCP, and national procedure. For central applica-
tions, the legal fundament for the conducting of a post-marketing safety study can be seen in
Article 10a(1a) of Regulation (EU) No 1235/2010, amending Regulation (EC) No 726/2004.
As a matter of principle, non-interventional PASS can be “initiated, managed, or financed
by the marketing authorization holder voluntarily or pursuant to obligations imposed by
regulators” (Fitt 2011) as depicted above. In the event of new drug applications these kind
of studies usually are part of a so-called “risk management plan” (RMP) (see Subsection
9.3.4) which is to be included in the drug application and/or may be required to be set up if
regulatory authorities consider that there is a need for additional safety information before
or after marketing.
For the purpose of ensuring quality standards and data validity, the European Medicines
Agency released a “Draft template for the study protocol of a non-interventional Post-
authorization safety study (PASS)” in August 2012 (EMA 2012)50. It mainly contains study
design aspects and quality control measures to be taken into account: building a synopsis of
current guidelines and recommendations for NIS (see Subsection 9.3.3), which are summa-
rized and listed in a checklist for study protocols by the European Network of Centres for
Pharmacoepidemiology and Pharmacovigilance (ENCePP).
A crucial aspect definitely is depicted by the timing of the proposed behavioral study. In
the case of a conditional Rx-to-OTC switch as mentioned above, the (preliminary) switch
approval decision would have to be taken by authorities merely on the basis of available Rx
data. However, the applying pharmaceutical company could be imposed with the genera-
tion of adequate OTC safety and utilization data over an agreed period of time post-switch,
being at the basis of the respective switch proposal’s entitlement to data exclusivity provi-
sion. This approach might be of advantage for pharmaceutical manufacturers, as it could,
if applicable, possibly extend the provided one-year data exclusivity period at least to the
time of study duration, due to the fact that results of the committed data will be required
before any generic follower will be approved. Furthermore, the responsible authority would
be able to provide short-term access to a new therapeutic option in self-medication with the
potential to increase public health on the basis of a well-controlled “monitored release”.
To date, the practical experience with this “conditional release” approach has been scarce,
as it is limited to the example of the Rx-to-OTC switch of tamsulosin (Flomax Relief
®
) in
the UK where a post-marketing safety study was agreed upon with the authorization of the
switch (q.v. Subsection 4.4.4). Yet, as demonstrated by the new draft guideline on “How
to change the legal classification of a medicine in the UK” issued by the MHRA in 2012, it
49 cf. http://ec.europa.eu/health/documents/eudralex/vol-9/index_en.htm, last accessed 2012-11-
09
50 On the contrary, instructions for interventional PASS are to be taken from EudraLex Volume 10 issued by the
European Commission (q.v. http://ec.europa.eu/health/documents/eudralex/vol-10/, last accessed
2012-11-09)
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seems to be a promising concept. The paper seizes the idea of a conditional switch stating
the following: “Where post-marketing studies have been agreed, to confirm safe supply in
a non-prescription setting, these may have an impact on the introduction of analogous or
similar products while studies are on-going. For example, where a company has committed
to undertake additional monitoring in order to validate the results of a study, there may
be limited opportunity for further presentations not subject to the same controls. This is
considered by the MHRA on a case by case basis” (MHRA 2012).
The model of “conditional release” was likewise suggested to expert interview partners with
most of them agreeing that they could indeed imagine such a concept of post-switch data
generation (cf. Figure 21).
In contrast, opponents of the approach legitimately pointed out the fact that in order to eval-
uate a switch candidate’s estimated benefit-risk profile in OTC at its best, data anticipating
drug usage under OTC real-life conditions should be sought to be already available prior
to the proposed reclassification. Potential risks might thus be minimized by the definition
and implementation of appropriate risk management strategies before the official Rx-to-OTC
switch approval.
Moreover, the feasibility of providing data exclusivity on the basis of notional data not yet
existing was considered as an important issue within the context of conditional release. Al-
ternatively, against this background and provided that an adequate setting will be able to
be permitted and realized, the generation of OTC-mimicking data during a drug’s post-
authorization phase as a prescription drug could be thought to already be implemented in a
drug’s life-cycle development plan, potentially even resulting in synergy effects. Especially
if neither a certain switch candidate nor its related indication have already been established
OTC, the generation of appropriate data pre-switch will be valuable in getting a more precise
estimation of the associated benefit-risk profile regarding both drug utilization and the abil-
ity to self-diagnose and self-manage respective conditions proposed to be reclassified OTC.
The “legal infrastructure” in large parts of EU member states is yet probably seen as major
hurdle to this ante-switch OTC-like data generation approach. In contrast to the US, where
the conduct of actual use studies in an OTC-mimicking setting is legally possible even though
the switch candidate itself has not yet been officially reclassified, similar legal provisions are
not in place in European countries.
Nevertheless, the legal fundament to conducting such a behavioral study under OTC-
mimicking conditions might again be the conditional performance of a post-authorization
safety/efficacy study with “post” this time not referring to the point of release from pre-
scription to nonprescription status (i.e., the Rx-to-OTC switch) but its authorization as
prescription drug instead. In this case the need for accordant justification and acceptance
of implementing OTC-mimicking study conditions goes without saying.
On the other hand, there are member states in the EU whose legislation inherently allows for
creating a study environment fairly close to an OTC-like setting. In the UK, for example,
so-called “patient group directions” (PGDs)51 anchored in UK legislation enable specially
trained pharmacists to supply certain prescription drugs to a well-defined target population
51 q.v. http://www.pharmacypgd.co.uk/, last accessed 2012-11-15
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under well-defined conditions (e.g., based on a detailed sales protocol, etc.). Although being
a rather bureaucratic model not mimicking OTC conditions at its best, it may be at the
basis of a non-interventional study concept and thus give an idea about a proposed switch
candidate’s real-life supply and utilization after being reclassified to OTC. As regards other
EU countries, the identification, definition, and creation of a legally accepted comparable
situation will be a major challenge for conducting an OTC-like behavioral study ante-switch.
As far as Germany is concerned, a pharmacy supply model of an Rx drug provided to pa-
tients in a similar way as if it was available OTC (i.e., including patient education, hand out
of questionnaires/patient diaries for data collection, etc.) possibly would come closest to the
UK model.
Apart from strategic approaches mentioned above, the easiest way of conducting a behav-
ioral study, if applicable, would presumably adhere to data collection in countries where the
proposed switch drug and/or indication has already been transferred from prescription to
nonprescription status. Of course, assignability of data to the respective country(/-ies) of
switch application will have to be justified (e.g., by data demonstrating that the target pop-
ulation does not differ with regards to self-diagnosis capabilities and self-treatment practices
in a specific indication, etc.). If necessary, a “bridging study” might help generate relevant
data in that respect.
To summarize, a legal legitimation for a “conditional release” including the performance
of a non-interventional, behavioral study under OTC-mimicking propositions can be found
in the current European and national legal and regulatory frameworks (PASS/PAES) pro-
vided that the rationale behind this is a comprehensive safety/efficacy testing under real-life
conditions. In the author’s opinion, data generation within the context of an OTC-like ob-
servational utilization study with a view towards the potential safe and effective release of
a specific Rx drug from prescription status does indeed comply with this postulation. The
main reason for this assumption is the fact that next to direct safety dangers related to
a certain drug’s toxicity profile indirect safety parameters, such as: correct self-selection,
administration of use, dosing, and therapy compliance, play a major role in a less controlled
OTC setting and the envisaged target population’s behavior and utilization pattern therefore
needs to be thoroughly assessed. In practice, as described above, depending on the individual
switch scenario such a study could be carried out as PASS during post-marketing as Rx drug
(mimicking OTC conditions) or after Rx-to-OTC switch approval as nonprescription drug
(real-life OTC conditions) based on § 4(34) referring to § 28(3) of the German Medicines
Law. Besides, alternative study concepts of respective OTC-like data collection (e.g., in the
US) were illustrated.
Against this background, according to the author’s opinion, any high quality data resulting
from an appropriately designed non-interventional behavioral study verified to be valid and
representative for the target population in question should in all events be considered rele-
vant and necessary for a proposed Rx-to-OTC switch and thus be eligible for the provision
of data exclusivity on the basis of Article 74a, Directive 2004/27/EC.
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9.3.4 Data related to risk management
In light of a constantly growing number of drug substances available on the market for the
treatment or prevention of many different kinds of diseases, the European Commission has
attributed increasing importance to all fields of pharmacovigilance. It therefore developed
further the legal basis which was set with Regulation (EC) No 726/2004 for central and Di-
rective 2001/83/EC for de-central, mutual recognition and national applications. Currently,
the legal framework for so-called “Good Pharmacovigilance Practices” as “a set of measures
drawn up to facilitate the performance of pharmacovigilance in the European Union (EU)”52
is laid down in Regulation (EU) No 1235/2010 (CP) and Directive 2010/84/EC (DCP, MRP,
national procedure), respectively. In Germany, respective provisions have been implemented
within the context of the aforementioned 16th amendment to the German Medicines Law in
§ 4(36-39), § 22(5+5a), § 28(3a+b), § 62 and § 63. In short, respective legislation stipulates
that a detailed so-called risk management plan describing an associated risk management
system (RMS) will be required for marketing approval of new drug applications (Article 8(3),
Directive 2010/84/EC and § 22(5+5a), German Medicines Law, as amended). Furthermore,
it allows for responsible authorities to require either before/with or after authorization ap-
proval the implementation of proposed measures if considered necessary from a drug safety
point of view (Article 21a, 22, 22a, Directive 2010/84/EC and § 28(3a+b) German Medicines
Law, as amended). By definition, a RMP constitutes of “a set of pharmacovigilance activities
and interventions, such as studies and reports, designed to identify, characterize, prevent or
minimize risks relating to a medicinal product, including the assessment of the effectiveness
of those activities and interventions” (Fitt 2011). A specific EU-RMP template has been
provided by the EMA as of 200653.
In contrast to new drug applications, the incorporation of a detailed RMP is not (yet)
mandatory for Rx-to-OTC switch applications and has not (yet) been included in the EU
switch guideline. Nevertheless, such a RMP was, for example, submitted within the context
of the central European switch application for orlistat (alli
®
) (EMA 2009a). Interestingly,
in its draft guideline on “How to change the legal classification of a medicine in the UK”,
the UK regulatory authority (MHRA) has now embedded the delivery of a detailed RMP
with the reclassification application of more complex switches as a mandatory requirement.
The rationale behind this is that it should outline “the important risks associated with the
reclassification of the product and the proposals to manage these risks such as clear prod-
uct information and in some cases other measures including any provisions for appropriate
education and training for pharmacists and pharmacy staff” (MHRA 2012).
Aiming at the protection of patients and consumers from risks known from Rx-marketing
(or OTC-marketing in other countries) by suitable amendments to the product information
and, as necessary, the roll-out of proposed measures for safety monitoring and risk reduction,
in the author’s opinion the elaboration and submission of a detailed RMP does in effect as
52 cf. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/
\document_listing_000345.jsp&mid=WC0b01ac058058f32c, last accessed 2012-11-15
53 cf. http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2009/\10/
WC500006317.pdf, last accessed 2012-11-24
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well make sense for drug products to be reclassified from a medically more or less supervised
prescription setting to a commonly less controlled nonprescription setting.
Of course, risk management strategies and measures will vary depending on the nature of
the individual switch scenario. For example, they should be particularly comprehensive for
reclassification proposals relating to so-called “first in class” OTC switch products for the
treatment of indications lacking any therapeutic experience in self-medication so far.
In practice, a detailed analysis of the actual safety and benefit-risk profile of the switch
candidate should be at the basis of the proposed RMP not only factoring into experiences
made during Rx marketing, but also focusing on the new target setting of self-medication.
In 2011, Brass and co-workers developed a framework for the assessment of the benefit-
risk profile of nonprescription drugs which was suggested by the MHRA as a useful tool
to be applied within this context by Rx-to-OTC switch applicants (see Figure 28). The
fundamental idea of this so-called “value-tree tool” is the assessment of common domains
relevant to nonprescription drug status with regards to benefits and risks on the basis of
product-specific attributes. According to the authors, “this method will help manufacturers
in designing development programs by identifying the data elements that are most important
to determining the magnitudes of the product-specific attributes” (i.e., associated potential
benefits and risks) (Brass 2011). Moreover, the authors suggest that non-interventional con-
sumer/patient behavior studies “can be used to address important product-specific questions
in a consumer-centered [. . . ] manner” so as to “risk-mitigation strategies can be evaluated
early in the drug development process [. . . ]”. Next, based on a comprehensive analysis of the
switch candidate’s benefit-risk profile taking into account both existing Rx and, if available,
OTC(-like) data, the determination and preferably evaluation of appropriate risk minimiza-
tion strategies is to be seen as a crucial step in the setup of an accordant RMP.
Major issues for the setup and implementation of a risk minimization system that most no-
tably apply to central European switches or switches in more than one EU member state,
respectively, probably will be adherence to consistency and uniformity of suggested activities
(e.g., communication, etc.) as best as possible. Inconsistency in healthcare professionals’
and especially pharmacists’ roles across Europe as well as the diversity of practices, cultures,
perceptions and organizations of healthcare systems have to be considered as major challenge
in this case.
In conclusion, based on the fact of a drug’s transfer from Rx to OTC confronting both HCPs
and patients with a new situation in a less controlled setting of self-medication, appropriate
and feasible risk management strategies are contemplated as crucial and relevant elements
in safeguarding a switch candidate’s establishment as OTC drug intending to afford the best
possible health benefit. The author thus postulates that if rigorous and valuable data re-
ferring to adequate and successful risk management/minimization measures proposed for a
certain Rx-to-OTC switch will be able to yield a positive switch decision, they should also be
able to qualify for an associated data exclusivity provision. In particular, if risk management
measures will be integrated into the course of any non-interventional behavioral study, as
discussed before, related data should, according to the author, come under the “clinical trial
data” category currently mentioned in Article 74a, Directive 2004/27/EC.
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Figure 28: Value-tree framework of benefit and risk domains for nonprescription
drugs (adapted from Brass 2011 and MHRA 2012, respectively)
Against this background and in allowance for the targeted setting of self-medication, ac-
tivities and measures described in the following are considered as valuable and necessary
elements of risk minimization provisions aiming at a safe and sustainable Rx-to-OTC reclas-
sification process. Proposals listed below could either be a supplementation to or part of the
generation of non-interventional utilization study data in an OTC-like setting as discussed
above (cf. Subsection 9.3.3).
Training programs/educational material The relevance of adequate training material and
educational information as integral parts of a switch and its associated benefit-risk decision
is well documented throughout the corresponding literature (Bond and Hannaford 2003;
Fuster and Mearns 2009; Hemwall 2010; Pawaskar 2007). Likewise, the essential role of com-
prehensive training concepts and educational information accompanying a drug’s change of
legal status was confirmed by interview partners by a major attribution to data exclusivity
potential (cf. Figure 22).
Depending on the complexity of the reclassification scenario in question, HCPs with phar-
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macists in particular should be provided with sufficient information regarding basic scientific
characteristics (i.e., safety and efficacy) of the drug substance itself focusing on its inherent
interaction profile which is of note as regards potential co-medication with OTC, but also
Rx drugs, of the drug product (e.g., development of a “treatment-algorithm” for usage in
the context of current OTC treatments), as well as of the targeted indication (diagnosis, po-
tential underlying conditions, alarm signals, available diagnostic tools, etc.). In particular,
if necessary, timely referral to primary physicians and/or medical specialists is an important
step in pharmacists’role as safeguarding intermediary in the self-care environment. Spe-
cial pharmacy sales protocols on the basis of scientific guidelines developed in collaboration
with scientific experts could assist in a switch drug’s recommendation and distribution by
concurrently providing the opportunity to register crucial patient safety data that could
be worthwhile to be further tracked/monitored. An appropriate legal and regulatory en-
vironment, however, including the disposability of a correspondent infrastructure would be
necessary in the latter case (cf. Subsection 9.3.4). Methodological and hardware possibili-
ties for training performances and/or the dissemination of educational material are manifold
ranging from paper-based manuals and counseling kits to interactive e-learning modules
that can be accessed via personal computers or special applications for mobile devices (e.g.,
mobile phones), to scenario based face-to-face on-site trainings. In order to ensure pene-
tration and sustainability of contents, certified trainings including commitments to regular
up-dates could be a reasonable model. By way of example, the aforementioned switch of
tamsulosin (Flomax Relief
®
) in the UK has obviously, inter alia, been backed by an ac-
credited pharmacist-training (OTC Bulletin 2009). Integrated training concepts involving
pharmacy personnel as a team instead of separate training guides for pharmacists could be
of avail in this respect (OTC Bulletin 2012). Additionally, a pharmaceutical manufacturer’s
commitment to continued or regular (external) quality controls of its training concept and
educational/informational materials in use is crucial in order to ensure sustainable imple-
mentation based on up-to-date information and therefore was also highly appreciated by
interview respondents (cf. Figure 23).
Beyond HCP training, consumer/patient information and education are key as they may
not only increase the general public’s disease awareness, but also its health and medica-
tion related knowledge (Pawaskar 2007). Educational programs focusing not only on the
Rx-to-OTC switch drug product but also on accompanying favorable life-style activities are
estimated to have a potential for a positive public health impact similar to the switched
pharmacotherapy itself (Fuster and Mearns 2009). Accordingly, convenient symptom-based
methods and/or algorithms to assist people in correct self-diagnosis were judged “very good”
regarding their potential for Rx-to-OTC switch exclusivity qualification (q.v. Figure 17).
Comprehensive behavioral self-help programs were offered, for instance, within the context
of the release of nicotine replacement therapies, the effectiveness of which has been analyzed,
evaluated, and published in the relevant literature (cf. e.g., Achanta and Rhodes 2003). Ma-
terials that are tailored to the needs of individuals (based on individuals’ demographic or
behavioral characteristics) evidently tend to outperform universally standard materials (e.g.,
provided at the point of sale) and may provide greater penetration (Curry et al. 2003). In
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case of switches aiming at the treatment of chronic risk factors consumer/patient support
programs most notably lend themselves to accompany the introduction and establishment
of a therapeutic option that has been released from prescription to nonprescription mar-
keting. Informational materials that have been disseminated with effective personalized
adjuncts and/or interactive elements (e.g., telephone counseling or toll-free hotlines) have
consistently proven better and longer-lasting effectiveness as opposed to written standards
to read-only (Curry et al. 2003; Lancaster and Stead 1999). In times of apparent growth
of digital media the availability of a variety of tools has paved the way for an increas-
ing importance of “e-health” information. Appropriately designed (personalized) websites
or applications (“apps”) for mobile devices provide the possibility for implementing interac-
tive support programs including data management and (personalized) feedback mechanisms.
Above all, “flexibility in the approaches used to support consumer self-selection is important
and may encompass a learned intermediary with accountability (e.g., pharmacist) or other
IT solutions to product use” has been declared by Soller and colleagues as one of eight guid-
ing principles for Rx-to-OTC switches (Soller 2012a).
In either case, three critical aspects that should be definitely taken into account are timing,
consistency, and suitability of information provided. As mentioned above, research on edu-
cational programs and materials (e.g., related to the switch candidate’s labeling, etc.) might
yield essential insights into its associated benefit-risk profile. If proven effective, programs
might eventually drive consumers and/or patients to not only readily self-treat in case of
acute, self-limiting conditions, but also to consult a health-care professional and, if appli-
cable, shift to more comprehensive medical care or prevention strategies after identifying a
more serious disease or respective risk factors (Hemwall 2010).
As to successful development of appropriate training and educational material, first of all
identifying the needs of the respective target groups is of utmost importance and the benefit-
risk model described above (see Figure 28) might be a helpful tool in this case. As well, de-
velopment of accordant informational material and communication strategies in co-operation
with those it is intended for (i.e., representatives of the various stakeholder groups) might en-
hance practicability and feasibility (MISG 2010). Proactive collaboration with professional
bodies, organizations, etc. involved may contribute to consistency of information. Moreover,
Soller and colleagues contemplate “standardization (e.g., through use of diagnostic and se-
lection protocols, quick reference guides, patient education sheets, staff training manuals)”
as “important to ensure consistency in counseling across community pharmacy practitioners
and across pharmacies” (Soller 2012a).
Any training programs and educational material developed should hence be pre-tested and
preferably be applied in a setting reflecting real-life conditions. Thereby manufacturers
should not only prove suitability and comprehensibility of accompanying measures developed
with a view to the various target groups affected, but also demonstrate that information and
guidelines provided are continuously considered and applied correctly. As mentioned be-
fore (q.v. Subsection 9.3.3), within this context a multifaceted, multiple-arm behavioral
study (e.g., as PASS) could be a valuable instrument to generate relevant and significant
“clinical data” demonstrating the potential benefit and/or further needs of supportive ma-
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terials and/or programs that are intended to facilitate the preparation, introduction, and
establishment of a certain drug’s release from prescription-only status.
Drug therapy monitoring According to the author’s understanding in the present work,
depending on its context the term “drug therapy monitoring” refers to several different
situations and therefore is associated with different potential data subcategories which will
be outlined below.
 HCP/Patient reporting systems
First of all, drug therapy monitoring relates to pharmacovigilance in terms of drug
safety and adverse event tracking. With the establishment of specific reporting sys-
tems for (suspected) adverse drug reactions, an important pharmacovigilance system
has been enacted by the EU legislative body. In pharmacoepidemiology, reporting sys-
tems commonly are used to report the occurrence of drug associated AEs. In fact, they
“are particularly useful for identifying types of errors that occur too infrequently for in-
dividual health care organizations to readily detect based on their own data” (Morlock
and Wu 2010). Generally, such a system not only helps keep its provider accountable
for performance, but also yields information that might be crucial to improve a drug
therapy’s safety. In its latest renewal of the respective legal framework (i.e., Direc-
tive 2010/84/EC) the EU has thus adopted the possibility for patients to report any
(suspected) ADR to a specific database provided by the responsible national authority
for subsequent evaluation, a system which obviously has successfully been realized in
a number of countries over a various period of time (e.g., the yellow card system in
the UK as of 2008) (Mergel et al. 2012). In Germany, an accordant test phase was
started as of late 2012. In addition to what was already mandatory for health care
sector members before, patients now are allowed to register any suspected AE them-
selves. However, individual patient confidentiality (i.e., data protection issues) are still
controversially debated and to be treated with caution in this matter. Likewise, the
introduction of fully integrated electronic patient record systems including both an in-
dividual patient’s OTC and Rx medication as well as primary and secondary care data
have been proposed elsewhere, yet again would be supposed to be rather constrained
or even fail due to the latter reason (Bond and Hannaford 2003).
Moreover, as respective systems are to be generally admitted and provided by super-
ordinate institutions, in the author’s opinion, associated data cannot be considered
appropriate for being eligible for data exclusivity provision to a single manufacturer’s
Rx-to-OTC switch proposal.
 Monitoring tools supporting drug therapy self-management
Apart from the pharmacovigilance reporting systems mentioned above, specific drug
monitoring tools that basically assist in the diagnosis, management, or prevention of
primarily chronic risk factors and diseases on the basis of respective diagnostic parame-
ters (e.g., blood cholesterol or sugar level) would equally come under the superordinate
concept of drug therapy monitoring. The author suggests that appropriate easy-to-use
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devices provided to consumers/patients within the context of an intended Rx-to-OTC
switch aiming at both the prevention and treatment of (semi-)chronic diseases could
largely contribute to a controlled and safe therapeutic self-management of respective
risk factors (e.g., high cholesterol levels, diabetes mellitus, hypertension, etc.), as long
as adequate training and education will be regularly warranted. Above all, it might
be a crucial element for a specific Rx-to-OTC switch decision as it could assure the
identification of the right target population, which is estimated to be a key element of
an appropriate Rx-to-OTC switch model. Depending on the complexity of the switch
scenario and in particular the target indication in question, self-management could be
supervised by regular checks through specialized (e.g., pharmacy) personnel. In some
cases, the interpretation of diagnostic findings from a nonprescription device requires
professional judgment (i.e., borderline results). Suitable software technology featuring
data security could enable direct data transfer from an individual patient’s measure-
ment device to the attending physician and/or pharmacist including the activation of
alarming systems, if applicable, for the sake of medical feedback.
As suggested above for the development of training concepts and educational materi-
als, the acceptability of the usage of such diagnostic measurement/monitoring devices
and/or software systems (such as e-health communication tools or applications) could
or rather should, respectively, as well be tested (e.g., in a non-interventional behavioral
study) under OTC real-life conditions. Expert interviews showed that the investiga-
tion of special patient groups and control through specialized personnel, if applicable,
might be of particular value in this regard. In case of preventive therapy switch pro-
posals (e.g., treatment of hypercholesterolemia/hyperlipidemia, etc.) data regarding
actual use should encompass compliance related to drug usage as well as acceptance of
concurrent consumer support activities referring to important life-style modifications
(e.g., weight loss, physical activity, etc.). Data evaluating consumer/patient diaries
with respect to diagnostic drug therapy monitoring results, for instance, could be
useful within this context. When asked about the kind of data they would consider
particularly relevant with a view towards potential eligibility for data exclusivity, data
demonstrating compliance of patients using the measurement devices/activities devel-
oped were estimated as extremely relevant by the majority of interview partners (see
Figure 19).
Of note, it is important to take into account that especially in the event of asymptomatic,
(semi-)chronic conditions, patients’ motivation to manage existing risk factors will increase
with the visibility of benefits and added value (e.g., in terms of therapeutic effect and re-
sulting improvement of QoL, etc.) of available treatment options (see also Subsection 3.5.3).
In the author’s opinion, concomitantly provided, appropriate, easy-to-use self-monitoring
devices and related educational measures might eventually contribute to responsible self-
management of existing (semi-)chronic pre-conditions. They, therefore, add to public health
in the event of corresponding prospective Rx-to-OTC switches to take place. This might
eventually be demonstrated, for example, by respective non-monetary data (see below).
Against this background, the author of the present work considers such data to be valuable
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for potential data exclusivity provision.
9.3.5 Data related to public health value
Different types of methods and data categories assessing demonstration of public health value
are available. A brief overview will be given below.
Pharmacoeconomic data By conventional definition, the term pharmacoeconomics is “the
description and analysis of the costs of drug therapy to healthcare systems and society”
(Bootman et al. 1996; Tsokeva et al. 2006). Depending on the method of evaluation, out-
come parameters might be tangible (i.e., monetary such as direct and indirect costs) or
intangible (i.e., non-monetary such as QoL, patient satisfaction, etc.). Accordingly, based
on the distinct measurement of health gain various types of pharmacoeconomic analyses
can be differentiated (Bodrogi and Kalo 2010). Whereas the majority of pharmacoeconomic
analyses investigate cost-benefit or cost-effectiveness implications (Neumann et al. 2008),
other approaches focus on analyzing cost-utility, cost-minimization (depicted in Table 14) or
humanistic assessments (not shown).
Table 14: Differentiation of pharmacoeconomic evaluations based on health gain
measurements (adapted from Bodrogi and Kalo 2010)
Type of evaluation Measurement of health gain Applicability
Cost-benefit-analysis Monetary value Comparison of any medical and
non-medical procedures and
investment options
Cost-effectiveness analysis Natural units (traditional clinical
endpoints)
Comparison of medical procedures
with non-equal health gain
measurable in the same health
dimension
Cost-utility analysis Quality adjusted life years
(QALYs)54
Comparison of any medical
procedures
Cost-minimization analysis Not specified Comparison of medical procedures
with equal health gain
However, when it comes to Rx and OTC drug approval decisions, pharmacoeconomic
data clearly have been affirmed to be out of regulator’s focus (Soller 2012a). This holds true
not only for the US, but also for Europe. In Germany, for example, the national regulatory
authority (BfArM) states in its information on the application for changing the legal status,
that “the committee will be evaluating [the] application mainly on the basis of sound data
concerning drug risks”55.
54 artificial unit integrating both quality and quantity of remaining life years (Tsokeva et al. 2006)
55 cf. http://www.bfarm.de/EN/vigilance/eacPrescription-only/application-changing-legal-
status.html, last accessed 2012-11-12
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Nevertheless, in order to get a qualitative feedback on this issue, experts were asked for their
personal opinion on the possibility of valid pharmacoeconomic data representing an eligible
contribution with regard to data exclusivity provision. As indicated by questionnaire results,
more than half of them could indeed imagine pharmacoeconomic data to be part of the Rx-
to-OTC switch documentation eligible for data exclusivity. More specifically, the majority of
these favored pharmacoeconomic analyses factoring into non-monetary assessment parame-
ters such as (health-related) QoL improvement, accelerated and convenient therapy access,
treatment satisfaction, or other so-called patient reported outcomes (PROs)56 (cf. Figures
24 and 25).
As a result of the aforementioned (i.e., current practice in reclassification approval decision
making and insights gained through qualitative expert feedback) the author holds the view
that the submission of classical pharmacoeconomic data resulting in monetary values only
will not be appropriate with regards to a claim on data exclusivity.
Non-monetary health-related data On the other hand, according to the author the deter-
mination of robust non-monetary patient and/or public health benefits, respectively (e.g., in
the form of patient related outcomes in epidemiological studies) might indeed be an option for
demonstrating a certain switch candidate’s potential to increase public health value thereby
positively influencing its associated benefit-risk ratio (e.g., based on the model provided by
Brass and colleagues) (Brass 2011). To give an example, sound scientifically conditioned
epidemiological or market research data verifying raising disease awareness and proactive
treatment by patients or populations at risk (who otherwise would not seek medical consul-
tation due to various reasons such as embarrassment, lack of time, etc.) or data comparing
treatment satisfaction of therapy options available OTC with possibly more effective or con-
venient Rx switch candidates might be important data supporting a positive Rx-to-OTC
switch decision in light of an estimated gain in public health. The author therefore promotes
the acknowledgement of valuable data (e.g., epidemiological survey data, market research
data, etc.) as being eligible (at least in support) for data exclusivity in case of the capability
to verify an estimated public health gain, even though it might neither be classified as “pre-
clinical test data” nor “clinical trial data” as indicated in the EU’s current legal framework,
yet, would have to be assigned to an additional data category instead (see below).
9.4 Non-clinical data as potential additional data category not reflected by
Article 74a, Directive 2004/27/EC
There might be specific programs, concepts, or models that may not be able to be imple-
mented and/or behaviorally evaluated before approval (Aker 2006). In order to be able to
account for these elements all the same, the author suggests that in this case elaborated
data with the potential of being eligible for or at least contributing to the grant of data
56 In practice, PROs subsume all measures which quantify patients’ state of health by analyzing outcomes reported
by them. Being complementary to classical biomedical measures, PROs are increasingly used as an integral part
of clinical trial and health care strategy evaluations (Refolo et al. 2012).
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exclusivity without representing a direct form of “pre-clinical test data” or “clinical trial
data” could possibly be subsumed under an additional data category such as, for example,
“non-clinical data”. Accordant data subcategories could adhere to any educational informa-
tion (e.g., theoretical, but innovative contents of training concepts, treatment algorithms,
digital/printed high-quality informational materials, etc.) and/or any kind of drug therapy
monitoring models (e.g., based on a specific technology/software) as well as to assessments of
demographics, drug utilization characteristics, and/or non-monetary data focused on patient
related outcomes and referring to public health benefit each possibly comprising correspond-
ing epidemiological or market research (i.e., consumer/HCP survey data, etc.). Above all,
a common requirement for eligibility to data exclusivity should be the fact that respective
data demonstrate a potential switch candidate being first and foremost safely, but also ef-
fectively, “OTCable” for the right target population with the implementation of proposed
risk management strategies thus improving the candidate’s benefit-risk profile and eventu-
ally enhancing public health. Within this context the author is convinced that a consumer-/
patient-centered approach towards the development of any pre- and post-marketing risk
management approaches, including accordant safety and effectiveness evaluations, will be
inevitable and of utmost importance for a respective Rx-to-OTC switch decision. In fact,
as can be derived from the centralized European reclassification of orlistat 60 mg (alli
®
)
(see Subsection 4.4.4), such data obviously are of major interest for authorities alike as the
applicant had to commit to the collection of appropriate survey data on demographics, clin-
ical characteristics, and usage patterns for reasons of safeguarding secure and effective OTC
usage.
Furthermore, the author assumes that especially in countries where reclassifications are not
product-specific, yet substance-specific, there might be few or no generic followers that will
be able to implement risk management measures similar to and as comprehensive as proposed
by the originator company initiating a specific Rx-to-OTC switch. According to the author’s
view, this is another reason why eligibility for data exclusivity should likewise admit and
encompass non-clinical data, thereby reassuring a specific switch proposal’s safety and re-
lated improved benefit-risk profile, which is critical to an associated positive reclassification
decision: a consistent and transparent post-approval implementation of risk management
measures, such as a well-controlled and sustainable switch supply model, for instance, will
thus be ensured
Against this background the author suggests that the current European legislation re-
ferring to data exclusivity provision for Rx-to-OTC switches (i.e., Article 74a, Directive
2004/27/EC) should be considered to be amended by the term “non-clinical data” as an-
other data category option to which applicants might be able to advert to when submitting
correspondent data with a claim on data exclusivity. Alternatively, replacing the term “pre-
clinical test data” by “non-clinical data” actually comprising the subcategory “pre-clinical
test data” could be worthy of consideration, thus offering an even broader range of data to
be handed in for data exclusivity than might have been intended by the legislative body with
the inclusion of “pre-clinical test data” in addition to “clinical trial data”.
However, as from experience, it might be a long and tough way until set legal provisions if
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at all are about to be changed. Therefore, in the short-term, the revision and amendment
of according guidelines, i.e. above all the European switch guideline in its version of 2006,
might be a viable mode of widening the scope for data to be submitted with a claim on data
exclusivity by introducing the acceptance of accordant non-clinical data.
9.5 Reasonable duration of the exclusivity period within the context of Rx-
to-OTC switches
As already depicted before, the current EU legal framework regarding the grant of data
exclusivity for Rx-to-OTC switches provides for a one-year data protection period in case of
data submitted being eligible according to Article 74a, Directive 2004/27/EC57.
As a result of the aforementioned, the author advances the view that a one-year period of
data protection might not be adequate and sufficient in light of the amount and quality of
data required to be generated and/or collected in addition to the data generally needed for
a reclassification request in order to be able to call for a data exclusivity provision.
This opinion is supported by two aspects deserving consideration: first of all, as can be
concluded from the foregoing discussion, non-interventional behavioral study data obviously
seem to be the kind of data with the highest potential of being accepted with respect to
data exclusivity qualification. Consequently, from the applicant’s point of view, the need
for conducting an appropriately sized, high-quality study possibly lasting several months to
even years is a major implication of the latter. In general, without knowing the outcome of
an accordant study as well as the chance of success in terms of data exclusivity, any study
conducted is to be seen as a risky and resource intensive project the positive accomplish-
ment of which should be rewarded in a way that adequately compensates the applicant’s
investment. Taking into account all stages of a properly conducted clinical trial as well as,
if applicable, the development of any educational/informational material or technology sys-
tems eventually to be tested within the context of such a trial, the author considers one year
of data exclusivity as not being adequate to enable a pharmaceutical company to recoup
associated investments. Thus, at present, its role as an incentive tool for innovative concept
creation and data generation aiming at improving a switch candidate’s benefit-risk profile
and eventually resulting in a benefit to public health might not be of adequate relevance.
Secondly, what is of even greater importance especially from a public health perspective,
depending on the complexity of the switch in question the introduction and establishment
of a new therapeutic option in a nonprescription setting including reasonable HCP and
patient/consumer education will take a considerable period of time. This was precisely ad-
dressed on the occasion of a discussion about widening access to medicines via reclassification
during the 6th UK “Ministerial Industry Strategy Group (MISG) New Technologies Forum”
in 2010 by participants pointing out that “[. . . ] exclusivity is not just about recouping costs
57 The original wording is as follows: “Where a change of classification of a medicinal product has been authorised
on the basis of significant pre-clinical tests or clinical trials, the competent authority shall not refer to the results of
those tests or trials when examining an application by another applicant for or holder of marketing authorisation
for a change of classification of the same substance for one year after the initial change was authorised.”
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but about providing the time for consumer and health care professionals’ engagement in the
switch and for the market to develop”(MISG 2010).
To give an example, in Germany it is said that in the case of ibuprofen as prominent rep-
resentative of the category of NSAIDs for symptomatic self-treatment of acute, mild to
moderate pain and fever, a period of almost up to ten years had passed after its reclassifi-
cation from prescription status until it reached sufficient acknowledgement and acceptance
by both HCPs and patients/consumers as a safe and effective therapeutic option in the face
of existing OTC alternatives. As noted before, transparency and in particular consistency
of information provided is to be seen as a crucial step within the process of a sustainable
introduction and implementation of a specific Rx-to-OTC switch model. Within this con-
text, the reclassification of the PPI omeprazole (q.v. Subsection 3.5.1) for the treatment of
heartburn and acid regurgitation in 2009 in Germany is indicative of a rather less commend-
able environment when transferring a drug from prescription to nonprescription status. In
particular, due to the absence of data exclusivity (which had not been applied for) apart
from the company having initiated the Rx-to-OTC switch (originator), a rash of generics
took the chance to simultaneously enter the market partly supported by none, partly by
informational/educational and training material often differing from that provided by the
originator in preparation of the switch. Consequently, associated precariousness and reserva-
tion experienced by both HCPs and patients/consumers might have resulted in OTC-PPIs
being an existent safe and effective though apparently not (yet) commonly accepted thera-
peutic alternative in the self-treatment of heartburn and acid regurgitation.
Of note, the author’s view obviously is shared by the majority of experts interviewed who
judged the one-year period as being “too short” (n = 6), whereas two of them considered it
as “just appropriate” and only one as being “too long” (see Figure 8). When asked about
an alternative time period of protection that would be more appropriate within the context
of Rx-to-OTC switches according to their view, three years were largely suggested as a min-
imum and five years as maximum to be provided.
As described earlier (see Subsection 4.4.1), in the US, if eligible, Rx-to-OTC switches will be
granted a three-year marketing exclusivity period on a similar basis as found in the current
EU legislation, i.e., in case of “significant” data judged essential by FDA assessors on a case-
by-case basis due to the fact that as in the EU no specific guidelines are in place. From the
author’s point of view, a three-year exclusivity period seems a lot more reasonable and ap-
propriate, even more so when considering that an adequate education and training of HCPs
assigned with supply and recommendation of the product as well as the accomplishment of
disease awareness campaigns, etc. means that an important part of the exclusive marketing
phase would have elapsed before the reclassified product could be successfully marketed.
The reason behind this is that from a legal perspective applicants in general will not be able
to officially start to prepare the market for a product-related switch before authorization.
Moreover, a three-year period of data exclusivity would arrange for comparable conditions
within Europe and the United States and thus could eventually close the gap with respect
to the value of exclusivity provision as an incentive tool in place for Rx-to-OTC switches
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potentially resulting in an overall EU switch climate that is as vital as in the US58.
Furthermore, the complexity of an individual Rx-to-OTC switch case and the extent to which
a certain switch model including all accompanying measures has to be elaborated and im-
plemented are important factors to be taken into account. Therefore, a kind of “sliding” or
“proportional” scale of exclusivity duration was suggested by one of the interview partners,
implicating a gradual period of data exclusivity to be granted depending on efforts made
and resources invested as well as on the respective public health gain associated with the
realization of a specific Rx-to-OTC switch model. In the author’s mind this proposal seems
to be an interesting approach, yet unless there will be well-defined prerequisites linked to the
granting of a distinct length of data exclusivity, the seemingly less transparent and arbitrary
provision of different phases of data exclusivity will be a crucial issue for further discussion.
Altogether, based on the data categories and criteria proposed in the work at hand with
respect to eligibility for data exclusivity provision and in light of the reasons mentioned
above, the author regards a data exclusivity period of not less than three years as essential
and reasonable.
58 However, whereas in the US the three-year exclusivity period refers to market exclusivity hence allowing com-
petitors to immediately enter the market after its expiration, in Europe generic abridged applications according
to current law would only be processed at the end of the three-year (data) exclusivity period. This procedure
implicates an effective prolongation of the latter, unless a marketing authorization will already be able to be
processed and granted before with the obligation to only enter the market after the data exclusivity period would
have expired.
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10 Conclusions and recommendations
The present work displays an attempt of substantiating the legal definitions referring to
the data exclusivity provision for Rx-to-OTC switches within Europe by suggesting different
data categories, outcome parameters, and criteria of varying relevance to be considered when
data intended for a claim on exclusivity are submitted.
It has been shown that along with recent sociocultural, sociopolitical, and socioeconomic
evolutions there is a trend in Rx-to-OTC switch movement aiming at the reclassification
of prevention or treatment options for increasingly complex diseases compared to previous
targets of acute, minor, and self-limiting ailments. If taken on successfully, this trend will
eventually contribute to the enhancement of public health value not only by raising disease
awareness and encouraging individuals to responsibly manage their own health/disease sta-
tus, but also from an increasingly burdened health care systems’ perspective. However, at
the same time requirements associated with the planning, realization, and sustainably safe
and effective implementation of a certain Rx-to-OTC switch will, on the other hand, con-
tinuously be rising. In conclusion, a supportive political, legal, and regulatory framework is
crucial in order that accordant switch projects be initiated and adequately prepared in the
future.
Within this context the provision of data protection for Rx-to-OTC switches anchored in the
European legislation is basically considered as a reasonable tool: in general, an Rx-to-OTC
switch changes the situation within self-medication by extending the availability of thera-
peutic alternatives in a specific category or by even creating a completely new therapeutic
area. Consequently, both HCPs and patients are confronted with a new situation regard-
ing OTC treatment options and/or indications. In order for pharmacy personnel, patients,
and other stakeholders to be equipped well in time for a certain Rx-to-OTC switch to take
place, manufacturers should start preparations (data review/generation, risk management
planning, etc.) in due time before the official authorization approval – a more or less risky
and costly investment when considering the uncertainty of a switch approval and even more
so the possibility of data exclusivity receipt. Only the latter though will help ensure a con-
sistent and transparent implementation of communication, education, and risk management
measures developed by the company originally initiating a certain switch as a result of re-
lated pre-switch data generation by exclusively consigning this company with the adequate
introduction and establishment as well as monitoring of a respective switch candidate in self-
medication. Concurrently, responsible authorities would be able to accompany and control
the switch process as a whole, e.g., by imposing, if applicable, appropriate conditions and
requirements (“conditional release”).
As to the entrepreneurial risk generally inherent in drug development efforts, maximum
predictability is an essential objective for promoting and facilitating the development pro-
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cess aiding companies in forecasting development costs and potential return on investment
(Soller 2012a). In order to work as such, incentive tools for pharmaceutical drug manufac-
turers aiming at fostering innovative drug development for the benefit of public health value
should therefore be associated with clear guidance and instructions regarding requirements
that need to be fulfilled.
However, the present work has demonstrated the actual European legal framework regarding
data exclusivity provisions for Rx-to-OTC switches (i.e., Article 74, Directive 2004/27/EC)
to be rather indefinite. Correspondingly, “pre-clinical test data” and “clinical trial data” are
judged eligible for the grant of data exclusivity if considered “significant” for the reclassifi-
cation requested. Yet, as long as the aforementioned terms are not further specified and/or
are interpreted in a conservative way, the practical applicability of data exclusivity is lim-
ited, as the possibilities to generate novel data in addition to drug-specific Rx data generally
extensively available for any potential switch candidate are quite restricted. Against this
background existent data categories provided by the current legislation have been discussed
as well as specified and amended considering aspects relevant to a change of classification
from Rx to OTC taking into account the view of representatives of all stakeholder groups
involved in such a process. The different proposals elaborated are summarized in Table 15
below.
Whereas the basic Rx-to-OTC reclassification process according to current EU switch crite-
ria as listed in the EU switch guideline mainly focuses on a drug substance’s inherent safety
and efficacy profile, usually derived from data collected prior to or during Rx marketing,
drug utilization in the targeted OTC setting - indicative of (if at all) very little medical
guidance and a broad and usually heterogeneous patient population - often can only be
anticipated (no OTC data at all or only from other countries/populations). Accordingly,
potential safety hazards emanating from OTC usage might be missed and adequate risk
management measures will thus not be readily in place. Therefore, the generation of OTC-
like, non-interventional study data is contemplated as crucial and a most valuable additional
element in either supporting or preventing a certain Rx-to-OTC switch decision by pointing
out indispensable risk management activities eventually to be implemented in order to enable
secure and effective self-medication. Furthermore, any kind of newly compiled or generated
data favoring and/or aiming at both safe and effective drug utilization in the targeted in-
dication and patient population within self-medication will complement a drug substance’s
existing Rx data largely rounding off its associated benefit-risk profile. By fulfilling the legal
requirement of Article 74a (i.e., being “significant” in the sense of necessary and relevant,
as well as being decisive for a certain switch proposal) the author concludes and stipulates
such data in principle to be valued as eligible for the provision of data exclusivity.
The items proposed in Table 15 have been rated based on the author’s estimation of their
potential eligibility for Rx-to-OTC data exclusivity provision. Of note, in order to embrace
data that typically is neither of pre-clinical nor clinical nature, yet is still able to provide
more or less valuable insight into a switch candidate’s envisaged OTC usage pattern, the
author puts forward to adapt the relevant legal framework including corresponding guide-
lines to the introduction of “non-clinical data” as an additional superordinate data category.
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Such data could, for example, encompass any data (model) related to risk management or
any kind of epidemiological or market research/consumer survey data indicating a benefit to
public health (e.g., by an increase in disease awareness, QoL improvement, etc.).
Having taken the aforementioned into consideration, the author postulates that the existent
EU data exclusivity period of one year’s time should be challenged aiming at a reasonable
and justifiable prolongation (e.g., to three years as in the US or a varying elongation de-
pending on an individual switch’s complexity). A suitably extended data exclusivity period
would not only be able to adequately allow for entrepreneurial switch efforts to be accounted
for, but also confer enough time for a certain switch candidate’s safe and successful settle-
ment in the self-medication sector on the basis of consistent and transparent information
and education as well as continuous monitoring and control (if applicable). Finally, the
author is aware of the fact that any change in respective legal settings, if at all, will only
be achieved in the long-term. However, given the ongoing sociocultural, sociopolitical, and
socioeconomic developments and trends, the author deems it crucial to have initiated the
debate on the appropriateness of respective legal provisions and their interpretations by chal-
lenging the status quo and elaborating proposals for adaptation most of which could more
or less be implemented in the short-term by modification and specification of correspond-
ing switch guidelines. Moreover, stakeholders most notably effected by suggestions made
and recommendations given in the present work are advised to be adequately prepared and
well-equipped in due time in order to be capable to cope with accordant future tasks and
requirements.
In practice, pharmaceutical manufacturers are appealed to consider the potential of prospec-
tive OTC usage and correspondent possibilities of data generation early in a drug’s life-cycle
development. Thereby, accurately timed seeking of regulatory advice regarding an individual
switch proposal and its potential for obtaining data exclusivity as well as early stakeholder
support are judged to be of major importance. In principle, data submitted in support of
exclusivity applications should be explicitly designated and come up with the need of being
“novel” (i.e., not derivable from “basic” and often already published data provided with the
general switch application). Last but not least, it is deemed to be of utmost importance
that any data based on an exclusivity request will have to reflect intended OTC conditions
at their best (e.g., targeted indication, dosage, duration, patient population, etc.).
Besides, regulatory authorities will, on the other hand, need to provide and build up, respec-
tively, special expertise with a view towards the assessment of OTC relevant data particularly
from a quality perspective (e.g., statistics, data reliability/validity, study design, method-
ological and analysis aspects, etc.).
To summarize, the author is positive about further innovative and complex switches
with a probable public health gain to come on the grounds of the availability and above all
applicability of appropriate incentive tools. Within this context data exclusivity provision
is regarded as a valuable approach. However, existent legal prerequisites and guidelines will
have to be revised and specified in order to be able to acknowledge efforts undertaken to
generate high quality data reliably demonstrating and safeguarding consumers’ and patients’
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safe and effective self-management practices in disease prevention and treatment. In any
case, Rx-to-OTC switch decisions should be based on a profound and transparent scientific
assessment of data relevant for the envisaged legal classification status and best possibly
beware of multiple influences due to different interests and opinions often affecting individual
Rx-to-OTC reclassification processes.
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Table 15: Overview of existing and proposed Rx-to-OTC switch criteria, data categories, and their estimated
relevance for data exclusivity (DE) provision according to Article 74a, Directive 2004/27/EC; 1 = low, 2 =
medium, 3 = high; (*) depending on outcome parameters; (**) possibly not appropriate/applicable for OTC
(cf. Section 8.1); (***) depending on switch scenario
Rx-to-OTC
switch data
categories
Pre-clinical test data Rele-
vance
for DE
Clinical trial data Rele-
vance
for DE
Non-clinical data Rele-
vance
for DE
Major
outcome
parameters
 Safety:
-toxicity 1
-interaction profile 2
-carcinogenic potential 1
 Safety:
-direct dangers
(detection/tracking of
AEs)
3
-indirect dangers (e.g.,
masking of serious
underlying diseases,
resistance)
3
 Risk management measures/plan:
-package
labeling/restriction
3
-HCP/Patient
education and training
3
-supply model 2-3***
-(diagnostic) drug
therapy monitoring
tools
2-3***
 Utilization/Actual use (daily-life):
-self-diagnosis 3
-self-selection 3
-label comprehension 3
-compliance 3
-ab-/misuse 3
-assessment of risk
management measures
3
Continued on next page. . .
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Table 15 – Continued
Rx-to-OTC
switch data
categories
Pre-clinical test data Rele-
vance
for DE
Clinical trial data Rele-
vance
for DE
Non-clinical data Rele-
vance
for DE
 Efficacy:
-dose-response
relationship
1
-bioequivalence, etc. (if
applicable, e.g., new
pharmaceutical form)
2
 Effectiveness:
-treatment effect of
medication in relevant
dose range under daily
life conditions in target
population
3
-comparison with
existing therapeutic
alternatives
2-3
-QoL improvement,
patient satisfaction
with treatment
(if applicable)
2-3
 Patient/Public health benefit:
-disease awareness 2-3
-access to medicine 2
-HCP contacts, etc. 2-3
-non-monetary
values/PROs: QoL
improvement, patient
satisfaction with
treatment,
convenience, e.g., also
compared with existing
therapy options
2-3
Kind of data
 Re-analysis of existing
Rx data under OTC
relevant aspects
1
 In vitro testing 1-2*
 Animal model testing 1-2*
 Diagnostic tool testing 2
 Re-analysis of existing
Rx data under OTC
relevant aspects
1
 Classical clinical trials
as RCTs (e.g., phase
III or IV studies)
3**
 NIS (e.g., as PASS or
PAES)
3
 AUS, LCS, SSS 3
 Bridging study using
data from abroad
(if applicable)
2-3
 Epidemiological data 2
 Market research data 2
 Consumer survey data
(demographics, clinical
characteris-
tics, usage patterns,
etc.)
2
 Embedded in clinical
data generation (e.g.,
NIS, if applicable)
3
Continued on next page. . .
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Table 15 – Continued
Rx-to-OTC
switch data
categories
Pre-clinical test data Rele-
vance
for DE
Clinical trial data Rele-
vance
for DE
Non-clinical data Rele-
vance
for DE
Important
criteria/
quality
aspects
 Data generation/evaluation:
-under OTC relevant
aspects (dosage
regimen, target
population, etc.)
3
-according to current
scientific knowledge
and standards
3
 Data generation/evaluation:
-under OTC relevant
aspects (dosage
regimen, target
population, etc.)
3
-according to current
scientific knowledge
and standards
3
 Adequate kind and size
of study population
3
 Bias reduction
(appropriate study
design and statistical
techniques such as
propensity scores, etc.)
3
 Control group
(if applicable)
2-3
 Data generation/evaluation:
-under OTC relevant
aspects (dosage
regimen, target
population, etc.)
3
-according to current
scientific knowledge
and standards
3
 Feasibility check (risk
management measures,
etc.)
2-3
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A Appendix
A.1 List of databases used for literature research
 Biomedical Core Database, Bayer HealthCare AG: meta-database consisting of six
different databases (cf. Table 16 below)
Table 16: Databases included in the Biomedical Core Database, Bayer Health-
Care AG (based on information from Bayer HealthCare AG)
Database Provider Discipline, Focus Coverage Update
Rhythm
BIOSIS
Previews
Thomson Reuters Biology, biomedicine,
pre-clinical research
1947 – present Weekly
Current Contents Thomson Reuters Life science, clinical
medicine
1991 – present Weekly
Derwent Drug
File
Thomson Reuters Drug-related publications,
enhanced abstracts used for
drug literature
1963 – present Weekly
EMBASE Elsevier Drug research and
pharmacology
1947 – present Daily
MEDLINE US National Library of
Medicine
Biomedicine and clinical
medicine
1950 – present Daily
Product
Literature
Information
(PLI)
Bayer HealthCare Global
R&D Information
Publications dealing with
Bayer HealthCare
development and marketed
drugs
1963 – present Daily
 Additional databases as depicted in the following Table 17:
Table 17: Additional databases used for literature research
Database Provider Discipline, Focus Coverage Update
Rhythm
Google Scholar Google Multidisciplinary N/A - present N/A
PubMed National Institutes of
Health, US National
Library of Medicine
Biomedical Late 1940s –
present59
Daily60
SpringerLink61 Springer Multidisciplinary 1996 – present Weekly
WorldCat62 Online Computer Library
Center
Multidisciplinary Before 1000 BC –
present
Daily
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A.2 Expert questionnaire regarding the issue of data exclusivity for Rx-to-
OTC switches (German and English version)
The questionnaire developed for qualitative interviews with selected national (i.e., German)
and international experts regarding the issue of data exclusivity provision for Rx-to-OTC
switches within Europe is depicted below in both the German and English version.
59 http://www.ncbi.nlm.nih.gov/books/NBK3827/#pubmedhelp.PubMed_Coverage, last accessed 2013-
02-27
60 (Falagas et al. 2008)
61 http://www.irelibrary.ie/resource.aspx?id=39, last accessed 2013-02-27
62 http://www.oclc.org/support/documentation/firstsearch/databases/dbdetails/details/
worldcat.htm, last accessed 2013-02-27
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A.2.1 Questionnaire German version
1 
 
 
 
Fragebogen zum Thema „Datenexklusivität bei der Entlassung von 
Arzneimitteln aus der Verschreibungspflicht“ 
 
PRÄAMBEL 
Aufgrund einer i.d.R. langjährigen und kostenintensiven Entwicklungsphase spielt das Thema 
„Datenschutz“ bei der Entwicklung von Arzneimitteln eine große Rolle und diesem wird im 
Rahmen des Patentschutzes größtenteils Rechnung getragen. Doch nicht alle Szenarien, die 
einen solchen Schutz verdienen, sind dadurch abgedeckt. Dementsprechend hat sich im Laufe 
der Jahre neben dem Patentrecht auch die Vergabe von Datenexklusivität als ein Instrument 
zum Schutz von geistigem Eigentum in der Gesetzgebung etabliert.   
So besteht z.B. bei der Entlassung von Arzneimitteln aus der Verschreibungspflicht in die 
Selbstmedikation (sog. Rx-to-OTC Switch) laut Art. 74a1 der EU-Richtlinie 2004/27/EC unter 
bestimmten Voraussetzungen die Möglichkeit zu einer einjährigen Datenexklusivität. Eine kurze 
Interpretation des Art. 74a findet sich in der aktuellen EU-Switchguideline (s. Anhang). Die 
Tatsache, dass diese Möglichkeit des Datenschutzes bei Rx-to-OTC Switchen bislang in Europa 
bis auf eine Ausnahme keine Anwendung gefunden hat, wirft  an dieser Stelle nicht nur die 
Frage nach der Bedeutung von Datenexklusivität für einen Rx-to-OTC Switch auf, sondern auch 
danach, wie realistisch eine solche Vergabe unter den aktuellen Rahmenbedingungen ist.  
Die in den letzten Jahren zunehmende Zahl an Entlassungen aus der Verschreibungspflicht ist im 
Wesentlichen zwei  Entwicklungen geschuldet – dem wachsenden Gesundheitsbewusstsein der 
Patienten inklusive deren Wunsch nach mehr Eigenverantwortung bei der eigenen 
Gesundheitsversorgung sowie steigenden Kosten der Gesundheitssysteme. Um diesem Trend 
bei immer größeren Anforderungen hinsichtlich der im Rahmen der Selbstmedikation zu 
etablierenden Therapieoptionen gerecht zu werden, bedarf es neben einer Konsensus basierten 
Kooperation aller beteiligten Interessengruppen auch adäquaten Anreizsystemen für 
Forschungsunternehmen.  
Vor diesem Hintergrund bietet die Möglichkeit der Datenexklusivität einerseits eine 
Motivationsgrundlage für Forschungsunternehmen bzw. Switchantragsteller, die den 
Switchanforderungen und –anstrengungen Tribut zollen soll. Damit eng verbunden ist 
andererseits jedoch auch der grundlegende Gedanke, dass den Bemühungen um 
Datenexklusivität entsprechende für den Switch relevante „therapeutische Konzepte“ zugrunde 
liegen, die letztlich dem Wohle und Schutz der Patienten dienen und eine optimale 
Gesundheitsversorgung gewährleisten sollen. Daraus resultiert nicht zuletzt die Forderung nach 
klaren und transparenten Exklusivitätskriterien, die das Instrument „Datenexklusivität“ für Rx-
to-OTC Switches entsprechend nutzbar werden lassen. 
                                                          
1
 “Where a change of classification of a medicinal product has been authorized on the basis of significant pre-clinical 
tests or clinical trials, the competent authority shall not refer to the results of those tests or trials when examining 
an application by another applicant for or holder of marketing authorization for a change of classification of the 
same substance for one year after the initial change was authorized.” 
 
2 
 
 
 
Im folgenden Fragebogen interessiert neben Ihrer generellen Haltung gegenüber  
„Datenexklusivität bei Rx-to-OTC Switchen“ insbesondere Ihre Meinung bezüglich möglicher 
Voraussetzungen bzw. Anforderungen an die Datengenerierung für die Vergabe einer solchen 
Datenexklusivität.  
Selbstverständlich werden alle Daten anonymisiert behandelt.  
 
Herzlichen Dank dafür, dass Sie sich die Zeit nehmen, den Fragebogen möglichst vollständig 
auszufüllen! 
 
Verantwortlich für den Inhalt und Ansprechpartner bei Fragen: 
Carolin Willmer  
Manager Scientific Affairs Consumer Care, Bayer Vital GmbH,  
Promotionsstudentin an der Philips-Universität Marburg  
Kontaktdaten:  e-mail: Carolin.Willmer@bayer.com 
                           Tel.: 0214 / 30 57 224, Fax: 0214  / 30 57 216 
                           Geb. K56, D-51368 Leverkusen 
  
 
--------------------------------------------------------------------------------------------------------------------------------------- 
Der Fragebogen befasst sich inhaltlich mit dem Thema „Vergabe von Datenexklusivität bei der 
Entlassung von Arzneimitteln aus der Verschreibungspflicht“. Die nachfolgend dargestellten Szenarien 
bezüglich der Entlassung aus der Verschreibungspflicht (Rx-to-OTC Switchszenarien) sollen Ihnen bei 
der Beantwortung der Fragen als Orientierungshilfe dienen. 
 
Im Hinblick auf die Entlassung eines Wirkstoffes bzw. Indikation aus der Verschreibungspflicht 
sind verschieden Szenarien theoretisch denkbar und auch teilweise praktisch schon erfolgt: 
A: Neuer OTC-Wirkstoff, bekannte  OTC-Indikation:  
Prominentes Beispiel hierfür ist die Entlassung von Protonenpumpeninhibitoren (PPI) 
aus der Verschreibungspflicht  zur Behandlung von Sodbrennen und saurem Aufstoßen. 
B: Neuer OTC-Wirkstoff, neue OTC-Indikation: 
Als Beispiel wäre hier die potentielle Entlassung von Arzneimitteln zur 
Blutdrucksenkung (z.B. Sartane) anzuführen. 
C: Bekannter OTC-Wirkstoff, neue OTC-Indikation: 
Hier wäre z.B. die Selbstmedikation der Arthrose mit bereits OTC-fähigen Wirkstoffen 
wie beispielsweise Naproxen theoretisch denkbar. 
------------------------------------------------------------------------------------------------------------------------------------ 
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--------------------------------------------------------------------------------------------------------------------------------------- 
Artikel 74 a, Direktive 2004/27/EC: 
“Where a change of classification of a medicinal product has been authorized on the basis of 
significant pre-clinical tests or clinical trials, the competent authority shall not refer to the results of 
those tests or trials when examining an application by another applicant for or holder of marketing 
authorization for a change of classification of the same substance for one year after the initial 
change was authorized.” 
-------------------------------------------------------------------------------------------------------------------------------------- 
1 Allgemeines 
1.1 Wie beurteilen Sie die rechtlichen Vorgaben2 zur Vergabe von Datenexklusivität  unter dem 
Gesichtspunkt „ Anforderungen bzw. Kriterien für die Datengenerierung  im Falle von 
Exklusivitätsanspruch“? 
Bitte treffen Sie Ihre Bewertung anhand der nachfolgenden Skala (1 = sehr gut, 6 = sehr schlecht) 
 1 2 3 4 5 6 Keine 
Meinung 
verständlich ○ ○ ○ ○ ○ ○ ○ 
präzise ○ ○ ○ ○ ○ ○ ○ 
relevant ○ ○ ○ ○ ○ ○ ○ 
1.2 Wie bewerten Sie die Dauer der innerhalb der EU für Rx-to-OTC Switches zu vergebenden 
Exklusivitätsperiode von einem Jahr? 
 □   Zu kurz            □  Genau richtig                Zu lang 
 
2 Präklinische Testdaten als  Basis für die Vergabe von Datenexklusivität bei Rx-to-OTC 
Switchen 
Im Rahmen einer Rx-Zulassung werden in der Regel umfangreiche präklinische Testdaten 
generiert. 
2.1 Wie schätzen Sie grundsätzlich die Eignung präklinischer Daten als Basis für die Vergabe von 
Datenexklusivität beim Rx-to-OTC Switch einer bestimmten Substanz ein? 
□  Halte ich im Hinblick auf das Sicherheitsprofil  der Substanz für notwendig   
□  Halte ich im Hinblick auf das Sicherheitsprofil der Substanz für geeignet  
□  Halte ich im Hinblick auf die für die Rx-Zulassung der Substanz generierten Daten nicht für 
     notwendig   
□  Halte ich im Hinblick auf die für die Rx-Zulassung der Substanz generierten Daten nicht für 
     geeignet   
                                                          
2
 Art. 74a, Direktive 2004/27/EC bzw. Guideline on changing the classification for the supply of a medicinal product 
for human use (EU-Switchguideline, 2006) 
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2.2 Könnte Ihrer Meinung nach auch eine Re-Analyse präklinischer Daten unter OTC relevanten 
Aspekten, die bereits im Rahmen der Rx-Zulassung generiert wurden, relevant sein? 
      Ja                         Nein (-> weiter  mit 3.1)                 □   Keine Meinung 
2.2.1 Bitte nennen Sie die Aspekte, die Sie vor diesem Hintergrund für besonders OTC relevant 
halten.  Als Beispiel seien hier  Interaktionsstudien mit neuen Wirkstoffen genannt.  
 
3 Klinische Studiendaten als  Basis für die Vergabe von Datenexklusivität bei Rx-to-OTC 
Switchen 
Ebenfalls in großem Umfang werden für die Rx-Zulassung eines Medikaments klinische Studien 
durchgeführt und ausgewertet. Hinzu kommen je nach Dauer der Zulassung im Rx-Markt 
zahlreiche Daten aus der Postmarketing-Überwachung. 
3.1 Könnte hier prinzipiell auch eine Aufarbeitung bereits existenter klinischer Rx-Daten im Sinne 
einer Re-Analyse bzw. –Strukturierung bzw. Extrapolation unter OTC-relevanten Aspekten zur 
Antizipation einer Anwendung in der Selbstmedikation vor dem Hintergrund eines Anspruches 
auf Datenexklusivität von Bedeutung sein? 
□   Ja                         Nein (-> weiter  mit 3.3)                 □  Keine Meinung 
3.2 Wie würden Sie die Bedeutung folgender  Ziel- bzw. Auswertungsparameter bei einer 
derartigen Re-Analyse in Bezug auf ihre Bedeutung für die Selbstmedikation einschätzen? 
Bitte treffen Sie Ihre Bewertung anhand der nachfolgenden Skala (1 = sehr wichtig, 6 = überhaupt nicht wichtig) 
 1 2 3 4 5 6 Keine 
Meinung 
Größe der Studienpopulation ○ ○ ○ ○ ○ ○ ○ 
Art der Studienpopulation ○ ○ ○ ○ ○ ○ ○ 
Spezielle Patientengruppen3 ○ ○ ○ ○ ○ ○ ○ 
Anzahl ausgewerteter Studien ○ ○ ○ ○ ○ ○ ○ 
Qualität ausgewerteter Studien ○ ○ ○ ○ ○ ○ ○ 
Monitoring (Art, Umfang) ○ ○ ○ ○ ○ ○ ○ 
Studiendauer ○ ○ ○ ○ ○ ○ ○ 
Sicherheit/Pharmakovigilanz ○ ○ ○ ○ ○ ○ ○ 
Wirksamkeit ○ ○ ○ ○ ○ ○ ○ 
Compliance ○ ○ ○ ○ ○ ○ ○ 
  
                                                          
3
 z.B. Ältere, Multimorbide, Schwangere etc. 
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3.2.1 Welche der genannten Parameter  sind Ihnen dabei  besonders wichtig (Top 3)? 
1.  
2.  
3.   
 
In den USA geben Studien in einem simulierten OTC-Umfeld Aufschluss über das Patientenver-
halten der Zielpopulation unter Alltagsbedingungen (Anwendungsbeobachtungen, Selbst-
Selektionstests, Lesbarkeitstests). 
3.3 Ist ein derartiges Konzept zur Generierung OTC-naher Daten für einen angestrebten Rx-to-OTC 
Switch  (d.h. vor einer Entlassung aus der Verschreibungspflicht) in Europa bzw. Deutschland 
Ihrer Auffassung nach grundsätzlich von Relevanz? 
       Ja                         Nein (-> weiter  mit  3.6)                 □  Keine Meinung 
3.4 Wie würden Sie die verschiedenen Studientypen hinsichtlich ihrer Bedeutung vor dem 
Hintergrund entsprechender  vom Antragsteller generierter, relevanter  Daten für die Vergabe 
von Datenexklusivität bei Rx-to-OTC Switches in der EU bewerten? 
  Bitte treffen Sie Ihre Bewertung anhand der nachfolgenden Skala (1 =äußerst relevant, 6 =überhaupt nicht relevant) 
 1 2 3 4 5 6 Keine 
Meinung 
Anwendungsbeobachtung ○ ○ ○ ○ ○ ○ ○ 
Selbst-Selektionstest ○ ○ ○ ○ ○ ○ ○ 
Lesbarkeitstest ○ ○ ○ ○ ○ ○ ○ 
3.5 Wie beurteilen Sie folgende Parameter im Hinblick auf ihre Relevanz für das Design solcher 
Studien vor dem Hintergrund der Generierung relevanter Daten für einen neuen OTC-
Wirkstoff (Szenario A), eine neue OTC-Indikation (Szenario B) oder einen neuen OTC-Wirkstoff 
und ein eine neue OTC-Indikation (Szenario C)? 
Bitte treffen Sie Ihre Bewertung anhand der nachfolgenden Skala (1 = äußerst relevant, 6 = überhaupt nicht relevant) 
 1 2 3 4 5 6 Keine 
Meinung 
Auswahl Studienpopulation A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
Repräsentativität A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
Randomisierung A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
Kontrollgruppe A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
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Spezielle Patientengruppen A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
Studiendauer A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
Monitoring A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
Follow-Up A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
3.5.1 Welche der genannten Parameter  sind Ihnen dabei  besonders wichtig (Top 3)? 
1.   
2.   
3.  
 
Die folgenden Fragen beziehen sich auf die Generierung von Datenexklusivität bei der 
potentiellen Entlassung von Indikationen im Rahmen der Prävention bzw. Therapie von oftmals 
(semi-) chronischen Erkrankungsbildern, die initial eine ärztliche Diagnose erfordern und deren 
Re-Diagnose, Monitoring bzw. Management in der  Folge durch den Patienten selbst unter 
ärztlicher Kontrolle erfolgt. Beispiele hierfür sind die bereits OTC-fähige Indikation der 
Vaginalmykose oder auch die Behandlung von Bluthochdruck mit z.B. noch ausschließlich 
verschreibungspflichtigen Sartanen. 
3.6 Könnten sich Ihrer Meinung nach Daten, die die Fähigkeit zur Eigendiagnose bzw. zum 
selbständigen Therapiemanagement  einer betroffenen Patientenpopulation (nach einer 
ärztlichen Initialdiagnose) zeigen, generell für die Vergabe von Datenexklusivität im Rahmen 
eines angestrebten Rx-to-OTC Switches  qualifizieren?  
       Ja                          Nein (-> weiter  mit 3.8 )                 □  Keine Meinung 
3.7 Verantwortungsbewusstes Therapiemanagement und –monitoring durch den Patienten spielt 
in der Selbstmedikation eine große Rolle, insbesondere im Falle von (semi-) chronischen 
Erkrankungsbildern bzw. Präventionstherapien wie  z.B. Bluthochdruck, Hyperlipidämie, 
Hypercholesterinämie, Diabetes mellitus u.a.. 
Bitte beurteilen Sie vor diesem Hintergrund die folgenden Punkte im Hinblick auf ihre Eignung 
für Datenexklusivität bei einem entsprechenden Szenario eines Rx-to-OTC Switches: 
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Bitte treffen Sie Ihre Bewertung anhand der nachfolgenden Skala (1 = sehr gut, 6 = sehr schlecht) 
 1 2 3 4 5 6 Keine 
Meinung 
Entwicklung einer Methode/eines Algorithmus für 
Patienten zur  eigenständigen Symptombewertung 
    
Entwicklung eines Messgerätes zur 
Therapieüberprüfung für Patienten 
 
Überprüfung/Messung der Maßnahmen zur 
Änderung des Lebensstils betroffener Patienten (falls 
erforderlich wie z.B. bei Prävention) 
 
 
 
 
   
 
 
 
 
Entwicklung einfach handhabbarer 
Softwareprogramme für Patienten zum 
eigenständigen Therapiemanagement (ggfs. mit 
Datenübertragung zum betreuenden Arzt/Apotheker) 
   
 
 
 
 
 
 
 
 
 
3.7.1 Wie bewerten Sie in diesem Zusammenhang folgende Möglichkeiten der Datengenerierung? 
  Bitte treffen Sie Ihre Bewertung anhand der nachfolgenden Skala (1= äußerst relevant, 6= überhaupt nicht relevant) 
 1 2 3 4 5 6 Keine 
Meinung 
Daten aus Umfragetests mit Patienten der Zielgrupppe ○  ○    ○
Daten aus Anwendungsbeobachtungen an Patienten der 
Zielgruppe (ohne Kontrolle durch Fachpersonal) 
     
Daten aus Anwendungsbeobachtungen an Patienten der 
Zielgruppe (mit Kontrolle durch Fachpersonal) 
     
Daten aus Anwendungsbeobachtungen an speziellen 
Patientengruppen (mit Kontrolle durch Fachpersonal) 
  
Daten, die eine erhöhte Compliance der Patienten unter 
Anwendung der entwickelten Messgeräte/Maßnahmen zeigen 
   
Regelmäßig zu generierende Daten aus Qualitätsüberprüfungen 
entsprechender Messgeräte/Maßnahmen 
 
 
Nachfolgend geht es um den Vergleich einer potentiell aus der Verschreibungspflicht zu 
entlassenden Substanz mit bereits existierenden therapeutischen Alternativen in einer 
bestimmten Indikation in der Selbstmedikation (als Beispielsszenario kann hier die Entlassung 
der Protonenpumpeninhibitoren zur Behandlung von Sodbrennen und saurem Aufstoßen aus der 
Verschreibungspflicht dienen). 
3.8 Ist  Ihrer Ansicht nach der Vergleich eines potentiellen OTC-Kandidaten mit bereits 
verfügbaren OTC-Alternativen im Rahmen einer Art klinischen Studie (z.B. Phase IV Studie)  in 
Bezug auf einen möglichen Anspruch auf Datenexklusivität von Bedeutung? 
      Ja                         Nein (-> weiter  mit  3.10)              □  Keine Meinung 
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3.9 Wie würden Sie die Bedeutung folgender Ziel- und Auswertungsparameter bei einer solchen 
Vergleichsstudie einschätzen? 
 1 2 3 4 5 6 Keine 
Meinung 
Größe der Studienpopulation    
Art der Studienpopulation 
Spezielle Patientengruppen  
Sicherheit/Pharmakovigilanz 
Wirksamkeit  
Compliance   
Überlegenheit 
Nicht-Unterlegenheit  
3.9.1 Welche der genannten Parameter sind Ihnen dabei  besonders wichtig (Top 3)? 
1. 
2. 
     3. 
3.10 Könnte  in Ihren Augen eine mit den entsprechenden Entscheidungsgremien abgestimmte 
nicht- interventionelle Studie im Sinne einer klassischen Anwendungsbeobachtung nach 
Entlassung aus der Verschreibungspflicht, die neue Erkenntnisse bezüglich Wirksamkeit, 
Sicherheit, Einnahmeverhalten und Patientenzufriedenheit unter Alltagsbedingungen liefert, 
Grundlage für die Vergabe von Datenexklusivität im Rahmen von Rx-to-OTC Switches sein? 
      Ja                         Nein                       □  Keine Meinung 
 
4 Informations- und Edukationsmaßnahmen 
Hier interessiert Ihre Meinung bezüglich umfangreicher und detaillierter fach- bzw. 
patientenspezifischer Informations- und Schulungsprogramme im Hinblick auf die Qualifizierung 
von Daten für Exklusivität im Rahmen eines Rx-to-OTC Switches. 
4.1 Könnten Sie sich generell umfangreiche und neuartige Informations- und Schulungsmaß-
nahmen sowohl für Patienten als auch für Fachkräfte als Voraussetzung für die Vergabe von 
Datenexklusivität vorstellen? 
      Ja                         Nein (-> weiter  mit  5.1)                 Keine Meinung 
4.2 Falls „Ja“, welche der genannten Punkte könnten Ihrer Ansicht nach in einem solchen Fall als 
Basis für Datenexklusivität dienen4? (Mehrfachauswahl möglich)  
 
                                                          
4
 auch wenn gemäß Wortlaut Art. 74a („präklinische oder klinische Studien“) nicht definiert                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
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Schulungskonzept 
Informations- und Schulungsmaterialien 
Testergebnisse von Materialien/Konzepten an Zielgruppe mit Fokus auf… 
- Lesbarkeit 
- Verständnis 
- Verhaltensänderung 
 
○
Daten/Maßnahmen, die eine entsprechende Nutzung der entwickelten Maßnahmen zeigen bzw. 
sicherstellen 
Commitment zu regelmäßigen Qualitätskontrollen  ○ 
Keine Meinung ○ 
4.2.1 Welche der genannten Punkte erachten Sie dabei als besonders relevant (Top 3)? 
1.
2.   
     3.   
 
5 Pharmakoökonomische Aspekte 
Klinische Studien allein können den Wert einer bestimmten Therapie für die „öffentliche 
Gesundheit“ oft nicht quantifizieren, weshalb diese häufig durch sog. Kosten-Nutzen-Analysen 
komplementiert werden. 
5.1 Könnten Sie sich derartige Analysen/Studien im Hinblick auf Rx-to-OTC Switches prinzipiell für 
die Vergabe von Datenexklusivität vorstellen? 
      Ja                         Nein (-> Ende der Befragung)                   Keine Meinung 
5.1.1 Falls „Ja“, welche Art von Analysen würden sich Ihrer Meinung nach am besten dafür eignen? 
      Kosten- Nutzen-Analysen (monetär) 
      Kosten-Nutzwert-Analysen (nicht monetär, z.B. Verbesserung der Lebensqualität etc.) 
      Sonstige:         
 
 
 
--------------------------------------------------------------------------------------------------------------------------------------
Vielen Dank für Ihre Unterstützung! 
-------------------------------------------------------------------------------------------------------------------------------------- 
Bitte senden Sie den ausgefüllten Fragebogen per Mail oder per Post zurück an: 
Carolin Willmer (Carolin.Willmer@bayer.com) 
Bayer Vital GmbH, Consumer Care 
Geb. K 56, D-51368 Leverkusen  
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Questionnaire with respect to the issue of „data exclusivity provision for 
the transfer of pharmaceuticals from prescription to non-prescription 
status“ 
 
PREAMBEL 
Due to a generally long-lasting and cost-intensive development phase the issue of „data 
protection“ plays an important role for which allowance is made for mainly within the context 
of patent protection. However, not all scenarios deserving such a protection are thereby 
covered. Correspondingly, the provision of data exclusivity has been established in legislation 
over the years as an instrument for protection of intellectual property apart from patent law.   
In the case of the transfer of pharmaceuticals from prescription status to self-medication (so-
called Rx-to-OTC switch), for example, there is under certain preconditions the opportunity of a 
one-year data exclusivity according to Art. 74a1 of EU-Directive 2004/27/EC (see attachment). 
The fact, that this option has not yet been exercised in Europe apart from one exceptional case, 
at this point raises the question not only regarding the relevance of data exclusivity for an Rx-to-
OTC switch, but also regarding the extent of how realistic such a provision actually is under the 
current framework.  
The increasing number of transfers from prescription to non-prescription status over the last 
years is mainly owing to two movements – the growing health consciousness of patients 
including their demand for more personal responsibility as well as rising costs within healthcare 
systems.  To come up with this trend while facing ever growing requirements as regards the 
therapeutic options to be established within self-medication,  there is a need for both a 
consensus based cooperation of all stakeholders involved and adequate incentive systems for 
research companies.  
Against this background the opportunity of data exclusivity on the one hand would provide a 
motivational fundament for research companies or switch applicants, respectively, in order to 
recognize the switch requirements and the efforts involved. On the other hand this comes 
ultimately along with the basic idea, that the efforts for data exclusivity are based on 
corresponding “therapeutic concepts” relevant for the switch and basically aiming at the well-
being and protection of patients and the guarantee of an optimal healthcare provision. Last but 
not least this should aim at the postulation of clear and transparent exclusivity criteria in order 
to enable to make use of the instrument of „data exclusivity“ within the context of Rx-to-OTC 
switches. 
  
                                                          
1
 “Where a change of classification of a medicinal product has been authorized on the basis of significant pre-clinical 
tests or clinical trials, the competent authority shall not refer to the results of those tests or trials when examining 
an application by another applicant for or holder of marketing authorization for a change of classification of the 
same substance for one year after the initial change was authorized.” 
 
2 
 
 
In the following questionnaire your opinion regarding potential preconditions and 
requirements for data generation targeting at the provision of such a data exclusivity are of 
particular interest apart from your general attitude towards „data exclusivity for Rx-to-OTC 
switches“. 
    
As a matter of course all data is treated anonymously.  
 
Thank you very much for taking your time to complete this questionnaire! 
 
Responsible for the content and contact person in the case of questions: 
Carolin Willmer  
Manager Scientific Affairs Consumer Care, Bayer Vital GmbH,  
PhD student at Philips University of Marburg  
Contact details:  E-mail: Carolin.Willmer@bayer.com 
                              Phone: +49 214 / 30 57 224, Fax: +49 214  / 30 57 216 
                             Building K56, 51368 Leverkusen, Germany 
  
 
---------------------------------------------------------------------------------------------------------------------------------------- 
As regards content the questionnaire deals with the issue of „data exclusivity provision within the 
context of transfer of pharmaceuticals from prescription to non-prescription status“. The scenarios 
depicted in the following relating to the transfer from prescription status (Rx-to-OTC switch 
scenarios) are intended to serve as guidance when answering the questions. 
 
Different scenarios with respect to the transfer of an active substance or an indication from 
prescription to non-prescription status are theoretically thinkable or have in parts occurred 
yet in practice: 
A: New OTC substance, known OTC indication:  
A prominent example here is the transfer of proton pump inhibitors (PPI) from 
prescription to non-prescription status for the treatment of heartburn and acid 
regurgitation (initial OTC indication in Germany). 
B: New OTC substance, new OTC indication:  
The potential transfer of pharmaceuticals for the reduction of high blood pressure (e.g. 
sartanes) would be such an option. 
C: Known OTC substance, new OTC indication:  
Self-treatment of osteoarthritis with active substances already OTC-compatible such as 
naproxen is theoretically thinkable here. 
------------------------------------------------------------------------------------------------------------------------------------- 
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----------------------------------------------------------------------------------------------------------------------------------------- 
Article 74 a, Directive 2004/27/EC: 
“Where a change of classification of a medicinal product has been authorized on the basis of 
significant pre-clinical tests or clinical trials, the competent authority shall not refer to the results of 
those tests or trials when examining an application by another applicant for or holder of marketing 
authorization for a change of classification of the same substance for one year after the initial 
change was authorized.” 
---------------------------------------------------------------------------------------------------------------------------------------- 
1 Preface 
1.1 How do you judge the legal specifications2 regarding the provision of data exclusivity from the 
viewpoint of “requirements or criteria, respectively, for the generation of data in the case of 
exclusivity demand”? 
Please judge with the help of the following scale (1 = very good, 6 = poor) 
 1 2 3 4 5 6 No 
opinion 
Comprehensible ○ ○ ○ ○ ○ ○ ○ 
Precise ○ ○ ○ ○ ○ ○ ○ 
Relevant ○ ○ ○ ○ ○ ○ ○ 
1.2 How do you assess the one-year duration of exclusivity periods to be awarded for Rx-to-OTC 
switches within the EU? 
□  Too short      □  Just appropriate      □  Too long 
 
2 Preclinical test data as basis for the provision of data exclusivity for Rx-to-OTC 
switches 
As a general rule, comprehensive preclinical test data are generated within the context of an Rx-
registration approval process. 
2.1 In principle, how do you estimate the eligibility of preclinical data as a basis for the provision of 
data exclusivity for the Rx-to-OTC switch of a certain substance? 
□  I consider it necessary with respect  to the safety profile of the substance   
□  I consider it appropriate with respect  to the safety profile of the substance   
□  I do not consider it necessary with respect  to the safety profile of the substance   
□  I do not consider it appropriate with respect  to the safety profile of the substance   
2.2 In your opinion, could a re-analysis of preclinical data that have already been generated within 
the context of the Rx-authorization under OTC pertinent aspects be relevant? 
□  Yes        □  No (-> continue with 3.1)                 □  No opinion 
                                                          
2
 Art. 74a, Direktive 2004/27/EC bzw. Guideline on changing the classification for the supply of a medicinal product 
for human use (EU-Switchguideline, 2006) 
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2.2.1 Against this background please mention all aspects that you assess particular relevant for 
OTC.  Interaction studies with new active substances are cited here as an example.  
     _________________________________________________________________________ 
_________________________________________________________________________ 
 
3 Clinical study data as a basis for the provision of data exclusivity for Rx-to-OTC 
switches 
Likewise, clinical trials are conducted and evaluated to a large extent for a pharmaceutical‘s Rx 
authorization. Additionally, depending on the duration of the Rx-registration in the market, 
much data from post-marketing surveillance accrues. 
3.1 As a matter of principle, could a recycling of already existing clinical Rx-data in the sense of a 
re-analysis, re-structuring or extrapolation, respectively, under OTC pertinent aspects in order 
to anticipate self-medication practice be of relevance against the background of data 
exclusivity? 
□  Yes        □  No (-> continue with 3.3)                 □  No opinion 
3.2 How would you assess the significance of the following outcome measures within such a re-
analysis regarding their relevance for self-medication? 
Please judge with the help of the following scale (1 = very important, 6 = not important at all) 
 1 2 3 4 5 6 No 
opinion 
Size of study population ○ ○ ○ ○ ○ ○ ○ 
Sort of study population ○ ○ ○ ○ ○ ○ ○ 
Special patient groups
3
 ○ ○ ○ ○ ○ ○ ○ 
Number of studies evaluated ○ ○ ○ ○ ○ ○ ○ 
Quality of studies evaluated  ○ ○ ○ ○ ○ ○ ○ 
Monitoring (kind, amount) ○ ○ ○ ○ ○ ○ ○ 
Study duration ○ ○ ○ ○ ○ ○ ○ 
Safety/Pharmacovigilance ○ ○ ○ ○ ○ ○ ○ 
Efficacy ○ ○ ○ ○ ○ ○ ○ 
Compliance ○ ○ ○ ○ ○ ○ ○ 
3.2.1 Which of the parameters mentioned do you think are particularly important in this respect 
(top 3)? 
1.   _________________________________________________________________________ 
2.   _________________________________________________________________________ 
3.   _________________________________________________________________________ 
 
                                                          
3
 e.g. elderly, multimorbid patients, pregnant women etc. 
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In the US, studies conducted in a simulated OTC environment give information about patient 
characteristics of the target population under conditions of everyday life (actual use studies, self-
selections studies, label comprehension studies). 
3.3 Do you perceive such a concept for the generation of OTC-like data for an envisaged Rx-to-OTC 
switch (i.e. before transfer from prescription to non-prescription status) to be basically 
relevant within Europe? 
□  Yes        □  No (-> continue with 3.6)                 □  No opinion 
3.4 How would you valuate the different study types with respect to their significance for the 
provision of data exclusivity for Rx-to-OTC switches within the EU against the background of 
accordant relevant data generated by the applicant? 
  Please judge with the help of the following scale (1 = extremely relevant, 6 = not relevant at all) 
 1 2 3 4 5 6 No 
opinion 
Actual use study ○ ○ ○ ○ ○ ○ ○ 
Self-selection study ○ ○ ○ ○ ○ ○ ○ 
Label comprehension study ○ ○ ○ ○ ○ ○ ○ 
3.5 How do you assess the following parameters regarding their relevance for the design of such 
studies against the background of generating relevant data for a new OTC-substance (scenario 
A), a new OTC-indication (scenario B) or a new OTC-substance and a new OTC indication 
(scenario C)? 
Please judge with the help of the following scale (1 = extremely relevant, 6 = not relevant at all) 
 1 2 3 4 5 6 No 
opinion 
Selection of study 
population 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
Representativeness A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
Randomization A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
Control group A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
Special patient groups A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
Study duration A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
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Monitoring A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
Follow-up A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
A: ○ 
B: ○ 
C: ○ 
3.5.1 Which of the parameters mentioned do you think are particularly important here (top 3)? 
1.   _________________________________________________________________________ 
2.   _________________________________________________________________________ 
3.   _________________________________________________________________________ 
 
The following questions refer to the generation of data exclusivity for the potential transfer of 
indications within the scope of prevention or therapy of mainly (semi-)chronic conditions.  Such 
indications initially require a medical diagnosis, but may subsequently enable patients 
themselves to re-diagnose, monitor and manage their conditions under medical control. 
Examples are the indication of vaginal mycosis which is already OTC in many countries or the 
therapy of hypertension with sartans currently still available prescription-only. 
3.6 Do you hold the opinion that data demonstrating the ability of a correct self-diagnosis or 
autonomous therapeutic management, respectively, by the patient population affected (after 
an initial medical diagnosis) could generally qualify for the provision of data exclusivity for an 
envisaged Rx-to-OTC switch?  
□  Yes        □  No (-> continue with 3.8 )                 □  No opinion 
3.7 Responsible therapy management and monitoring by patients plays an important role in self-
medication, especially in the case of (semi-)chronic diseases or preventive therapies, 
respectively, such as hypertension, hyperlipidemia, hypercholesterolemia, diabetes mellitus 
and others. 
Against this background could you please evaluate the following aspects with regard to their 
appropriateness for data exclusivity for an accordant scenario of a Rx-to-OTC switch: 
Please judge with the help of the following scale (1 = very good, 6 = poor) 
 1 2 3 4 5 6 No 
opinion 
Development of a method/an algorithm for patients 
to self-assess their symptoms 
○ ○ ○ ○ ○ ○ ○ 
Development of  a measurement device for patients 
to control their therapy 
○ ○ ○ ○ ○ ○ ○ 
Control/measurement of  activities of patients 
affected to change their way of life (if applicable as 
for example in case of preventive therapies)  
 
○ 
 
○ 
 
○ 
 
○ 
 
○ 
 
○ 
 
○ 
Development of easy-to-use software programs for 
therapeutic self-management by patients (where 
appropriate with data transfer to the supervising 
doctor/pharmacist) 
 
○ 
 
○ 
 
○ 
 
○ 
 
○ 
 
○ 
 
○ 
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3.7.1 Within this context, how do you assess the following possibilities of data generation? 
  Please judge with the help of the following scale (1= extremely relevant, 6= not relevant at all) 
 1 2 3 4 5 6 No 
opinion 
Data from surveys with patients from the target group ○ ○ ○ ○ ○ ○ ○ 
Data from actual use studies with patients from the target 
group (without control through specialized personnel) 
○ ○ ○ ○ ○ ○ ○ 
Data from actual use studies with patients from the target 
group (with control through specialized personnel) 
○ ○ ○ ○ ○ ○ ○ 
Data from actual use studies with special patient groups (with 
control through specialized personnel) 
○ ○ ○ ○ ○ ○ ○ 
Data demonstrating increased compliance of patients using the 
measurement devices/activities developed 
○ ○ ○ ○ ○ ○ ○ 
Data to be regularly generated on the basis of quality controls 
of corresponding measurement devices/activities  
○ ○ ○ ○ ○ ○ ○ 
 
Below it is about the comparison of a substance potentially to be removed from prescription 
status with already existing therapeutic alternatives in a specific indication within self-
medication (to give an example the transfer of certain proton pump inhibitors from prescription 
to non-prescription status in Germany for the treatment of heartburn and acid regurgitation 
might be quoted here). 
3.8 From your perspective, is the comparison of a potential Rx-to-OTC switch candidate with 
already available OTC-alternatives by means of a clinical study or the like (e.g. phase IV study) 
of relevance in reference to a potential claim of data exclusivity? 
□  Yes        □  No (-> continue with  3.10)              □  No opinion 
3.9 How would you estimate the importance of the following outcome measures within the 
context of such a comparative study? 
 1 2 3 4 5 6 No 
opinion 
Size of study population ○ ○ ○ ○ ○ ○ ○ 
Kind of study population ○ ○ ○ ○ ○ ○ ○ 
Special patient groups ○ ○ ○ ○ ○ ○ ○ 
Safety/Pharmacovigilance ○ ○ ○ ○ ○ ○ ○ 
Efficacy ○ ○ ○ ○ ○ ○ ○ 
Compliance ○ ○ ○ ○ ○ ○ ○ 
Superiority ○ ○ ○ ○ ○ ○ ○ 
Non-inferiority ○ ○ ○ ○ ○ ○ ○ 
3.9.1 Which of the parameters mentioned do you think are particularly important in this respect 
(top 3)? 
1.   _________________________________________________________________________ 
2.   _________________________________________________________________________ 
     3.   _________________________________________________________________________ 
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3.10 From your point of view, could the provision of data exclusivity for Rx-to-OTC switches be 
based on a non-interventional study in the sense of a classical actual use study after transfer 
from prescription to non-prescription status? Agreed upon with the accordant decision-making 
bodies, such a study could provide new insights concerning efficacy, safety, intake and patient 
satisfaction under daily-life conditions. 
□  Yes        □  No                       □  No opinion 
 
4 Informational and educational measures 
Your opinion regarding comprehensive and detailed subject- and patient specific informational 
or training programs, respectively, is of interest here with reference to the qualification of data 
for exclusivity within the context of an Rx-to-OTC switch. 
4.1 In principal, could you imagine novel comprehensive informational and educational activities 
both for patients and health care professionals as a requirement for the provision of data 
exclusivity? 
□  Yes        □  No (-> continue with  5.1)                 □   No opinion 
4.2 If  „yes“, which of the items listed below could provide the bases for data exclusivity from your 
point of view4? (Multiple selection possible)  
Training concept ○ 
Informational and educational material ○ 
Results from tests with target group regarding materials/concepts focusing on… 
- readability 
- comprehension 
- behavioral change 
 
○ 
○ 
○ 
Data/measures demonstrating or ensuring, respectively, adequate utilization of the activities 
developed 
○ 
Commitment to regular quality checks  ○ 
No opinion ○ 
4.2.1 Which of the parameters mentioned do you think are particularly important here (top 3)? 
1.   _________________________________________________________________________ 
2.   _________________________________________________________________________ 
     3.   _________________________________________________________________________ 
 
5 Pharmacoeconomic aspects 
Clinical studies on their own often are not able to quantify the value of a certain therapy for the 
“public health” and therefore often are complemented by so-called cost-benefit analyses. 
                                                          
4
 even if not defined according to the wording of Art. 74a („preclinical or clinical studies“)  
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5.1 Could you imagine such analyses/studies with regard to Rx-to-OTC switches for the sake of the 
provision of data exclusivity? 
□  Yes        □  No (-> end of survey)           □  No opinion 
5.1.1 If „yes“, according to you, what sort of analysis would suit best for it? 
□ Cost-benefit-analyses (monetary) 
□ Cost-effectiveness/utility-analyses (non-monetary, e.g. improvement of quality of life etc.) 
□ Others        
 
 
---------------------------------------------------------------------------------------------------------------------------------------- 
Thank you very much for your support! 
---------------------------------------------------------------------------------------------------------------------------------------- 
Please send back the completed questionnaire by e-mail or airmail to: 
Carolin Willmer (Carolin.Willmer@bayer.com) 
Bayer Vital GmbH, Consumer Care 
Building  K 56, 51368 Leverkusen, Germany  
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